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  Chapter 1 
THE GENETIC BASIS OF CANCER 
 
 
CANCER GENETICS 
 
Cells have several safeguards to ensure that cell division, differentiation and death occur correctly 
and in a coordinated fashion, both during development and in the adult body. The strict regulation 
of these processes may be undermined through the accumulation of (epi)genetic defects, providing 
a single cell with a selective growth advantage. This unrestricted growth potential will lead to the 
clonal expansion of the abnormal cell that, in time, will form a tumor1 (Figure 1). 
 
 
 
 
 
 
 
 
Figure 1. Model for stepwise progression of cancer in association with accumulation of 
(epi)genetic alterations in the cell (adapted from2). 
 
During the course of tumor development most cancers acquire an essential set of functional 
capabilities, i.e. self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion 
of programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis3. These alterations in cell physiology are acquired, directly or 
indirectly, through successive genetic events that target two major classes of cancer-related genes: 
oncogenes and tumor suppressor genes. 
 
Oncogenes 
 
Oncogenes are mutated forms of proto-oncogenes. In normal cells, proto-oncogenes function as 
components of growth promoting signaling and anti-apoptotic pathways. Proto-oncogenes can act as 
cancer promoting genes when inappropriately (over-) expressed, which is caused by gain-of-function 
mutations3. Mutations leading to gain of function are dominant, since only one mutated allele is 
enough to push the cell towards the cancerous behavior. Examples of proto-oncogenes are growth 
factor receptors (e.g. EGFR), transcellular transducers (e.g. K-RAS), and DNA-binding nuclear 
proteins or transcription factors (e.g. MYC). Activation of oncogenes can occur through a wide 
variety of different mechanisms, such as gene amplifications, point mutations and chromosomal 
translocations. 
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Tumor suppressor genes 
 
Tumor suppressor genes (TSGs) are targeted in the opposite way by genetic alterations: these genes 
are affected by loss-of-function mutations. According to Knudson’s two-hit hypothesis4, inactivation 
of both TSG alleles is required for tumor development (Figure 2). This two-hit paradigm was derived 
from mathematical modeling of cancer incidence in retinoblastoma, a rare embryonic pediatric 
tumor developing in the retina of the eye. Based on the remarkable age-of-onset difference 
between hereditary and sporadic forms of retinoblastoma, it was proposed that the presence of a 
germline mutation (‘first hit’) in heritable retinoblastoma followed by a rate-limiting somatic 
mutation (‘second hit’) on the other allele significantly accelerated the onset of the cancer 
phenotype. In sporadic tumors, both inactivating mutational events (first and second hit) have to 
occur in the same somatic cell and therefore it will take longer time for tumors to develop4. At the 
time this hypothesis was formulated, the nature of the genetic defect was not known. Subsequent 
molecular analyses on RB1 and other TSGs confirmed the two-hit paradigm and illustrated that the 
general mechanisms to inactivate the remaining wild-type allele are gross chromosomal alterations, 
leading to loss of heterozygosity (LOH) over large regions of the chromosome5. More subtle 
inactivating mechanisms include intragenic mutations6 and epigenetic silencing7 due to 
hypermethylation of the CpG island spanning the promoter region and deacetylation of lysine 
residues on key histones in the chromatin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Knudson’s two-hit model for the inactivation of a tumor suppressor gene (TSG). 
In familial tumor syndromes (panel A), the initial inactivation of one allele is present in germ cells. 
The rate-limiting step for tumor formation is an additional inactivation event that affects 
somatically the second allele. Somatic inactivation events include subchromosomal deletion (a), 
mitotic recombination (b), nondisjunctional chromosome loss with (c)/ without (d) reduplication of 
the chromosome carrying the mutated TSG, intragenic mutation (e) or an epigenetic event (f). In 
sporadic tumors (panel B), the initial and second inactivating mutational events occur in the same 
somatic cell of an individual4,5 (adapted from8). 
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Tumor suppressor genes have been classified into ‘gatekeepers’ and ‘caretakers’9. ‘Gatekeeper’ 
genes directly inhibit cell growth by suppressing proliferation, inducing apoptosis or promoting 
differentiation. Their loss of function is rate-limiting for a particular step in multi-stage 
tumorigenesis and restoring the ‘gatekeeper’ function suppresses neoplasia. In patients with 
familial adenomatous polyposis (FAP), for example, an inherited defect in the APC gene leads to the 
development of hundreds of adenomatous polyps. Because of their great numbers, some polyps are 
virtually guaranteed to progress to cancer9 (cfr. Infra). In contrast, ‘caretaker’ genes act indirectly 
to suppress growth by repairing mistakes made during normal DNA replication or induced by 
exposure to mutagens. These genes also control processes that are responsible for mitotic 
recombination and chromosomal segregation. The task of ‘caretaker’ genes is to keep genetic 
alteration to a minimum. Consequently, when these genes become inactivated it allows mutations 
in other genes (e.g. oncogenes and ‘gatekeeper’ genes) to accumulate. Defects in the mismatch 
repair genes MSH2, MLH1 and MSH6, for example, are the genetic basis of hereditary non-polyposis 
colorectal cancer (HNPCC). While patients with HNPCC develop adenomatous polyps at about the 
same rate as the general population, these polyps progress to cancer much more often because of 
defective mismatch repair9. 
 
Some TSGs have been hypothesized to exert a selective advantage on a cell when only one allele is 
inactivated10. Potential mechanisms are a dominant negative mutation blocking the function of the 
remaining wild-type gene product, and haploinsufficiency, meaning that the protein product level 
of a single active allele is insufficient to suppress tumor development. One of the first examples of 
evidence for haploinsufficiency for tumor suppression was provided for the p27 gene. P27 acts to 
arrest the cell cycle and has been implicated as a critical player in the progression of a wide variety 
of neoplasms. Murine data show a strong selective advantage to tumor development with loss of a 
single p27 allele. More specifically, p27+/- mice exhibit a tumor latency and aggressive tumor 
behavior between the phenotypes observed in p27-/- and p27+/+ mice. In the tumors of the p27+/- 
mice, the p27 wild-type allele is retained and continued to be expressed11. Although there is 
growing evidence supporting the concept of TSG haploinsufficiency in mouse models of cancer 
(reviewed in10), it is not clear yet whether loss of one wild-type allele confers a phenotype which is 
relevant to human carcinogenesis. 
 
Recent evidence indicates that small non-protein-coding RNA molecules, called microRNAs 
(miRNAs), might also function as tumor suppressors and oncogenes. These short RNA sequences of 
21 to 25 nucleotides play essential roles in many basic physiologic processes including proliferation, 
differentiation, and apoptosis. MicroRNAs negatively regulate protein-coding genes by binding to 
complementary or partially complementary target mRNAs and thereby targeting the mRNA for 
degradation or translational inhibition12. More than half of miRNAs are located at sites in the human 
genome that are frequently amplified, deleted, or rearranged in cancer, suggesting that miRNA 
abnormalities play a broad role in cancer pathogenesis13. Also consistent with this notion is the 
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observed dysregulation of miRNA expression in diverse cancer subtypes including lung cancer14, 
breast cancer15 and glioblastoma16. 
 
The multistep colorectal cancer model 
 
Colorectal cancer is one of the most extensively investigated tumor types, and its model of 
progression due to the stepwise accumulation of genetic abnormalities serves as a paradigm for 
many other neoplasms. Germline mutations in the tumor suppressor gene APC result in familial 
adenomatous polyposis (FAP), one of the principal hereditary predispositions to colorectal cancer. 
Patients with FAP typically develop hundreds to thousands of colorectal adenomas and are prone to 
a variety of specific extracolonic features, such as gastrointestinal polyps, retinal lesions, desmoid 
tumors and brain tumors. Although the colorectal polyps are benign, some adenomas ultimately 
progress to malignant adenocarcinomas by 30-40 years of age17. Somatic mutations in APC are also 
found in the majority (85%) of sporadic colorectal cancers18. 
 
Inactivation of both APC alleles can be detected in the very earliest stages of the adenoma-
carcinoma sequence, illustrating that this event is the initiating trigger for clonal evolution. 
Remarkably, the position and type of the second hit in FAP and sporadic polyps is determined by the 
localization of the first hit19. Apparently, the APC mutation spectrum reflects the fact that there 
exists an optimal APC genotype for providing the nascent tumor cell with a selective advantage20,21. 
Additional oncogenic mutations, often in K-RAS, are required for adenoma growth and progression. 
Subsequent clonal expansion and malignant transformation is driven by additional mutations and 
allelic losses in TP53, SMAD4 and other 18q TSGs9. Taken together, not simply the accumulation, but 
rather also the type, position and temporal order of mutations determine the propensity for 
neoplasia. 
 
The disease severity varies among FAP patients with respect to the number of adenomas which is 
related to the risk of developing cancer22. Disease severity is influenced by the site of the germline 
APC mutation22,23 and there is evidence that additional inherited factors, determined by so-called 
modifier genes, influence the FAP phenotype24. The murine counterpart of human FAP, the ApcMin/+ 
mouse model, shows great phenotypic variability depending on the genetic background25. Two 
modifier loci, Mom1 and Mom2 (Modifier of Min), have been identified that significantly affect polyp 
multiplicity26,27. The secretory phospholipase A2 (Pla2g2a) gene, which is part of the prostaglandin 
synthesis pathway involved in inflammation, has been associated with the Mom1 locus28. There is 
little doubt that similar modifier genes exist in humans29, however it seems that polymorphisms in 
the human orthologue of Pla2g2a do not account for significant variation in susceptibility to 
colorectal cancer30. 
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The cancer stem cell hypothesis 
 
Normal stem cells and cancer cells share several important properties. These include the capacity 
for self-renewal, the ability to differentiate, active telomerase expression, activation of anti-
apoptotic pathways, increased membrane transporter activity and ability to migrate31. At present, 
an increasing body of evidence indicates that tumor initiation might be orchestrated by cancer stem 
cell-like cells. The existence of cancer stem cells was first documented in hematological 
malignancies where only a subset of cancer cells, representing the stem cell subset with the 
potential to self-renew and differentiate, were capable of forming new tumors32. More recently, 
cancer stem-cell like cells have also been identified in breast33,34 and central nervous system 
tumors35-38. The cancer stem cell concept suggests that cancers originate in tissue stem or 
progenitor cells through dysregulation of self-renewal pathways. This subsequently leads to 
expansion of the cell population that then may undergo further genetic and epigenetic changes to 
become fully transformed. It is still not clear if the cancer stem cells are derived from true tissue-
derived stem cells, bone marrow stem cells or mature cells that have undergone a de-
differentiation process. Regardless, the observation that cancer stem cells give rise to 
phenotypically diverse cancers has fundamental implications for understanding the biology of 
carcinogenesis as well as important clinical implications for early detection, prevention, and 
therapy of human malignancies. 
 
 
TUMOR MICROENVIRONMENT 
 
Apart from genetically abnormal cancer cells, a tumor is composed of several other cell types 
including fibroblasts, endothelial cells and immune cells such as macrophages and mast cells. It is 
clear that tumor progression is the product of an evolving crosstalk between different cell types 
within the tumor and its surrounding supporting tissue, or tumor stroma39. Cancer cells generate a 
supportive microenvironment by producing stroma-modulating growth factors and proteases acting 
in autocrine and paracrine manners. The activated stromal cell types in turn, secrete additional 
fluxes of growth factors and proteases, resulting in an activated stroma that promotes tumor 
progression and metastasis. The extensive crosstalk between the microenvironment and the cancer 
cells induces a cascade of stromal reactions such as angiogenesis40, inflammation41 and remodeling 
of the extracellular matrix42. There is increasing evidence that the tumor stroma can also have a 
more direct role in tumorigenesis, by acting as a mutagen. As a consequence of mutations in stromal 
cells, the adjacent epithelial cells may be at an increased risk of neoplastic transformation43. The 
concept of neoplastic transformation as a result of an abnormal microenvironment, can be thought 
of as a ‘landscaper’ defect44. 
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THERAPEUTIC TARGETING 
 
Elucidating the molecular mechanisms leading to cancer development offers a unique potential for 
therapeutic intervention. During the last years, dramatic advances have come from agents 
specifically targeting critical genetic lesions. The tyrosine kinase inhibitor imatinib (Gleevec, 
Novartis), for example, has tremendously improved the treatment of advanced sporadic 
gastrointestinal stromal tumors, showing a clinical benefit in up to 80% of patients with KIT or 
PDGFRA mutations45,46. Another relatively new and particularly promising approach is the clinical 
targeting of the tumor microenvironment. It is clear that anti-angiogenic47 and anti-inflammatory 
drugs48, together with components restoring the extracellular matrix49, can act as chemopreventive 
agents. Nevertheless, there is still an overwhelming need to develop more effective and safer 
agents to minimize cancer morbidity and mortality in the long term. 
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NEUROFIBROMATOSIS TYPE 1 
 
 
Neurofibromatosis type 1 (NF1; OMIM 162200, http://www.ncbi.nlm.nih.gov/Omim) is one of the 
most common autosomal dominant genetic disorders, affecting approximately 1 in 3500 individuals 
worldwide50,51. The condition is caused by defects in the NF1 tumor suppressor gene. The primary 
clinical features are café-au-lait spots, skin-fold freckling and neurofibromas. Characteristic for NF1 
is its extreme clinical variability. 
 
 
CLINICAL ASPECTS OF NF1 
 
The most common manifestations in NF1 are pigmentary abnormalities, such as café-au-lait spots, 
skin-fold freckling and Lisch nodules (iris hamartomas), together with the development of benign 
peripheral nerve sheath tumors or neurofibromas. However, other complications, such as skeletal 
dysplasias, learning disabilities, mental retardation, seizures and optic gliomas fall within the wide 
clinical spectrum of the disease50. Table 1 displays the diagnostic criteria of NF1 following the 
National Institutes of Health (NIH) guidelines52. Patients are diagnosed with NF1 if they demonstrate 
two or more of these criteria. 
 
Table 1. Diagnostic criteria for NF1 according to NIH Consensus Conference in 1987. 
● Six or more café-au-lait spots of over 5 mm in prepubertal individuals and over 15 mm in 
postpubertal individuals 
● Two or more neurofibromas of any type or one plexiform neurofibroma 
● Freckling in the axillary or inguinal regions 
● Optic glioma 
● Two or more Lisch nodules (iris hamartomas) 
● A distinctive osseous lesion such as sphenoid dysplasia or thinning of long bone cortex with 
or without pseudoarthrosis 
● A first-degree relative (parent, sibling or offspring) with NF1 by the above criteria 
 
 
THE NF1 GENE AND PROTEIN 
 
NF1 gene 
 
The NF1 gene was identified by positional cloning in 199053-55. It is located on chromosome 17q11.2 
and spans approximately 300 kb of genomic DNA56. The NF1 promotor is embedded in a ~10 kb CpG-
rich region and contains several conserved transcription factor binding motifs57. From the start to 
the stop codon the NF1 gene measures 278861 bp58. The NF1 gene is composed of 60 exons with at 
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least 4 alternatively spliced exons which are expressed in a developmental- and tissue- specific 
pattern59-62. The processed full-length NF1 mRNA transcript can be detected in nearly all adult 
tissues and is about 11 to 13 kb in length, with a 3.5 kb 3’-untranslated region63-65. 
 
Numerous NF1-related sequences are distributed throughout the human genome. These NF1 
pseudogenes are suggested to have arisen by duplication and transposition of the NF1 locus. They 
are non-processed and non-functional66,67. Three genes, OMGP, EVI2A and EVI2B, are embedded in 
NF1 intron 27b and are transcribed in the opposite orientation68,69. There is no apparent correlation 
between these genes and the NF1 phenotype. 
 
The mutation rate in the NF1 gene is one of the highest among human genes and about half of the 
NF1 patients are sporadic, i.e. they do not have a familial history for NF170,71. Although mutation 
analysis has been proven to be difficult and labour intensive due to the large size of the gene, the 
presence of several pseudogenes, the lack of mutation hotspots and the very diverse spectrum of 
NF1 lesions, the NF1 mutation can be identified in the vast majority of NF1 patients fulfilling the 
NIH criteria if a comprehensive approach for mutation detection is applied72. 
 
NF1 protein 
 
The NF1 gene encodes neurofibromin, a 2818 amino acids (AA) containing protein that harbors a 
functional GAP (GTPase activating protein) related domain (GRD, AA 1205-1536) in its central 
region73-75. Neurofibromin is ubiquitously expressed and most abundant in the nervous system58. The 
protein is highly conserved among vertebrates76 and shows 60% identity with the Drosophila 
homolog77. 
 
Neurofibromin functions as a negative regulator of Ras-mediated signaling (Figure 3). Ras proteins 
are small molecular weight GTPases that link cell surface receptors to intracellular effector 
pathways that regulate proliferation, differentiation and apoptosis. Downstream effectors of Ras 
include the Raf/Mek/Erk, PI3Kinase/AKT and Rho GTPase pathways. Ras also activates a family of 
GDP-GTP exchange factors for the Ral small GTPases (e.g. Ral-Gds). Ras switches between active, 
GTP-bound, and inactive, GDP-bound, conformations. This GTPase cycle is catalyzed by interactions 
with guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs)78. Through 
its GRD, neurofibromin accelerates the conversion of active GTP-bound Ras to the inactive GDP-
bound form73-75. Increased activity of Ras and its downstream effectors has been observed in NF1-
associated tumors and NF1-deficient cells79-88. Thus, NF1 acts as a tumor suppressor gene since loss 
of neurofibromin function results in dysregulated Ras activity and aberrant growth. Importantly, the 
consequences of activated Ras are pleiotropic and the mechanisms and signaling pathways by which 
Ras effects its biological consequences might exhibit significant species-specific and tissue-specific 
differences89. Mutations of many genes in the Ras pathway have been detected in a variety of 
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human cancers90. Moreover, reduced expression of a conserved microRNA (let-7) that targets the 3’-
untranslated region of Ras mRNA has been associated with elevated Ras activity in lung tumors14,91. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Neurofibromin (NF1) and Ras regulation. 
Neurofibromin modulates intracellular signaling that originates from receptor tyrosine kinases 
(RTKs) by accelerating inactivation of active GTP-bound Ras. Loss of neurofibromin leads to 
increased activity of Ras and its downstream effectors resulting in dysregulated cell growth 
(adapted from92). 
 
The Ras-GAP domain of neurofibromin comprises only 13% of the entire polypeptide, what has raised 
the question whether other regions of the molecule are important for modulating cell growth or 
other processes involved in NF1-related disease. Initial studies in Drosophila have shown that 
neurofibromin acts not only as a Ras-GAP, but also as a regulator of the cAMP pathway by regulating 
adenylyl cyclase (AC) activity (Figure 4)77,93. Activation of the Gα subunit of G-protein coupled 
receptors (GPCRs) upon ligand binding, stimulates the enzyme AC that synthesizes cyclic AMP 
(cAMP) from ATP. Cyclic AMP activates the cAMP-dependent protein kinase A (PKA), which in turn 
phosphorylates target proteins involved in a wide range of biological responses94. The NF1-regulated 
AC/cAMP pathway is important for controlling body size77, neuropeptide responses93 and learning95 
in flies, as well as neuropeptide-stimulated AC activity in both flies and mammals96,97. Only 
recently, it was shown that, in Drosophila brains, AC can be activated by at least three distinct 
pathways: an NF1/Ras-dependent, an NF1/Gα-dependent and a classical NF1-independent 
pathway98. Analysis of human NF1 mutations and deletions, expressed in flies without NF1, showed 
that separate domains of neurofibromin control the different AC pathways. RasGAP activity is 
necessary for NF1/Ras-dependent but not NF1/Gα-dependent AC signaling, whereas part of the C-
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terminal region (AA 1748-2818) is sufficient for NF1/Gα-dependent AC signaling and regulation of 
body size98. The functionality of human neurofibromin in the fly system, and the high degree of 
identity between human and fly homologs, suggests that distinct protein domains influencing 
different pathways for AC activation may also be operative in mammals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Neurofibromin (NF1) and adenylyl cyclase (AC) regulation. 
In Drosophila brains, neurofibromin modulates intracellular signaling that originates from G-protein 
coupled receptors (GPCRs) by regulating AC activity. AC can be activated by at least three distinct 
pathways: an NF1/Ras-dependent, an NF1/Gα-dependent and a classical NF1-independent pathway 
(adapted from98). 
 
Homology searches have revealed several other putatively functional domains in the NF1 protein. 
Neurofibromin shares high homology with the lipid-binding domain of Saccharomyces cerevisiae 
Sec14p99,100, which mediates the exchange of phospholipids between membrane bilayers101. The 
inhibition of neurofibromin RasGAP activity by specific lipids102,103 suggests that Ras GTPase function 
may be co-regulated by this putative lipid-binding domain (AA 1562-1714). The Sec14p domain 
overlaps with a protein sequence containing four caveolin-binding domains (AA 1601-2110)104. 
Caveolin proteins have been shown to bind to signaling molecules, such as Ras, within cholesterol-
rich lipid raft microdomains105,106. Both putative lipid-binding domains may target neurofibromin to 
the plasma membrane, where the Ras protein is located. 
Yeast two-hybrid screening revealed that two widely separated regions in neurofibromin (AA 1356-
1562 and AA 2616-2812) can bind to syndecan107. The syndecan family of transmembrane proteins is 
believed to play roles in cell adhesion and intercellular signaling, often acting as binding sites for 
growth/differentiation factors and as co-receptors for conventional receptors108,109. The binding of 
neurofibromin to syndecan provides again a potential mechanism for localizing neurofibromin in 
specialized molecular microdomains with specific cell surface receptors and other cell signaling 
molecules. 
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A functionally active nuclear localization signal has been characterized in exon 43 of NF1110. 
Translocation to the nuclear compartment could be a mechanism to regulate the RasGAP function of 
neurofibromin by sequestration from the cytoplasm. Alternatively, neurofibromin may have a 
specific but yet unknown function in the nucleus.  
Upstream of the GRD, neurofibromin contains a cysteine- and serine-rich domain (CSRD, AA 543-
909), harboring three potential PKA recognition sites which are constitutively phosphorylated64,111. 
Also the C-terminal region of the protein (AA 2260-2818) is constitutively phosphorylated by PKA112. 
Therefore, phosphorylation-dependent NF1-associated proteins may have regulatory effects on the 
function of neurofibromin. 
Neurofibromin has been shown to associate with the three major cytoskeletal systems: the 
microtubule (tubulin)113-115, microfilament (actin)116-118, and filamentous (keratin)119,120 cytoskeleton. 
Closely related to the cytoskeleton is the association of neurofibromin with the motor protein 
kinesin-1121. Moreover, an interaction between the amyloid precursor protein (APP) and the GRD of 
neurofibromin was identified122. APP has been proposed to function as a vesicle cargo receptor for 
kinesin-1 in neurons123 and melanocytes124. Together, these observations suggest a role for 
neurofibromin in cytoskeletal-mediated intracellular signal transduction pathways and vesicular 
cargo transport. 
 
 
GENOTYPE-PHENOTYPE CORRELATIONS IN NF1 
 
A hallmark of NF1 is the extreme clinical heterogeneity, even among related individuals carrying the 
same NF1 mutation. Although the major diagnostic features are present in the large majority of 
affected individuals, the number and location of lesions varies enormously. In addition, NF1 patients 
are prone to other phenotypic features. As a result, the clinical phenotype varies from mild 
manifestations to severe morbidity. Epidemiologic studies suggest that the molecular basis 
underlying this phenotypic variability is determined to a large extent by the genotype at modifying 
loci and that these modifying genes are trait specific125-128. Unlike the highly penetrant mutations in 
TSGs, polymorphic modifier genes exert a more subtle effect by changing the efficiency of different 
steps in tumorigenesis. These steps could occur within the tumor cell, such as the efficiency of cell 
cycle checkpoints or DNA repair, or systematically in the organism, such as the efficiency of 
antitumor immune responses129. 
 
Five percent of NF1 patients have a constitutional microdeletion that encompasses NF1 and its 
neighbouring genes. A total of seventeen genes are located in the typical ~1.5 Mb NF1 microdeletion 
region130. In comparison with the general NF1 population, individuals with an NF1 microdeletion 
frequently show a phenotype with more dermal neurofibromas at an earlier age, a lower average 
IQ131 and facial dysmorphy132-135. In addition, an increased risk for the development of malignant 
peripheral nerve sheath tumors (MPNSTs) has been reported136. As yet, the biological basis for this 
association remains unclear. 
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NF1-ASSOCIATED TUMORS 
 
The most common NF1-associated tumor is the benign peripheral nerve sheath tumor or 
neurofibroma. Neurofibromas have been subdivided into localized neurofibromas, which are 
discrete lesions associated with a single peripheral nerve, diffuse neurofibromas, which are more 
extended beyond the confines of the nerve, and plexiform neurofibromas, which involve multiple 
nerve fascicles. In a small percentage of NF1 patients, plexiform neurofibromas progress to 
malignant peripheral nerve sheath tumors (MPNSTs). NF1 patients are also predisposed to astrocytic 
brain tumors, spinal tumors, pheochromocytoma, myeloid leukemia and gastrointestinal stromal 
tumors50,137. 
 
Neurofibroma 
 
Cutaneous neurofibromas grow as discrete lesions in the dermis or subcutis and are the most 
common type of neurofibroma encountered in NF1. They typically arise during the second decade of 
life, are often associated with the onset of puberty, and continue to increase in number and size 
throughout adulthood. In females, there is often a clear increase in number and size during 
pregnancy. While these tumors are benign, patients can develop thousands of them which, 
depending on location, can be painful and disfiguring. Plexiform neurofibromas are more diffuse and 
can develop internally, sometimes involving an entire limb or body region. They represent 
congenital tumors that seem to enlarge more rapidly during the first decade of life. They can be 
debilitating and can progress to malignancy50. Plexiform neurofibromas are virtually pathognomonic 
for NF1. Diffuse neurofibromas are an uncommon but distinctive form of neurofibroma occuring 
principally in the head and neck region of children and young adults. About 10% of patients with this 
lesion also have NF1. 
 
Histopathology 
Normal peripheral nerve 
Peripheral nerves are complex well-organized structures in which single peripheral nerve fibers are 
wrapped by one Schwann cell that forms a protective sheath. The peripheral nerve sheath provides 
structural and metabolic support to nerves and, in the case of myelinated fibres, potentiates the 
conduction of action potentials. Several nerve fibers and associated Schwann cells are clustered 
into a nerve bundle (or fascicle) and each fascicle is surrounded by concentric layers of perineurial 
cells. Multiple nerve fascicles, bound by loose connective tissue, constitute an individual nerve 
(Figure 5a). Different cell types are present in a normal nerve fascicle: neural cells, Schwann cells, 
perineurial cells, fibroblasts, endothelial cells and occasionally mast cells. During development and 
regeneration following injury, the migration, proliferation, survival, growth arrest, and 
differentiation of each of these cell types is dependent on cues from surrounding cells138. 
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Peripheral nerve sheath tumor 
During neurofibroma formation, cell-cell interactions are disrupted, leading to the loss of the 
normal nerve structure. Schwann cells are found dissociated from nerves and the perineurium is 
disrupted. In addition, neurofibromas contain increased numbers of all cell types present in the 
normal peripheral nerve. The most abundant cell type in this complex are Schwann cells, which 
comprise 60-80% of the cell population (Figure 5b)139. The mixed cell composition in a myxoid 
background is important for diagnosis of neurofibromas and can be confirmed by 
immunohistochemistry, which shows a subset of S100 protein-positive cells (Schwann cells). The 
lesions are often transversed by nerve axons (positive neurofilament immunostaining) and may 
contain varying amounts of collagen fibers and mast cells140. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Normal peripheral nerve and model of neurofibroma development. 
(A) Peripheral nerves are comprised of multiple cell types: neurons (pale blue) with surrounding 
Schwann cells (red), perineurial cells (blue) and fibroblasts (yellow). Occasional mast cells are also 
observed (green). (B) Neurofibromas exhibit an increased number of all cell types. In addition, 
Schwann cells are often dissociated from neurons and the perineurium is disrupted. (C) 
 25
Chapter 1 
Neurofibroma development is initiated by mutation or loss of the inherited wild-type NF1 allele in 
Schwann cells (pink cells are NF1-/-). This may trigger tumor development by initiating a cascade of 
changes in other cell types as a result of their interdependency and/or haploinsufficiency (adapted 
from141). 
 
Model of neurofibroma development 
Neoplastic Schwann cell 
Molecular analyses of neurofibromas have shown that only a subpopulation of the Schwann cells 
(SCNF1-/-) in these tumors exhibit biallelic inactivation of the NF1 gene142-144. First, genotyping the 
NF1 locus in an NF1-associated neurofibroma and the derived Schwann cells and fibroblasts, 
revealed loss of heterozygosity (LOH) in both the original tumor and the Schwann cells, but not in 
the tumor-derived fibroblasts142. Second, it was demonstrated that fibroblasts isolated from 
neurofibromas carried at least one normal NF1 allele and expressed both NF1 mRNA and protein, 
whereas the S100 positive cells typically lacked the NF1 transcript143. Third, using a cell culture 
system that allows isolation and selective expansion of human Schwann cells from neurofibromas145, 
pure populations of Schwann cells and fibroblasts were grown from 10 neurofibromas with 
characterized constitutional and somatic NF1 mutations. It was found that Schwann cells, but not 
fibroblasts, harbored the somatic NF1 mutation in all studied tumors. Moreover, by culturing 
neurofibroma-derived Schwann cells under different in vitro conditions, the authors were able to 
obtain two genetically distinct (NF1+/- and NF1-/-) Schwann cell subpopulations144. The other cellular 
elements are genetically heterozygous for an inactivating NF1 mutation (NF1+/-). Accordingly, based 
on Knudson’s two-hit hypothesis4, Schwann cells can be considered as the initiating cell type in 
neurofibroma formation (Figure 5c). Neurofibromin-deficient Schwann cells demonstrate increased 
Ras activity and have a substantial growth advantage compared with the other neurofibroma-
derived cellular components80,146. Moreover, they have angiogenic and invasive properties147. It is 
unclear whether interdependence between both hits, as described for FAP and sporadic polyps, 
exists. 
 
NF1 mouse models confirm that NF1 loss in Schwann cells is the genetic bottleneck for neurofibroma 
formation. Because Nf1+/- mice don’t develop neurofibromas148 and Nf1-/- mice die during 
embryogenesis148,149, the question of second-hit mutation in murine neurofibroma development was 
addressed experimentally through the creation of chimeric mice partially composed of Nf1-/- 
cells150,151. Nearly all of these mice develop numerous neurofibromas that histologically resemble 
human plexiform neurofibromas. To identify the initiating cell type, Zhu and coworkers generated a 
conditional NF1 mouse model in which a floxed Nf1 allele is deleted by a Cre transgene under 
control of the Schwann cell-specific promoter, Krox-20. All progeny with the Nf1flox/-;Krox20-Cre 
genotype develop plexiform neurofibromas, confirming that Nf1 loss in the Schwann cell lineage is 
sufficient to generate tumors152. 
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Tumor microenvironment 
To address whether the heterozygous state of NF1 in somatic cells other than the tumor-initiating 
Schwann cell plays an active role in neurofibroma formation, Zhu and coworkers constructed 
Nf1flox/flox;Krox20-Cre mice that have intact Nf1 function in all cells (Nf1+/+), except in the Schwann 
cells (SCNf1-/-). In contrast to the wide-spread plexiform neurofibromas of the Nf1flox/-;Krox20-Cre 
mice, the Nf1flox/flox;Krox20-Cre mice only developed small, infrequent hyperplastic lesions152. This 
finding has led to the emerging view that NF1 heterozygosity in the tumor environment actively 
contributes to neurofibroma formation. Implicit is the requisite that heterozygous inactivation of 
NF1 has functional consequences (haploinsufficiency). 
 
Mast cells accumulate in the stroma of certain tumors and selectively secrete molecules involved in 
growth promotion, neovascularization and remodeling of the ECM153. Mast cells show marked 
infiltration in neurofibromas and have been considered as a major player in neurofibroma 
formation154,155. It has been demonstrated that Nf1+/- mast cells have increased survival and 
proliferation, and are hypermigratory compared to wild-type cells in response to Kit Ligand (KitL) 
secreted by Nf1-/- Schwann cells. Reintroduction of the GRD into Nf1+/- mast cell reduces their 
migration to wild-type levels in response to KitL, providing direct evidence that an Nf1+/- motile 
phenotype is secondary to increased Ras activity84,156,157. Together, these findings illustrate that Nf1-
/- neoplastic cells alter the tumor microenvironment by secreting growth factors and that the 
haploinsufficient state of non-neoplastic cells might be permissive for the progression of 
tumorigenesis. 
 
It is likely that other cells within the tumor microenvironment contribute to neurofibroma 
progression by similar paracrine interactions. Previous studies, for example, have shown that Nf1-/- 
Schwann cells secrete increased concentrations of various angiogenic growth factors, such as 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and platelet-
derived growth factor (PDGF)82,158-160. Further, Nf1+/- mast cells secrete increased concentrations of 
VEGF and bFGF161. There is recent genetic and biochemical evidence that, in response to bFGF and 
VEGF, Nf1+/- endothelial cells have increased migration and proliferation properties162-164 and that 
Nf1+/- fibroblasts are hypersensitive to low concentrations of PDGF165,166, both via hyperactivation of 
the Ras-Erk pathway. In addition, Nf1+/- Schwann cells are able to induce angiogenesis and are more 
invasive than their wild-type counterparts167 though the biochemical mechanisms for these 
observations are not determined. 
 
Taken together, a growing body of experimental evidence supports the idea that Nf1 
haploinsufficiency in the tumor environment promotes neurofibroma formation in mice. The Nf1 
gene may hence play the role of ‘gatekeeper’ and ‘landscaper’ depending on the tissue type. The 
tumors that have been observed in the murine model to date have been plexiform neurofibromas 
derived from dorsal root ganglia and cranial nerves152. Whether this is a consequence of the 
expression pattern of the Cre transgene used in those experiments or alternatively reflects a slightly 
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different pathogenesis from the dermal neurofibromas remains an important question. Moreover, 
the recurrent discrepancies in the tumor phenotypes between humans and mice, especially in the 
context of Ras-related neoplasms168, emphasize the value of dissecting tumorigenesis in human 
cells. 
 
MPNST 
 
Approximately 10% of individuals with NF1 will develop an MPNST, a clinically aggressive, often fatal 
cancer, which is poorly responsive to chemotherapy or radiation. Some MPNSTs arise in pre-existing 
plexiform neurofibromas implying a model of multi-step tumor progression, as has been 
demonstrated for the adenoma-carcinoma sequence. Besides NF1 inactivation, additional genetic 
changes have been identified in MPNSTs but not in benign neurofibromas. Alterations required for 
malignant progression include homozygous deletion of CDKN2A which encodes p16INK4A and p14ARF 
169,170, TP53 loss171,172, and inactivation of CDKN1B encoding p27KIP 173. Aberrant expression of the 
epidermal growth factor receptor (EGFR) has also been implicated in the development of MPNST in 
humans and in mouse models174-176. 
 
Mice carrying Nf1 and Trp53 mutations on the same chromosome (cisNf1/Trp53 mice) develop tissue 
sarcomas that resemble MPNSTs150,151. Tumor susceptibility in this mouse model appears to be highly 
dependent on the genetic background177. Recent evidence suggests that genetic interaction 
between an imprinted locus, linked to Nf1 and Trp53, and other polymorphic susceptibility loci 
strongly modifies the incidence of MPNSTs in mice129. The relevance of these results to NF1 patients 
will need to be tested by human association studies. 
 
Other NF1-associated tumors 
 
While defects in glial cells in the peripheral nervous system (Schwann cells) underlie neurofibroma 
development, NF1 patients are also predisposed to developing gliomas or astrocytomas, tumors 
derived from glial cells in the central nervous system (astrocytes). Between 15% and 50% of NF1 
patients develop some type of glioma, although they are often indolent in nature58. Similar to 
neurofibroma formation, Nf1 loss in astrocytes alone is insufficient for murine glioma formation178. 
Factors produced by the Nf1+/- brain environment are possibly required for the formation of low-
grade tumors179. High-grade glioma has been observed in cisNf1/Trp53 mice177. However, high-grade 
gliomas in individuals with NF1 do not develop from pre-existing low-grade tumors. 
 
Juvenile myelomonocytic leukaemia (JMML) is a relentless myeloid malignancy of young children 
characterized by overproduction of myeloid lineage cells that infiltrate hematopoietic and non- 
hematopoietic tissues180,181. The incidence of JMML is increased more than 200-fold in children with 
NF1182. Studies on human NF1 leukemia-derived tumor cells have shown that neurofibromin loss in 
bone marrow cells183,184, which is associated with hyperactive Ras87, results in hypersensitivity to 
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granulocyte-macrophage colony stimulating factor (GM-SCF), which promotes the survival, 
proliferation and differentiation of myeloid lineage cells185. 
 
Spinal nerve sheath tumors are described as symptomatic findings in ~2% of NF1 patients, but can be 
visualized by magnetic resonance imaging (MRI) in ~40% of NF1 patients186. The wide, symmetrical 
distribution of spinal neurofibromas occurring in all adult affected members of the same family and 
segregating in an autosomal dominant fashion, is however extremely rare. Besides café-au-lait 
spots, other typical cutaneous manifestations of NF1 are usually absent or very mild in these 
patients. Familial spinal neurofibromatosis (FSNF, OMIM 162210) has therefore been considered as 
an ‘alternate’ form of NF1. It is noteworthy that the NF1 mutations found in the FSNF families are 
mild mutations, i.e. truncating mutations at the very 3’ end of the gene, splicing and missense 
mutations187,188. It has been suggested that modifier genes might cooperate with the NF1 mutation 
to result in FSNF187. 
 
Pheochromocytomas usually arise within the adrenal medulla and are catecholamine-secreting 
tumors that can present with hypertension. Inherited cancer syndromes with pheochromocytoma as 
a component feature include von Hippel-Lindau syndrome (OMIM 193300), multiple endocrine 
neoplasia type 2 (OMIM 171400) and, to a much lesser extent, NF1189. Somatic NF1 inactivation is 
the underlying mechanism of NF1-associated pheochromocytoma development190. 
 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract191. KIT and PDGFRA activating mutations are the oncogenic mechanisms in 
most sporadic GISTs192,193. In addition to sporadic occurrences, GISTs are increasingly being 
recognized in association with NF1137, yet the underlying pathogenic mechanism remains elusive. 
 
 
THERAPEUTIC TARGETING 
 
Therapeutic interventions designed to inhibit Ras function have been proposed as treatments for 
NF1194. One approach is the administration of molecules that inhibit the enzyme farnesyl 
transferase. Post-translational farnesylation of Ras proteins is absolutely necessary for Ras function 
since this modification is required for anchoring of Ras to the plasma cell membrane where it exerts 
its function195. Preclinical studies have shown that farnesyl transferase inhibitors (FTIs) decrease 
hyperproliferation of neurofibromin-deficient Schwann cells167,196. FTIs have found their way into 
clinical trials for NF1-associated plexiform neurofibromas197,198. Statins, commonly used agents to 
prevent cardiovascular disease, function in the mevalonate pathway as small-molecule inhibitors of 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Besides reducing cholesterol levels, 
statins also inhibit the formation of lipid isoprenoids such as farnesyl and geranylgeranyl 
pyrophosphate with beneficial effects on cancer prevention199. Recently, it was reported that 
lovastatin decreased the enhanced brain Ras-MAPK activity in Nf1+/- mice and reversed their 
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learning and attention deficits200. These observations demonstrate that statins may prove useful in 
the treatment of various NF1-related symptoms. In addition, it might be important to consider 
targeting more specific downstream effectors of Ras. Aberrant activation of mTOR in Nf1-deficient 
cells, for example, depends on Ras and PI3K, which inactivate the TSC2 gene product tuberin via 
AKT (Figure 3)83. Importantly, tumor cell lines derived from NF1 patients are highly sensitive to the 
mTOR inhibitor rapamycin83, suggesting the potential utility of rapamycin and its derivatives in 
treating NF1 tumors. Another biological-based therapeutic approach may include pharmacological 
inhibition of KIT activity by Gleevec in order to reduce mast cell infiltration into neurofibromas156. 
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RESEARCH OBJECTIVES 
 
 
One major effort in NF1 research has been to dissect the genetic events underlying different 
aspects of disease development. While determining when and in what cell type the crucial 
molecular defect actually occurs, is critical for understanding the basic pathology of any phenotype, 
this exercise has proven to be surprisingly difficult for many NF1-related symptoms. Impeding 
factors include the large size of the NF1 gene, the presence of several NF1 pseudogenes, the 
complex interactions between cell types within affected tissues, and the NF1 heterozygous state of 
all cells in the body. In order to gain insight in the developmental concepts underlying various NF1-
related symptoms, this thesis aimed at exploiting improved somatic mutation detection strategies 
on a diverse spectrum of NF1-associated cellular entities. 
 
(1) Characterization of the somatic mutation spectrum in neurofibromas 
Since characterization of somatic mutational spectra may provide important clues about different 
aspects of tumorigenesis, the first research objective of this thesis was to investigate thoroughly the 
status of the somatically affected NF1 allele in neurofibromas. To this purpose, we developed an 
improved somatic mutation detection strategy on selectively cultured Schwann cell populations and 
screened a large panel of neurofibromas. In a next step, we compared the germline versus the 
somatic mutation spectrum, studied the interdependence between first and second hits and 
searched evidence for the existence of modifier genes as triggers for particular mechanisms of 
somatic inactivation preceding tumorigenesis. Our initial analyses were suggestive for a different 
mechanism of somatic inactivation between NF1 microdeletion patients and the general NF1 
population. In order to study the putative association between germline mutation and type of 
second hit in further detail, we compared a larger number of neurofibromas from both NF1 patient 
groups. The results of these studies are reported in Papers 1 and 2. 
 
(2) Molecular dissection of isolated disease features in mosaic NF1 patients 
As opposed to classic NF1 where all cells of the body bear at least one mutated NF1 allele, NF1 
segmental phenotypes provide the opportunity to study cell populations differing only with regard 
to the mutation(s) giving rise to the localized disease manifestations. As a second research 
objective, this thesis aimed at molecularly dissecting different clinical subtypes emerging within 
mosaic NF1 in order to gain insight into developmental concepts underlying particular NF1-related 
disease features. To this purpose, we developed a real-time quantitative PCR assay capable of 
detecting low-percentage mosaic point mutations against backgrounds of wild-type and pseudogene 
alleles and investigated mosaic NF1 patients with different clinical manifestations (neurofibromas 
only, pigmentary changes only, and association of both symptoms) at the molecular level. The 
results of these studies are reported in Papers 3 and 4. 
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(3) Identification of the molecular pathogenesis underlying the development of NF1-related 
gastrointestinal stromal tumors 
While KIT and PDGFRA activating mutations are the oncogenic mechanisms in most sporadic 
gastrointestinal stromal tumors (GISTs), the underlying pathogenic mechanism for NF1-related GIST 
development remains elusive. A third goal of this thesis was to gain insight into the mechanisms 
underlying GIST formation in NF1 patients. For this purpose, we studied several NF1-associated 
GISTs with a combination of different techniques: mutation analysis (KIT, PDGFRA and NF1), 
Western blotting, array CGH and ex vivo imatinib response experiments. The results of these studies 
are reported in Paper 5. 
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Neurofibromatosis type 1 (NF1) is mainly characterized by the occurrence of benign peripheral nerve sheath
tumors or neurofibromas. Thorough investigation of the somatic mutation spectrum has thus far been
hampered by the large size of the NF1 gene and the considerable proportion of NF1 heterozygous cells within
the tumors. We developed an improved somatic mutation detection strategy on cultured Schwann cells derived
from neurofibromas and investigated 38 tumors from nine NF1 patients. Twenty-nine somatic NF1 lesions were
detected which represents the highest NF1 somatic mutation detection rate described so far (76%).
Furthermore, our data strongly suggest that the acquired second hit underlies reduced NF1 expression in
Schwann cell cultures. Together, these data clearly illustrate that two inactivating NF1 mutations, in a
subpopulation of the Schwann cells, are required for neurofibroma formation in NF1 tumorigenesis. The
observed somatic mutation spectrum shows that intragenic NF1 mutations (26/29) are most prevalent,
particularly frameshift mutations (12/29, 41%). We hypothesize that this mutation signature might reflect
slightly reduced DNA repair efficiency as a trigger for NF1 somatic inactivation preceding tumorigenesis. Joint
analysis of the current and previously published NF1 mutation data revealed a significant difference in
the somatic mutation spectrum in patients with a NF1 microdeletion vs. non-microdeletion patients with
respect to the prevalence of loss of heterozygosity events (0/15 vs. 41/81). Differences in somatic inactivation
mechanism might therefore exist between NF1 microdeletion patients and the general NF1 population.
Hum Mutat 27(10), 1030–1040, 2006. r 2006 Wiley-Liss, Inc.
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INTRODUCTION
Neurofibromatosis type 1 (NF1; MIM] 162200) is a genetic
disorder affecting one in 3,500 individuals worldwide. The primary
clinical features are cafe´-au-lait spots, skin-fold freckling, and
benign peripheral nerve sheath tumors or neurofibromas [Riccardi,
1992]. Characteristic for NF1 is its extreme clinical variability.
Epidemiologic studies suggest that the molecular basis underlying
this phenotypic variability is determined to a large extent by the
genotype at modifying loci and that these modifying genes are trait
specific [Easton et al., 1993; Szudek et al., 2000, 2002, 2003].
The NF1 gene spans 350 kb of genomic DNA, contains 60
exons, and is transcribed in an 11–13 kb transcript coding for the
protein neurofibromin with an open reading frame of 2,818 amino
acids [Cawthon et al., 1990; Viskochil et al., 1990; Wallace et al.,
1990; Marchuk et al., 1991; Li et al., 1995]. The only known
functional domain of neurofibromin is the GAP related domain
(GRD) which is involved in Ras downregulation [Ballester et al.,
1990; Martin et al., 1990; Xu et al., 1990; Bollag et al., 1996]. In
accordance with Knudson’s two hit hypothesis [Knudson, 1971],
both copies of the NF1 gene have been found to be inactivated in
NF1 related tumors [Xu et al., 1992; Legius et al., 1993; Shannon
et al., 1994; Colman et al., 1995]. NF1 promoter methylation
appears to be an uncommon event in NF1 tumorigenesis [Horan
et al., 2000; Luijten et al., 2000; Harder et al., 2004; Upadhyaya
et al., 2004; Fishbein et al., 2005].
Neurofibromas are comprised of multiple cell types, including
Schwann cells, mast cells, perineurial cells, fibroblasts, and
endothelial cells [Riccardi, 1992]. Schwann cells are the most
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prevalent cell type in this complex and have been proposed to be
the tumorigenic cell population [Kluwe et al., 1999; Rutkowski
et al., 2000; Serra et al., 2000]. Notably, only a subpopulation
of the Schwann cells harbors the somatic NF1 alteration [Serra
et al., 2000].
Thorough investigation of the somatic mutation spectrum has
thus far been hampered by the large size of the NF1 gene and
the considerable proportion of NF1 heterozygous cells within
the tumors. Here we show that these problems can be resolved
by performing comprehensive analysis of the NF1 gene on
selectively cultured Schwann cell populations of neurofibromas.
Comparison of the germline vs. the somatic mutation spectrum
and the study of the interdependence between first and second
hits might reveal genotypes with a higher risk for tumorigenesis.
Furthermore, comparison of somatic mutation spectra in different
types of tumors and patients might reflect distinct mutational
mechanisms and might provide evidence for the existence of
modifier genes as triggers for particular mechanisms of somatic
inactivation preceding tumorigenesis.
MATERIAL ANDMETHODS
Tumor Specimens
Thirty-eight dermal neurofibromas were obtained from nine
unrelated NF1 patients who signed informed consent. All patients
fulfilled the NF1 clinical criteria established by the NIH [Stumpf
et al., 1988]. Since patients with a high tumor burden are more
likely to undergo neurofibroma excision for reasons of discomfort,
the individuals included in this study may have been biased
towards those NF1 patients with a more severe tumor phenotype.
Indeed, compared to the age-matched NF1 population [Huson
et al., 1988], most individuals suffered from a severe to excessive
neurofibroma burden.
Schwann Cell Culture
Culture conditions for neurofibroma derived Schwann cells
were as described by Rosenbaum et al. [2000] and Serra et al.
[2000]. The presence of forskolin in the Schwann cell medium
promotes proliferation of cells bearing only the germline mutation
(SC F1). Replacement of proliferation medium by serum-free N2
medium [Bottenstein and Sato, 1979] followed by proliferation
medium without forskolin, promotes proliferation of cells contain-
ing both hits (SC F-). To estimate the purity of Schwann cell
cultures, immunofluorescence was performed. Briefly, fixated
cells were incubated for 1 hr at room temperature with rabbit
S100 primary antibody (1/1000) (Dako; www.dako.com). Alexa
Fluor 488 goat anti-rabbit antibody (1/1000) (Molecular Probes;
http://probes.invitrogen.com) was added for 45min at room
temperature. Cells were mounted with Vectashield (Vector;
www.vectorlabs.com) plus 40,6-diamidino-2-phenylindole (DAPI,
Sigma Aldrich; www.sigmaaldrich.com) and analyzed on a Zeiss
(www.zeiss.com) fluorescence microscope. Cells were passaged
when cultures were confluent and harvested not earlier than at
passage four.
NF1Mutation Analysis
NF1 mutation analysis (GenBank reference sequence
NM_000267.1, www.ncbi.nlm.nih.gov/GenBank) was performed
essentially as described by Messiaen et al. [2000]. Briefly, genomic
DNA (gDNA) was extracted from Schwann cell cultures with
the QiaAmp procedure (Qiagen; www.qiagen.com) following the
manufacturer’s instructions. Schwann cell cultures were treated
with puromycin (200mg/ml, 4–6 hr) before RNA extraction
(RNeasy kit, Qiagen). The entire NF1 complementary DNA
(cDNA) was sequenced using the ABI3100 genetic analyzer
(Applied Biosystems; www.appliedbiosystems.com). All mutations
found at the cDNA level were confirmed on gDNA by cycle
sequencing. Detection of loss of heterozygosity (LOH) in the NF1
gene was performed by genotyping two microsatellite markers
distal from (30NF1-3, 30NF1-1) [Lopez Correa et al., 1999] and
four within the NF1 gene (Alu, IVS27AC33.1, IVS38GT53.0,
IVS27TG24.8) [Xu et al., 1991; Lazaro et al., 1993a,b, 1994].
Genomic DNA from paired Schwann cell and lymphocyte cultures
was investigated by three sets of multiplex PCR for the
microsatellite markers and subsequently analyzed on the
ABI3100 genetic analyzer (Applied Biosystems) with the Genes-
can software version 3.7 (Applied Biosystems). In case no somatic
hit was detected with the previous techniques, multiplex
ligation-dependent probe amplification (MLPA) analysis using
the P081/P082 kit (MRC Holland; www.mrc-holland.com) was
performed following the manufacturer’s instructions.
Semiquantitative Mutation Screening
In order to determine putative traces of SCNF1–/– in SC F1
cultures and NF11/– cells in SC F cultures, a semiquantitative
assay was performed on the tumors with detected somatic hits (SC
F) from patients NF96-1 (tumors A, B, C, and E), NF253-UHG
(tumors D and E), and L-004 (tumors B and D). SC F1, SC F and
control gDNA samples were subjected to PCR amplification using
primers surrounding the respective somatic hit, except for tumors
E and B of patients NF253-UHG and L-004, respectively. PCR
products were sequenced following the BigDye Terminator
Sequencing protocol (Applied Biosystems). A liz-tagged size
standard was added and the samples were analyzed on a
ABI3130XL platform (Applied Biosystems) using a standard
fragment analysis protocol. Using the Genemapper analysis
software version 3.7 (Applied Biosystems), peak height ratios of
the somatic hit were calculated relative to an internal control peak
of the same nucleotide type at least five nucleotides apart and
these ratios were compared to the control gDNA sample (wild-
type sequence). Each gDNA sample was PCR amplified and
sequenced in triplicate. SC F1, SC F, and control cDNA samples
of tumor B from patient L-004 were amplified in a multiplex PCR
using primers in NF1 exon 17 (internal control) and primers
surrounding NF1 exon 23.1. Relative peak heights of amplified
fragments (with/without exon 23.1 and exon 17) were analyzed by
the Genemapper analysis software version 3.7 (Applied Bio-
systems). All analyses were performed in triplicate. For tumor E of
patient NF253-UHG, LOH analysis was performed using six
microsatellite markers as described under the NF1 mutation
analysis paragraph; two markers were informative.
In order to evaluate allele-specific NF1 expression in tumors D
and E from patient NF253-UHG, SC F1 and SC F cDNA
samples were amplified in a multiplex PCR using primers located
in NF1 exon 17 (exclusive amplification of the allele not bearing
the germline NF1 mutation, 100 bp) and TBP (a stable reference
gene in Schwann cells as determined by geNorm (http://
medgen.ugent.be/genorm/) [Vandesompele et al., 2002b], 90 bp).
Relative peak heights of amplified fragments (TBP vs. NF1) were
analyzed by the Genemapper analysis software version 3.7
(Applied Biosystems). All analyses were performed in triplicate.
Real-TimeQuantitative PCR
In order to evaluate the correlation between NF1 messenger
RNA(mRNA) expression, somatic mutation detection, and cell
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admixture, a real-time quantitative PCR assay was performed on
the tumors from patients NF96-1, NF253-UHG, and L-004.
Relative NF1 expression levels were determined using an
optimized two-step SYBR Green I RT-PCR assay [Vandesompele
et al., 2002a] in Schwann cell cultures (SC F1 and parallel SC F).
PCR reagents were obtained from Eurogentec (www.eurogentec.com)
as SYBR Green I mastermixes and used according to the manu-
facturer’s instructions. Primers in NF1 exons 45 and 46 were
previously described [Vandenbroucke et al., 2002]. Reactions were
run on an ABI5700 instrument (Applied Biosystems). NF1 mRNA
expression levels were normalized using the geometric mean of the
three most stably expressed reference genes in Schwann cells (i.e.,
TBP, HPRT1, and HMBS) as determined by the geNorm software
[Vandesompele et al., 2002b]. Automated analysis of real-time
quantitative PCR data was performed using our in-house
developed qBase software which employs a delta-Ct relative
quantification model with PCR efficiency correction and multiple
reference gene normalization (http://medgen.ugent.be/qbase/).
Each sample was tested in duplicate and all PCR runs were
performed twice, starting from newly synthesized cDNA.
Mismatch Repair GeneAnalysis
As a first attempt to determine the putative contribution of
DNA repair variation in NF1 tumor predisposition, we screened
the mismatch repair (MMR) genes MLH1 (GenBank
NM_000249.2, www.ncbi.nlm.nih.gov/GenBank), MSH2 (Gen-
Bank NM_000251.1, www.ncbi.nlm.nih.gov/GenBank), and
MSH6 (GenBank NM_000179.1, www.ncbi.nlm.nih.gov/Gen-
Bank) in peripheral blood lymphocytes of all nine NF1 patients
(eight Belgian and one Dutch). The entire coding regions and
the splice junctions were amplified by PCR using 23 primer pairs
for each gene. All amplicons were subjected to denaturing gradient
gel electrophoresis (DGGE) except for exons 12 (MLH1), exons 1
and 5 (MSH2), and exons 1 and 10 (MSH6), which were analyzed
by direct cycle sequencing. Amplification and DGGE analysis was
performed as described [Wu et al., 1998]. The observed MMR
gene variants p.I219V (MLH1), p.G322D (MSH2), and p.G39E
(MSH6) were screened in a control population (non-NF1
individuals, geographically matched to the NF1 patients under
study) to determine the respective allele frequencies. The
p.G322D (MSH2) variant was tested in 15 additional geographi-
cally matched NF1 patients selected for an excessive neurofibroma
burden compared to the age-matched NF1 population [Huson
et al., 1988].
Microsatellite Instability Analysis
In order to evaluate microsatellite instability in the neurofi-
bromas from patients L-002 and NF482-UHG, SC F cultures
and corresponding blood samples were subjected to PCR using
microsatellite markers for BAT25, BAT26, D2S123, D5S346,
and D17S250 from the reference panel for evaluation of micro-
satellite instability in colorectal tumors [Boland et al., 1998],
together with D18S55, D18S58, and D18S61. PCR products were
analyzed on the ABI3100 genetic analyzer (Applied Biosystems)
with the Genescan software version 3.7 (Applied Biosystems).
Statistical Analysis
A comprehensive overview of the current findings and
previously reported data is shown in Table 4. Only those studies
applying a systematic somatic mutation detection approach
(combination of LOH analysis and search for NF1 intragenic
mutations) were taken into account. These comprise the studies of
Sawada et al. [1996], Eisenbarth et al. [2000], Serra et al. [2001],
Wiest et al. [2003], and Upadhyaya et al. [2004]. Moreover, only
those neurofibromas for which both germline and somatic
mutations were characterized were included in the survey. In
total, 96 neurofibromas derived from 34 NF1 patients were
withheld: 29 neurofibromas from this report and 67 from the
literature. For both groups of mutations (germline and somatic),
distinct categories were made according to the type of mutation
(splice, missense, nonsense, NF1 microdeletion, deletion, inser-
tion, LOH) and their respective region of occurrence within
the NF1 gene (GenBank reference sequence NM_000267.1:
50 (proximal to c.3613), GRD (c.3613_c.4608), 30 (distal to
c.4608)). Fisher’s Exact and Binomial tests were performed using
SPSS 12.0 (www.spss.com) for Windows.
RESULTS
Schwann Cell Culture
By using selective culture media with and without forskolin, we
cultured from each tumor Schwann cells expected to carry only
the first hit (SCNF11/) in parallel with cells expected to carry
both hits (SCNF1/). In general, SC F1 cultures grew at a slower
pace than SC F cultures and fibroblast contamination,
determined by immunofluorescence staining and morphological
evaluation of cell cultures, appeared to be the most persistent
problem. The purity of 22 out of 38 SC F- cultures, estimated by
S100 immunofluorescence staining, is presented in Table 1.
NF1Mutation Analysis and Semiquantitative
Somatic Mutation Screening
Germline mutations were identified in all patients and
confirmed on blood lymphocytes. NF1 somatic mutation analysis
was performed on Schwann cell cultures of 38 dermal neurofi-
bromas derived from nine NF1 patients. Somatic mutations were
found in 29 tumors. Of these, 26 represented subtle mutations of
different types whereas three samples showed LOH of the NF1
region. In summary, 12 small deletions ranging from 1 to 19 bp,
one single exon deletion, seven nonsense mutations, six splicing
mutations (four leading to out-of-frame exonic dropouts), and
three LOH events were detected (Table 1). Semiquantitative
estimation of the percentage of somatic hit in SC F1 and SC
F cultures derived from tumors of patients NF96-1, NF253-
UHG, and L-004 are presented in Table 2.
NF1mRNA Expression in Schwann Cell Cultures
Data from two independent real-time quantitative PCR
experiments were combined (average of normalized logarithmic
NF1 expression levels) and are presented in Table 2 and Figure 1.
The average NF1 expression ratio (SC F1/SC F) of the eight
neurofibromas without detected second hit (tumor D from patient
NF-96-1; tumors A, B, C, and F from patient NF253-UHG; and
tumors A, C, and E from patient L-004) equals 1.08 (95%
confidence interval [CI]: 0.79–1.48). The average NF1 expression
ratio (SC F1/SC F-) of six of the eight neurofibromas with
detected second hit (tumors A, B, and C from patient NF-96-1;
tumors D and E from patient NF253-UHG; and tumor B from
patient L-004) falls outside this 95% CI. Notably, only in the SC
F cultures derived from the six latter tumors (average fold
reduction in NF1 expression being 3.33 [95% CI: 2.20–5.05]), was
a substantially high percentage of somatic hit (31–100%, Table 2)
detected compared to the parallel SC F1 cultures. Moreover,
semiquantitative evaluation of allele-specific NF1 expression in
tumors D and E from patient NF253-UHG revealed that
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decreased expression is due to the allele not bearing the germline
NF1 mutation (data not shown). Since the constitutional
mutation in patient NF96-1 is a NF1 microdeletion, the same
holds true for the tumors of this individual. Taken together, these
data strongly suggest that the acquired second hit results in
reduced NF1 expression (P5 0.0023; Fisher’s Exact test).
Mismatch Repair GeneAnalysis
In all patients, several alterations in MLH1, MSH2, and MSH6
were detected (data not shown). All alterations were known
polymorphisms (InSight database, www.insight-group.org). Those
variants leading to amino acid alterations were selected for further
evaluation, i.e., p.I219V (MLH1), p.G322D (MSH2), and p.G39E
(MSH6). Respective allele frequencies of these variants were
74/184 (40%), 5/364 (1%), and 37/186 (20%) in a control
non-NF1 population, geographically matched to the NF1 patients
under investigation, and 6/18 (33%), 2/18 (11%), and 4/18
(22%) in the NF1 patients (Table 3). Only the frequency of the
p.G322D (MSH2) polymorphism is statistically different
(P5 0.038; Fisher’s Exact test) in the NF1 patients compared
to the control population, but this significance at the 5% level
disappeared after correcting for multiple testing. Analysis of 15
additional geographically matched NF1 patients with a similar
tumor burden did not reveal the MSH2 polymorphism in any
individual. No microsatellite instability could be detected in any
of the analyzed tumors.
Germline vs. Somatic Mutation Spectrum
In order to compare the germline and somatic mutation
spectrum and to explore a putative interdependence between
both, a descriptive and statistical analysis on the germline and
somatic NF1 mutation data set of 96 neurofibromas from 34 NF1
patients was performed. Twenty-nine neurofibromas are described
in this report and the remaining 67 were compiled from the
literature (Table 4). In summary, the 34 germline mutations
include seven splice and nine nonsense mutations, nine small
deletions (1–4 bp), four insertions, and five total NF1 deletions.
Nineteen of these reside in the 50 region of the NF1 gene, while
two and eight mutations, respectively, are present in the GRD and
the 30 region. The 96 somatic hits include 15 splice, 15 nonsense
TABLE 1. Germline and SomaticNF1Mutations in 38 DermalNeuro¢bromas Derived from 9 NF1PatientsTogether With Estimated
Purity of SCF- Cultures
Patient Tumor
NF1
SCFGermline Somatic
L-001 TumorA g.AC127024.4_AC129917.6del (5NF1microdeletion) c.5026_5032del 95%
TumorB c.3189T4A (p.C1063X) 95%
TumorC c.4086_4092del 95%
TumorD c.396_403del 95%
Tumor E c.3774G4A (p.W1258X) 95%
L-002 TumorA c.1246C4T (p.R416X) c.655-1G4T 95%
TumorB c.3757_3764del 95%
TumorC LOH 95%
TumorD c.1105C4T (p.Q369X) 95%
Tumor E c.1153del 95%
TumorF c.246_247del 95%
NF96-1 TumorA g.AC127024.4_AC129917.6del(5NF1microdeletion) c.[7395^1G4A;7395G4A] NA
TumorB c.3330del NA
TumorC c.7438del NA
TumorD ND NA
Tumor E c.2050C4T (p.P684X) NA
L-004 TumorA c.6791dup ND NA
TumorB c.3871-?_39741?del NA
TumorC ND NA
TumorD c.4729del NA
Tumor E ND NA
L-005 TumorA c.311311G4A LOH NA
NF253-UHG TumorA c.28512A4G ND 75%
TumorB ND 70%
TumorC ND 10%
TumorD c.1663_1666del 95%
Tumor E LOH 95%
TumorF ND 95%
NF339-UHG TumorA g.AC127024.4_AC129917.6del(5NF1microdeletion) c.4697T4A (p.L1566X) 95%
TumorB c.2851^2A4G 80%
TumorC c.[1007G4A;1008G4A] (p.W336X) 95%
TumorD c.240911G4A 95%
Tumor E ND 70%
NF482-UHG TumorA c.3525_3526del c.2252-30_2252-6delinsT NA
TumorB c.603_621del NA
TumorC c.118511G4A NA
TumorD c.359_375del NA
NF116-UHG TumorA c.5122dup c.4537C4T (p.R1513X) NA
GenBankNF1 reference sequenceNM_000267.1with mutation numbering beginningwith 11as A of theATG codon.
LOH, loss of heterozygosity; ND, not detected; SC F-, estimated Schwann cell percentage of SC F- cultures determined by S100 immuno£uorescence
staining; NA, no data available.
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and one missense mutation, 22 small deletions (1–31 bp), one
single exon deletion, one insertion, and 41 LOH events. Thirty-
one of the intragenic somatic mutations reside in the 50 region,
10 in the GRD, and 14 in the 30 region of the NF1 gene. Cross
tabulation did not reveal a statistically significant association
between the location of the germline mutation and the location or
type of somatic mutation. The somatic mutation spectrum in
patients with a NF1 microdeletion vs. patients with a minor lesion
as germline mutation was significantly different with respect to the
prevalence of LOH events (0/15 vs. 41/81: P5 0.0001; Fisher’s
Exact test) (Table 5). Thirteen of the 15 neurofibromas with a
germline NF1 microdeletion are described in this report. To avoid
TABLE 2. AssociationBetween Somatic MutationDetection,Cell Admixture andNF1Expression for theTumors of PatientsNF96-1,
NF253-UHG, and L-004
Patient Germline Tumor Somatic C SQ qPCR
NF96-1 NF1microdeletion A c.[7395-1G4A;7395G4A] F1 0% 3.7070.34
F^ 72% 1.0070.09
B c.3330del F1 0% 3.7470.75
F^ 31% 1.0070.09
C c.7438del F1 0% 6.1071.52
F^ 100% 1.0070.12
D ND F1 NA 0.9170.14
F^ NA 1.0070.11
E c.2050C4T (p.P684X) F1 0% 1.1870.22
F^ 9% 1.0070.18
NF253-UHG c.2851^2A4G A ND F1 NA 0.7470.08
F^ NA 1.0070.12
B ND F1 NA 1.4070.17
F^ NA 1.0070.27
C ND F1 NA 1.0170.27
F^ NA 1.0070.07
D c.1663_1666del F1 0% 3.0170.56
F^ 50% 1.0070.21
E LOH F1 0% 2.9770.22
F^ 94% 1.0070.07
F ND F1 NA 1.2070.28
F^ NA 1.0070.17
L-004 c.6791dup A ND F1 NA 1.3870.24
F^ NA 1.0070.26
B c.3871-?_39741?del F1 0% 1.8170.45
F^ 100% 1.0070.13
C ND F1 NA 1.9470.17
F^ NA 1.0070.06
D c.4729delA F1 80% 1.4670.53
F^ 100% 1.0070.19
E ND F1 NA 0.6170.45
F^ NA 1.0070.13
GenBankNF1 reference sequenceNM_000267.1.
C, culture condition; F1, with forskolin; F, without forskolin; SQ, semiquantitative estimation of percentage NF1^/^ cells; ND, not detected; NA, not
applicable; qPCR, relativeNF1 expression in SC F1 vs. the parallel SC F cultures (rescaled to 17Standard error of the mean [SEM]) determined by
real-time quantitative PCR.
FIGURE 1. NF1mRNA expression levels in Schwann cell cultures (SC F1 left from SC F, whereby SC F levels are rescaled to one
for each tumor) derived from di¡erent tumors from patients NF96-1, NF253-UHG, and L-004 (mean of two independent
experiments7standard error of themean [SEM]).
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TABLE 3. MismatchRepairGeneVariants Leading toAminoAcidChanges Detected inNineNF1Patients
Patient MLH1 MSH2 MSH6 Tumor phenotype (age/]NFB)
Severe tumor burden andNF1microdeletion
L-001 c.655A4G (p.I219V) ç ç 49 years/100^500
NF96-1 ç ç ç 33 years/4100
Severe tumor burdenwithoutNF1microdeletion
L-002 c.655A4G (p.I219V) (hom) c.965G4A (p.G322D) c.116G4A (p.G39E) (hom) 34 years/TNTC
L-004 c.655A4G (p.I219V) ç ç 58 years/100^500
L-005 c.655A4G (p.I219V) ç c.116G4A (p.G39E) 55 years/TNTC
NF482-UHG ç c.965G4A (p.G322D) c.116G4A (p.G39E) 48 years/TNTC
NF116-UHG ç ç ç 49 years/4100
Moderate tumor burden
NF253-UHG c.655A4G (p.I219V) ç ç 33 years/o50
Mild tumor burden
NF339-UHG ç ç ç 41years/segmental
GenBankMLH1 reference sequenceNM_000249.2,MSH2 reference sequenceNM_000251.1,MSH6 reference sequenceNM_000179.1.
hom, homozygous alteration; NFB, neuro¢broma;TNTC, too numerous to count.
TABLE 4. Overview ofGermline and SomaticNF1Mutations inNeuro¢bromas Revealed by aCombination of LOHAnalysis
andNF1MutationDetectionTechniques
NF1germline NF1Somatic
ReferenceMutation Type Region Mutation Type Region
g.AC127024.4_AC129917.6del Microdeletion ^ c.5026_5032del Deletion 30 Current report
c.3189T4A (p.C1063X) Nonsense 50
c.4086_4092del Deletion GRD
c.396_403del Deletion 50
c.3774G4A (p.W1258X) Nonsense GRD
c.1246C4T (p.R416X) Nonsense 50 c.655^1G4T Splice 50
c.3757_3764del Deletion GRD
LOH LOH ^
c.1105C4T (p.Q369X) Nonsense 50
c.1153del Deletion 50
c.246_247del Deletion 50
g.AC127024.4_AC129917.6del Microdeletion ^ c.[7395^1G4A;7395G4A] Splice 30
c.3330del Deletion 50
c.7438del Deletion 30
c.2050C4T (p.P684X) Nonsense 50
c.6791dup Insertion 30 c.3871-?_39741?del Deletion GRD
c.4729del Deletion 30
c.311311G4A Splice 50 LOH LOH ^
c.2851-2A4G Splice 50 c.1663_1666del Deletion 50
LOH LOH ^
g.AC127024.4_AC129917.6del Microdeletion ^ c.4697T4A (p.L1566X) Nonsense 30
c.2851^2A4G Splice 50
c.[1007G4A;1008G4A]
(p.W336X)
Nonsense 50
c.240911G4A Splice 50
c.3525_3526del Deletion 50 c.2252-30_2252-6delinsT Splice 50
c.603_621del Deletion 50
c.118511G4A Splice 50
c.359_375del Deletion 50
c.5122dup Insertion 30 c.4537C4T (p.R1513X) Nonsense GRD
g.AC027793_AC004526del Microdeletion ^ c.543_546del Deletion 50 Sawada et al. [1996]
c.126011G4A Splice 50 c.4021C4T (p.Q1341X) Nonsense GRD Eisenbarth et al. [2000]
c.4084C4T (p.R1362X) Nonsense GRD
c.1246C4T (p.R416X) Nonsense 50 LOH LOH ^
c.2041C4T (p.R681X) Nonsense 50 c.2246C4G (p.S749X) Nonsense 50 Serra et al. [2001]
LOH LOH ^
LOH LOH ^
c.3525_3526del Deletion 50 c.2928_2940del Deletion 50
c.2266C4T (p.Q756X) Nonsense 50
c.126011604A4G Splice 50
c.126011G4A Splice 50
c.451411G4C Splice GRD
c.587-8_587-3del Splice 50
c.7676^2A4T Splice 30
c.2815del Deletion 50
c.5774del Deletion 30
c.6292_6322del Deletion 30
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an ascertainment bias against LOH, only those neurofibromas
derived from NF1 patients with an intragenic germline mutation
were taken into account for further comparison. The frequency
of LOH in our cohort (3/16, 19%) is similar to literature data
(42/205, 20%) [Colman et al., 1995; Daschner et al., 1997; Serra
et al., 1997; Eisenbarth et al., 2000; Rasmussen et al., 2000; Serra
et al., 2001; Wiest et al., 2003; Upadhyaya et al., 2004] but is
significantly different from the group of tumors with both
characterized hits derived from the systematic somatic mutation
detection studies (3/16 vs. 38/65: P5 0.0053; Fisher’s Exact test).
DISCUSSION
Unbiased NF1 somatic mutation screening has been challenging
due to the large size of the NF1 gene, the diversity of lesions
found within the NF1 gene, and the cellular heterogeneity of
NF1 related tumors. Here, we present an improved strategy for
NF1 somatic mutation detection. Extensive screening of the NF1
gene in selectively grown Schwann cells derived from neurofi-
bromas resulted in the highest NF1 somatic mutation detection
rate described up to now (76%). Moreover, it was demonstrated
that the acquired somatic hit reduces NF1 mRNA expression. As
a reduction in NF1 expression was not observed for SC F- cultures
with undetectable somatic NF1 mutations (Table 2) and Schwann
cell purity could not be assessed for several of these (Table 1), we
postulate that a high proportion of NF11/– cells was still present in
at least some of these cultures. Fibroblast admixture in Schwann
cell cultures is a persistent problem in this context and the purity
of Schwann cell subpopulations during successive passages may
LOH (12) LOH (12) ^
c.979delinsTT Deletion 50 LOH LOH ^
LOH LOH ^
c.3419C4G (p.S1140X) Nonsense 50 LOH LOH ^
LOH LOH ^
c.57491332A4G Splice 30 LOH LOH ^
c.910C4T (p.R304X) Nonsense 50 LOH LOH ^
c.225112T4C Splice 50 LOH LOH ^
LOH LOH ^
c.387011G4T Splice GRD LOH LOH ^
c.910C4T (p.R304X) Nonsense 50 LOH LOH ^
c.1754_1757del Deletion 50 LOH LOH ^
c.3525_3526del Deletion 50 LOH LOH ^
c.801G4A (p.W267X) Nonsense 50 c.164111G4A Splice 50 Wiest et al. [2003]
c.1528-14_1546del Splice 50
c.3049C4T (p.Q1017X) Nonsense 50
c.3916C4T (p.R1274X) Nonsense GRD
c.520511G4A Splice 30
c.5767_5770del Deletion 30
LOH LOH ^
LOH LOH ^
c.801G4A (p.W267X) Nonsense 50 c.1381C4T (p.R461X) Nonsense 50
c.7237_7253del Deletion 30
c.3303_331417del Splice 50
c.4750_4751ins Insertion 30
LOH LOH ^
c.2731del Deletion 50 c.7285C4T (p.R2429X) Nonsense 30 Upadhyaya et al. [2004]
c.6788_6791del Deletion 30 c.1888del Deletion 50
c.6791dup Insertion 30 c.2033del Deletion 50
c.4374_4375del Deletion GRD
LOH LOH ^
LOH LOH ^
LOH LOH ^
g.AC127024.4_AC129917.6del Microdeletion ^ c.6387A4C (p.R2129S) Missense 30
c.2851-2A4G Splice 50 LOH LOH ^
c.4537C4T (p.R1513X) Nonsense GRD LOH LOH ^
c.6788_6791del Deletion 30 LOH LOH ^
c.7267dup Insertion 30 LOH LOH ^
c.7268_7269del Deletion 30 LOH LOH ^
GenBankNF1 reference sequenceNM_000267.1.
50, proximal to c.3613;GRD,GAP-related domain (c.3613-4608); 30, distal to c.4608.
TABLE 5. ComparisonNF1Somatic Mutation SpectrumofNF1
Microdeletion (MD) andNon-microdeletionPatients
SomaticNF1mutation
GermlineNF1
mutation
Fisher’s Exact
Type Number MD Non-MD test (a50.008)
Splice 15 3 12 P50.7
Nonsense 15 5 10 P50.06
Missense 1 1 0 P50.2
Deletion 23 6 17 P50.2
Insertion 1 0 1 P51
LOH 41 0 41 P50.0001
Total 96 15 81
TABLE 4. Continued
NF1germline NF1Somatic
ReferenceMutation Type Region Mutation Type Region
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depend on the composition of the original tumor. Regardless, the
high somatic mutation detection rate and the observed NF1
mRNA reduction in SC F cells illustrate that two inactivating
events, in a subpopulation of the Schwann cells, are required for
neurofibroma formation and emphasize the importance of genetic
inactivation mechanisms, instead of epigenetic factors, in NF1
tumorigenesis.
The high prevalence of somatic minor lesion mutations (26/29)
compared to LOH events in our cohort (3/29) is striking. This is in
contrast with previous somatic mutation reports where LOH has
been detected more often than small somatic lesions. This might
be explained by the fact that: 1) LOH is technically easier to
detect than intragenic mutations, 2) somatic mutation detection
approaches were used that were not sensitive enough to detect
all types of mutations, 3) the coding NF1 region was not entirely
analyzed, and 4) some patient groups might exist with a tendency
to acquire a particular type of somatic alteration. The high
prevalence of frameshift mutations (12/29, 41%) as second hit
is remarkable. The occurrence of deletions comprising Z4
nucleotides (7/29, 24%) is especially high in comparison with
the germline mutation spectrum (71/804, 9%; own unpublished
data) (P5 0.012; Binomial test). Recently, NF2 frameshift
mutations were reported to be more prevalent in sporadic tumors,
particularly with increasing age at diagnosis, compared to classic
and mosaic neurofibromatosis type 2 [Evans et al., 2005]. The
high occurrence of somatic frameshift mutations might therefore
be explained by an age related shift in mutation mechanism,
possibly due to an age related decline in DNA repair efficiency
[Evans et al., 2005]. Compared to the general age matched NF1
population [Huson et al., 1988], most individuals included in the
current report suffer from a severe to excessive neurofibroma
burden. While it is well known that NF1 microdeletion patients
develop more neurofibromas at an earlier age [Kayes et al., 1994;
Cnossen et al., 1997; Leppig et al., 1997; Tonsgard et al., 1997],
for other NF1 patients this remarkable tumor phenotype remains
unexplained. It is tempting to speculate that reduced DNA repair
efficiency influences the NF1 somatic mutation rate and hence
tumor development and tumor burden. Several lines of evidence
strengthen this hypothesis. First, there is increasing evidence that
mild reductions in DNA repair capacity, assumed to be the
consequence of common genetic variation, affect cancer predis-
position [Mohrenweiser et al., 2003]. Second, the NF1 gene has
been shown to be a mutational target in cells deficient for the
MMR process [Wang et al., 2003]. Third, epidemiologic studies
suggest that the molecular basis underlying the phenotypic
variability in NF1 is determined to a large extent by the genotype
at modifying loci [Easton et al., 1993; Szudek et al., 2000, 2002,
2003]. Genes involved in eukaryotic MMR are responsible for the
repair of base:base and single to larger base insertion/deletion
mispairs [Kolodner and Marsischky, 1999]. The somatic mutation
signature (high occurrence of larger frameshift mutations) might
reflect impairment of the latter DNA repair mechanism. In a first
attempt to determine the putative contribution of DNA repair
variation in NF1 tumor predisposition, we screened the MMR
genes MLH1, MSH2, and MSH6 in peripheral blood lymphocytes
of all patients in this report. In accordance with the extensive
genetic variation found in repair genes in the general population,
distinct polymorphisms were detected for all genes in all NF1
patients. Only those variants leading to amino acid alterations
were selected for further evaluation, i.e., p.I219V (MLH1),
p.G322D (MSH2), and p.G39E (MSH6), because of their
potential impact on protein structure and activity. The Polyphen
algorithm (http://tux.embl-heidelberg.de/ramensky; [Xi et al.,
2004]) indicates that, of the three selected polymorphisms, only
p.G322D in MSH2 could have a potential impact on the
respective protein activity. This finding is supported by functional
assays in yeast since quantitative in vivo DNA MMR assays in
Saccharomyces cervisiae indicate that the homologous yeast
p.G317D allele variant exhibits a slightly reduced efficiency of
MMR compared with the wild-type yeast MSH2 [Drotschmann
et al., 1999; Ellison et al., 2001]. The triggers for development of
multiple tumors might be different in NF1 microdeletion patients
(17 genes are present in the typical NF1 microdeletion region)
compared to individuals with an intragenic NF1 mutation.
Therefore, we subdivided the patient group with a severe tumor
burden into two different entities: 1) severe tumor burden and
NF1 microdeletion (L-001, NF96-1) and 2) severe tumor burden
without NF1 microdeletion (L-002, L-004, L-005, NF482-UHG,
and NF116-UHG). While the frequency of the MLH1 and MSH6
variants in the NF1 patients and the control population is roughly
similar, the occurrence of the MSH2 variant in NF1 patients with
multiple neurofibromas and an intragenic NF1 germline mutation
(five patients) is higher than expected (2/5 vs. 5/182: P5 0.011;
Fisher’s Exact test). Microsatellite instability analysis of the tumors
of the two NF1 patients was negative. Analysis of 15 additional
NF1 patients selected with a similar tumor burden did not reveal
theMSH2 polymorphism in any individual. One might expect that
genetic predisposition to tumor development is the result of an ‘‘at-
risk’’ genotype composed of small contributions of functionally
significant variants in multiple DNA repair genes. Therefore,
epidemiological studies in large NF1 patient groups will be
essential for evaluating the association between variant DNA
repair genotypes and tumor predisposition.
To study the interdependence between germline and somatic
hits. we made an overview of the current findings together with
previously reported cases (Table 4). In total, combined germline
and somatic mutation data of 96 neurofibromas derived from 34
NF1 patients were subjected to descriptive and statistical analysis.
These results have to be interpreted with caution. Inadequate
detection techniques and the mixed cellular pools that were used
for mutation analysis in previous studies together with the
selection of only those neurofibromas for which both germline
and somatic mutations were characterized, might have led to
biased results. More specifically, somatic NF1 minor lesion
mutations might be underestimated compared to LOH events,
and certain types of small somatic lesions might be under/
overrepresented due to the specific technologies applied in the
former studies.
Both intragenic germline and somatic mutations tend to reside
in the 50 region of the NF1 gene (19/29, 66% and 31/55, 56%,
respectively). In contrast with observations in familial adenoma-
tous polyposis (MIM] 175100) [Lamlum et al., 1999; Crabtree
et al., 2003], no association was found between the location of the
germline and the location or type of the somatic NF1 mutation.
When focusing on the minor somatic lesions, the frequency of
somatic missense mutations (1/55) is remarkably low in compar-
ison with the NF1 intragenic germline mutation spectrum (114/
851, 13%; own unpublished data) (P5 0.003; Binomial test).
It is tempting to speculate that the described somatic missense
mutation might have only a mild impact on protein activity and
will only contribute to tumorigenesis when occurring in combina-
tion with a ‘‘dramatic’’ constitutive hit such as the NF1
microdeletion (leading to loss of 17 genes) in the particular
tumor. More tumors will need to be studied, including tumors from
patients with a missense alteration as the constitutive hit, to clarify
this further. The somatic mutation spectrum of NF1 microdeletion
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and non-microdeletion patients was revealed to be significantly
different with respect to the prevalence of LOH events (0/15 vs.
41/81: P5 0.0001; Fisher’s exact test) (Table 5). This finding
points to a putative difference in somatic inactivation mechanism
between both NF1 patient groups. This phenomenon was also
observed in patient UHG-339, who is mosaic for a NF1
microdeletion. We investigated this hypothesis in more detail on
an extended series of tumors [De Raedt et al., 2006]. A similar
discrepancy in the frequency of LOH between patients with a
germline total gene deletion vs. a germline intragenic mutation has
been observed in tumors of patients with the von Hippel-Lindau
syndrome and in patients with retinoblastoma [Hagstrom and
Dryja, 1999; Vortmeyer et al., 2002; Wait et al., 2004].
In conclusion, we developed an improved strategy for somatic
screening of the NF1 gene on selectively cultured Schwann cells
and analyzed the somatic mutation spectrum in neurofibromas.
The high somatic mutation detection rate (76%) together with
the observed NF1 mRNA reduction in SC F cultures illustrate
that two inactivating mutations, in a subpopulation of the
Schwann cells, are required for neurofibroma formation. Given
the high occurrence of somatic frameshift mutations, a putative
role of reduced DNA repair efficiency as a trigger for NF1 somatic
inactivation and hence tumorigenesis was suggested. The absence
of LOH as second hit in NF1 microdeletion patients compared to
the general NF1 population, led to the hypothesis that differences
in somatic inactivation mechanism might exist between both
patient groups. Studies on a larger series of tumors are needed to
confirm these observations and will be important to further
elucidate the molecular basis underlying tumorigenesis in NF1.
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Somatic Loss of Wild Type NF1 Allele in
Neuroﬁbromas: Comparison of NF1Microdeletion
and Non-microdeletion Patients
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Neuroﬁbromatosis type I (NF1) is an autosomal dominant familial tumor syndrome characterized by the presence of multiple
benign neuroﬁbromas. In 95% of NF1 individuals, a mutation is found in the NF1 gene, and in 5% of the patients, the germline
mutation consists of a microdeletion that includes the NF1 gene and several ﬂanking genes. We studied the frequency of loss
of heterozygosity (LOH) in the NF1 region as a mechanism of somatic NF1 inactivation in neuroﬁbromas from NF1 patients
with and without a microdeletion. There was a statistically signiﬁcant difference between these two patient groups in the pro-
portion of neuroﬁbromas with LOH. None of the 40 neuroﬁbromas from six different NF1 microdeletion patients showed
LOH, whereas LOH was observed in 6/28 neuroﬁbromas from ﬁve patients with an intragenic NF1 mutation (P ¼ 0.0034, Fish-
er’s exact). LOH of the NF1 microdeletion region in NF1 microdeletion patients would de facto lead to a nullizygous state of
the genes located in the deletion region and might be lethal. The mechanisms leading to LOH were further analyzed in six neu-
roﬁbromas. In two out of six neuroﬁbromas, a chromosomal microdeletion was found; in three, a mitotic recombination was
responsible for the observed LOH; and in one, a chromosome loss with reduplication was present. These data show an impor-
tant difference in the mechanisms of second hit formation in the 2 NF1 patient groups. We conclude that NF1 is a familial tu-
mor syndrome in which the type of germline mutation inﬂuences the type of second hit in the tumors. VC 2006 Wiley-Liss, Inc.
INTRODUCTION
Neuroﬁbromatosis type I (NF1) is an autosomal
dominant disorder with a prevalence of 1/4,000
(Huson, 1989). It is caused by mutations in the
NF1 tumor suppressor gene located at chromosome
band 17q11.2 (Legius et al., 1993). Neuroﬁbromin,
the NF1 gene product, is a negative regulator of
the Ras-Map kinase pathway. The main features of
the NF1 phenotype are multiple cafe´-au-lait spots,
axillary freckling, Lisch nodules, benign neuroﬁ-
bromas, and learning disabilities. Most individuals
with NF1 show a mutation in the NF1 gene (point
mutation, small deletion, insertion, or duplication)
(Messiaen et al., 2000). Five percent of NF1 indi-
viduals have a microdeletion (Clementi et al.,
1996; Cnossen et al., 1997; Rasmussen et al., 1998;
Kluwe et al., 2004) that encompasses NF1 and its
neighboring genes. Individuals with an NF1 micro-
deletion exhibit on average a larger neuroﬁbroma
burden, have a lower average IQ (Descheemaeker
et al., 2004; Venturin et al., 2004) compared with
non-microdeletion patients, and often show dis-
tinct facial characteristics (Venturin et al., 2004). In
addition, an increased risk for the development of
malignant peripheral nerve sheath tumors has been
reported (De Raedt et al., 2003). Two recurrent
types of NF1 microdeletions have been described.
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The type I microdeletion is the most prevalent, is
meiotic in origin (Lopez-Correa et al., 2000a), and
has a length of 1.4 Mb. The breakpoints are
located in the low copy repeats (NF1REPA and C)
ﬂanking the NF1 microdeletion region (Lopez-
Correa et al., 2001; Kehrer-Sawatzki et al., 2004),
and 17 genes are localized in this region (De Raedt
et al., 2004). The type II NF1 microdeletion is
smaller (about 1.2 Mb) and mitotic in origin. The
breakpoints are located in the JJAZ1 (SUZ12)
gene/pseudogene region, and a total of 16 genes
are deleted. These patients are often mosaic for
the NF1 microdeletion, which may be the reason
why their phenotype is less severe (Petek et al.,
2003; Kehrer-Sawatzki et al., 2004).
A common mechanism for the somatic inactiva-
tion of a tumor suppressor gene is loss of heterozy-
gozity (LOH), i.e., loss of the wild type allele at a
heterozygous locus. This chromosomal event may
arise by several mechanisms such as deletion of
part of the chromosome, mitotic recombination
between the centromere and the locus of the tu-
mor suppressor gene, or chromosome loss with or
without reduplication of the homologous chromo-
some. Mitotic recombination has been suggested
as a common mechanism for LOH at the NF1
locus in neuroﬁbromas of patients with NF1 (Serra
et al., 2001b) and has been reported in malignant
myeloid cells from children with NF1 (Cooper
et al., 2000). LOH in the NF1 region in neuroﬁbro-
mas from individuals with a known NF1 germline
mutation has been reported in 42 of 208 neuroﬁ-
bromas (21%) (Colman et al., 1995; Lothe et al.,
1995; Sawada et al., 1996; Daschner et al., 1997;
Serra et al., 1997; Eisenbarth et al., 2000; Rasmus-
sen et al., 2000; Serra et al., 2001a; Wiest et al.,
2003; Upadhyaya et al., 2004). Thus far, we found
only three publications describing LOH data each
in one neuroﬁbroma from an NF1 microdeletion
patient. (Sawada et al., 1996; Serra et al., 2001a;
Upadhyaya et al., 2004). This is the ﬁrst study that
systematically compares the frequency of somatic
loss of the NF1 wild type allele in a large number
of neuroﬁbromas from both NF1 microdeletion and
non-microdeletion patients.
MATERIALS ANDMETHODS
Samples
Forty neuroﬁbromas from six patients with a
constitutional type I NF1 microdeletion and 28
neuroﬁbromas from six NF1 patients without a
microdeletion were investigated. Twenty neuroﬁ-
bromas were formalin-ﬁxed and parafﬁn-embed-
ded (FFPE), and 42 had been fresh frozen. In
addition, neuroﬁbroma-speciﬁc Schwann cell cul-
tures were available from six other neuroﬁbromas
(Table 2). All neuroﬁbromas investigated were
located cutaneously or s.c., and none were plexi-
form or spinal neuroﬁbromas. Peripheral blood leu-
kocyte DNA from each patient was used as
matched control DNA. All patients fulﬁlled the
NIH diagnostic criteria for NF1 (Stumpf et al.,
1988). None of the 6 NF1 microdeletion patients are
mosaic, and all deletions are de novo and of type I. They
have their proximal breakpoint located in the low copy
repeats ﬂanking NF1 (Lopez-Correa et al., 2001)
between chromosome 17 reference positions (build 35)
25996120 and 26022120. Their distal breakpoint is
located between positions 27412117 and 27438208.
The other six patients have intragenic NF1 mutations
(GenBank reference sequence NM_000267.1): c.2851-
2A>G (NF253-UHG), c.4515-2A>T (NF44-UHG),
c.1261-19G>A (NF93-UHG), c.5546G>A (p.R1849Q)
(NF37-UHG), c.1246C>T (p.R416X) (L-002) and
c.988_989insA (NF24-UHG).
DNA Extraction from Frozen Tissue
and Cultured Cells
Frozen tumor tissue fragments were pulverized
with a mortar. Culture conditions for neuroﬁbroma-
derived Schwann cells were applied as described
in (Rosenbaum et al., 2000; Serra et al., 2000). In
both cases, gDNAwas extracted using the QiaAmp
procedure (Qiagen, The Netherlands) following
the manufacturer’s instructions.
DNA Extraction from FFPE Tissue
Ten-micrometers thick unstained slides were
dewaxed through successive xylene and ethanol
washes. DNA was extracted from archival FFPE
neuroﬁbroma tumor samples following manual
microdissection of the neoplastic regions, visual-
ized by comparison with one parallel H&E stained
slide. DNA was extracted from these microdis-
sected tissue fragments using the QiaAmp proce-
dure (Qiagen, The Netherlands) following the
manufacturer’s instructions and was subsequently
puriﬁed and concentrated on Microcon ﬁlters
(Millipore, Belgium).
LOH Analysis
Genomic regions at both sides of the NF1 micro-
deletion region were sequenced, and heterozygous
SNPs were detected in all patients (Table 1). Tu-
mor and control DNA samples were subjected to
PCR ampliﬁcation (Hotgoldstar mix, Eurogentec,
Belgium) using primers for the informative SNPs
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(primers available on request). For each SNP, a
short amplicon could be designed (<130 bp). In
the individuals NF44-UHG (c.4515-2A>T), L-002
(c.1246C>T), NF93-UHG (c.1264-19G>A), and
NF37-UHG (c.5546G>A), the intragenic constitu-
tional NF1 mutation was used as an additional
intragenic SNP. PCR products were sequenced fol-
lowing the BigDye Terminator Sequencing proto-
col (ABI, Applied Biosystems, Belgium). A liz-
tagged size standard was added, and the samples
were analyzed on an ABI3100 machine using a
standard fragment analysis protocol. Using the
Genescan analysis software (Applied Biosystems,
Belgium), peak height ratios of the two alleles of
the SNP were calculated relative to an internal
control peak of the same nucleotide at least ﬁve
nucleotides apart, and these ratios were compared
between tumor and corresponding control DNA.
Every DNA sample was PCR ampliﬁed (35 cycles)
and sequenced for each SNP in triplicate. LOH for
an SNP was scored when the average ratio (SNP
nucleotide/control nucleotide) of the two alleles in
tumor tissue fell outside the 95% conﬁdence inter-
val of the ratios observed in control DNA of the
same patient and when the average ratios in tumor
versus control tissue were at least 20% different. If
one SNP showed LOH, a second SNP was tested
to conﬁrm the presence of LOH in the tumor.
Given the cutoff of 20% used in this study, LOH
will not be detected if less than 20% of the tumor
cells are pathogenic. Figure 1A shows the typical
output when LOH is observed for a SNP (tumor
33 of patient NF253-UHG, SNP rs1018190).
Newly identiﬁed SNPs were submitted to the
NCBI SNP database (http://www.ncbi.nlm.nih.
gov/snp).
NF1 Somatic Mutation Analysis
Selective Schwann cell cultures (SCNF1/)
derived from the neuroﬁbromas of patient L-001
were treated with puromycin before RNA extraction
(RNeasy kit, Qiagen, Belgium). The entire NF1
cDNAwas sequenced using the ABI3100 genetic an-
alyzer (Applied Biosystems) (Messiaen et al., 2000).
All mutations found at the cDNA level were con-
ﬁrmed on gDNA by cycle sequencing. Comparison
of the mutations found in the SCNF1/, the parallel
SCNF1+/ cultures, and blood lymphocytes allowed to
conclude which mutation represented the somatic
alteration. Tumors from patients C174, C176, and
C186 were screened for a deletion of the NF1 gene,
using FISH (clones P1-9 and P1-12; Leppig et al.,
1996), dHPLC, and direct sequencing as described
by Upadhyaya et al. (2004), combined with MLPA
and deletion PCR.
TABLE 1. Overview of SNPs Used in the LOH Analysis and
Clones Used in Array CGH Experiments in Positional
Reference to NF1
SNP number Chr17 reference position Polymorphism
rs8082669 10335232 A/G
rs4791544 13125881 A/T
rs1634421 18792051 C/T
Centromere
RP11-138P22 23.14 Mb
rs1018190 24571352 C/G
rs6505129 24777744 A/G
RP11-104I20 25.11 Mb
rs29001484 25562640 G/A
rs4583306 25562840 T/C
Proximal BP 25996120-26022120
NF1 26.44 Mb
Distal BP 27412117-27438208
rs9891455 27534262 C/T
RP11-474K4 27.58 Mb
rs8074061 27625458 C/T
rs753750 27638817 A/T
rs2055091 27961859 A/T
rs28909978 28053334 T/C
rs11869264 28135095 C/T
RP11-47L3 30.68 Mb
BP, breakpoint.
Figure 1. Example of LOH assay. A: Overlay of the traces of SNP
rs1018190 (G/C polymorphism) from blood and tumor 32 of individual
NF253-UHG, only the G- (top) and the C-trace (bottom) are shown.
The SNP peak and the control peak of the tumor DNA are represented
in black. It is clear that in tumor 32 the G-allele of rs1018190 is lost
compared with that in the blood. B: Overlay of the traces of the semi-
quantitative PCR used to determine if the LOH of NF1 is caused by a
copy number loss. Blood DNA of patient L-002 was compared with
DNA of tumor 3 (represented in black). The ﬁrst peak (103 bp) repre-
sents NF1, and the second peak (107 bp) represents the NF1 pseudo-
gene located on chromosome 15. Tumor 3 has copy number loss of
NF1.
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Identiﬁcation of the Mechanism of LOH
Semiquantitative PCR
Several pseudogenes of NF1 are present in the
human genome, some of which contain deletion/
insertions when compared with the functional copy
of NF1. PCR primers were designed in an area pres-
ent in both the NF1 gene and an NF1 pseudogene
in such a way that both loci would be ampliﬁed with
the same primers in the same PCR reaction. The
PCR ampliﬁcation would result in two PCR prod-
ucts with a size difference of only a few basepairs
(bp). A semiquantitative PCR can be used to test
whether one or two copies of NF1 are present in the
tumor in relation to the pseudogene. Using a pseu-
dogene as control fragment has an advantage over a
classical semiquantitative PCR because only one
primer set is needed and variations caused by PCR
efﬁciency of test and control fragment is minimized,
resulting in increased accuracy of the assay. Primer
pairs were designed to amplify a small fragment of
NF1 exon 22 located at 17q11.2 (103 bp) together
with the corresponding fragment of its pseudogene
located on chromosome 15 (107 bp) and character-
ized by a 4-bp insertion. Tumor and normal DNA
samples were subjected to 35 cycles of PCR (Hot-
goldstar mix, Eurogentec, Belgium). Relative peak
heights of ampliﬁed fragments were analyzed by the
Genescan software (Applied Biosystems, Belgium),
and the ratios of gene versus pseudogene fragments
were compared between tumor and normal DNA for
each patient. Every analysis was performed in tripli-
cate. Similar to SNP LOH analysis, copy number
loss was deﬁned when the average ratio (NF1/NF1
pseudogene) fell outside of the 95% conﬁdence
interval of the corresponding ratio in normal DNA
with a minimum difference of at least 20%. Figure
1B shows the output of this semiquantitative PCR
for NF1. DNA from a tumor with copy number loss
of NF1 was compared to the blood DNA of the same
individual (L-002 tumor 3).
LOH analysis of markers on the p arm of chromosome 17
To distinguish LOH caused by mitotic recombi-
nation from LOH caused by deletion and reduplica-
tion of the homologous chromosome 17, SNPs
rs8082669, rs1634421, and rs4791544 located on the
p arm of chromosome 17 were analyzed. If LOH of
NF1 was caused by a mitotic recombination, markers
on chromosome 17p would not show LOH. Only
tumors showing LOH not caused by a somatic dele-
tion were tested (i.e., tumor 32 (NF253-UHG), tu-
mor 5 and 12 (L-002), and tumor 41 (NF44-UHG)).
Array CGH
The array CGH experiments were performed
according to the protocol described by Vermeesch
et al. (2005). The arrays were constructed using a 1
Mb Clone Set and contain 3527 BAC and PAC
clones (Fiegler et al., 2003) spotted in duplicate.
Tumor DNA was directly compared to DNA
extracted from blood leukocytes of the same indi-
vidual, and both were labeled by a random prime
labeling system (Bioprime DNA Labeling System,
Invitrogen, Belgium) using Cy3- and Cy5-labeled
dCTPs (Amersham Biosciences, Belgium). Follow-
ing incubation of about 36 hr, the slides were
washed and scanned at 532 nm (Cy3) and 635 nm
(Cy5) on the Agilent G2565BA MicroArrayScanner
System (Agilent; Palo Alto, CA). Image analysis
was performed using ArrayVision software (Imag-
ing Research; St Catharines, Ontario, Canada).
Further analysis was performed with Excel (Micro-
soft; Diegem, Belgium). For each clone, a normal-
ized log2 ratio was calculated. Subsequently, a 2D
Lowess normalization was performed (Yang, 2003).
Datapoints for which the variation between the in-
tensity ratios of the duplicated spots was larger than
10% were excluded from the analysis. The quality
of an array experiment was considered good when
the SD was lower than 0.096 and the hybridization
efﬁciency was higher than 90%. The fold change of
a single clone is considered signiﬁcantly different if
it falls outside of the 6|(log2 (1.5)  2 3 SD)| inter-
val. The fold change of two or more consecutive
clones is considered signiﬁcantly different if it falls
outside of the 64 3 SD interval (Vermeesch et al.,
2005).
Real-time quantitative PCR
Real time quantitative PCR (primers available
on request) was performed on C17orf41 with
HPRT1 as housekeeping gene as described by Jun
et al. (2001), with the exception that an ABI
PRISM 7000 instrument (Applied Biosystems, Bel-
gium) was used.
RESULTS
Detection of LOH
As the somatic point mutation in NF1 had already
been identiﬁed in 10 neuroﬁbromas of microdele-
tion patients, these samples were excluded from
LOH analysis. These somatic mutations are shown
in Table 2.
896
  Chapter 2 
 61
LOH in the Neuroﬁbromas
LOH of NF1 was detected in six of the 28 neu-
roﬁbromas (21%) from NF1 non-microdeletion
patients, compared with none of the 40 neuroﬁbro-
mas from the NF1 microdeletion patients. This is a
signiﬁcant difference in LOH frequency (P ¼
0.0034, Fisher’s exact test). The percentage LOH
observed varied between 30% and 75%. Table 2
TABLE 2. Overview of Results of the LOH Analysis
(Continued)
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TABLE 2. Overview of Results of the LOH Analysis (Continued)
(Continued)
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gives an overview of the results obtained in the dif-
ferent tumors. In addition to these six neuroﬁbro-
mas with LOH tumor 33 from patient NF253-
UHG (a nondeletion patient) has LOH of two
markers (rs6505129 and rs1018190) located centro-
meric of NF1. The semiquantitative PCR (NF1
(pseudo)exon 22) did not show any evidence of
copy number loss of NF1 in this tumor. Because of
the poor quality of the DNA, we were unable to
prove the involvement of NF1 in the area with
LOH. Therefore, we did not include this tumor in
our calculations. In the individuals NF44-UHG
(c.4515-2A>T), L-002 (c.1246C>T), NF93-UHG
(c.1264-19G>A), and NF37-UHG (c.5546G>A),
the intragenic constitutional NF1 mutation was
used as an additional intragenic SNP for testing
LOH. Each time LOH was observed in NF1 (Ta-
ble 2), the wild type allele was lost in the tumor.
Mechanism Leading to LOH
In three tumors (L-002 tumor 5 and 12 and
NF253-UHG tumor 32), the observed LOH
resulted from a mitotic recombination event as
LOH for markers on 17q was shown in the pres-
ence of two copies of the NF1 gene without any
LOH on 17p. Two neuroﬁbromas had lost one copy
of NF1 because of a deletion on chromosome 17
(L-002 tumor 3, NF44-UHG tumor 1). These two
samples were used for array CGH analysis. In both
cases, array CGH conﬁrmed the presence of a so-
matic deletion that affected the NF1 region on
chromosome 17 (Fig. 2A). The deletions were
large and different in size. The somatic deletion of
NF44-UHG tumor 1 was at least 2.5 Mb and
encompassed clones RP11-104I20 to RP11-474K4
(25.11–27.58 Mb on the ENSEMBL contig of
chromosome 17). L-002 tumor 3 had a somatic de-
letion of at least 7.5 Mb encompassing clones
RP11-138P22 to RP11-47L3 (23.14–30.68 Mb on
the ENSEMBL contig of chromosome 17). For ref-
erence, NF1 is located at position 26.44 Mb. More
than the entire NF1 microdeletion region was
somatically deleted in these two tumors. No copy
number aberrations were observed for clones in
other regions of chromosome 17 or on other chro-
mosomes (Fig. 2B). Array CGH was also performed
on a neuroﬁbroma with LOH resulting from a mi-
totic recombination (L-002 tumor 12), and on a
TABLE 2. Overview of Results of the LOH Analysis (Continued)
The column NF1 (germ line) shows if LOH was observed using the germline NF1 mutation of the individual; the column NF1 (somatic mut) shows the
somatic mutation found in the respective tumor.
NF1 SQ, semiquantitative PCR (number of NF1 copies indicated) relative to NF1 pseudogene; F, frozen; H, marker heterozygous; SC, Schwann cell cul-
ture; P, parafﬁn; L, marker not heterozygous (LOH); U, ampliﬁcation failed; NI, not informative; ND, not determined; 17p, 17p marker analysis.
aTumors have LOH of NF1 and not of markers on 17p; LOH is thus caused by a mitotic recombination.
bTumors have LOH of NF1 and for markers on 17p; no copy number loss of NF1 is observed; LOH is thus caused by chromosome loss and reduplica-
tion. The dark gray areas represent the minimal region of LOH due to a somatic deletion. The light gray areas represent the minimal region of LOH
due to a mitotic recombination.
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neuroﬁbroma without LOH (L-002 tumor 1). As
expected, neither of these DNA samples showed
any copy number changes across the genome. Tu-
mor 41 of individual NF44-UHG did not show any
copy number loss of NF1. Besides LOH in the
NF1 region, LOH was also present for markers
located on 17p. This points to the mechanism of
chromosome loss and reduplication.
Real Time PCR of C17orf41
C17orf41 is located in the NF1 microdeletion
region and is possibly essential for the survivals of
Figure 2. Array CGH output of neuroﬁbromas. A: Array CGH out-
put of NF44-UHG tumor 1 (top) and L-002 tumor 3 (bottom). The nor-
malized log2 ratio for each clone from chromosome 17 is shown. The
clones are arranged from chromosome 17pter to 17qter. The deleted
region is indicated in gray. NF1 is deleted in both neuroﬁbromas. B:
Array CGH output of L-002 tumor 3. The normalized log2 ratio of all
clones is depicted. The clones are arranged from pter on chromosome
1 on the left to qter of the Y chromosome on the right. The fold change
of a single clone is considered signiﬁcant if it falls outside of the 6|(log2
(1.5)  2 3 SD)| interval (indicated by the dashed line on the ﬁgure).
The fold change of two or more consecutive clones is considered signif-
icant if it falls outside of the 64 3 SD interval (indicated by the bold
line on the ﬁgure). Similar to all other neuroﬁbromas tested on array
CGH, L-002 tumor 3 has a stable karyotype and a somatic deletion only
in the NF1 region (indicated by the arrow). [Color ﬁgure can be viewed
in the online issue, which is available at www.interscience.wiley.com.]
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cells. The expression of C17orf41 was tested with
real time PCR on seven cell lines from Schwann
cells of neuroﬁbromas (four cell lines of NF1
microdeletion patients and three of non-microdele-
tion patients). On average, the expression of
C17orf41 was ﬁve times lower than the housekeep-
ing gene HPRT1 (DCt ¼ 2.25, South Dakota ¼
0.80). There was no difference in expression
between both patient groups.
DISCUSSION
The tumor suppressor NF1 can be inactivated in
tumors by different mechanisms. In this report, we
showed that the relative proportion of one of these
mechanisms (LOH) differs signiﬁcantly in NF1
microdeletion patients when compared with that
in NF1 patients with an intragenic NF1 mutation.
Thus, although LOH was responsible for the so-
matic inactivation of NF1 in a quarter of the neuro-
ﬁbromas from NF1 non-microdeletion patients (6/
28 ¼ 21%; 95% CI, 8–41%), LOH was never
observed in 40 neuroﬁbromas (0/40; 95% CI, 0–
7%) from known NF1 microdeletion patients (P ¼
0.0034, Fisher’s exact test). The ﬁnding of LOH in
neuroﬁbromas from NF1 patients with an intra-
genic mutation are in concordance with published
data from the literature: LOH being detected in
DNA from 42/205 neuroﬁbromas (21%; 95% CI,
15–27%) from patients in whom the germline
mutation was not a microdeletion (Colman et al.,
1995; Lothe et al., 1995; Sawada et al., 1996;
Daschner et al., 1997; Serra et al., 1997; Eisenbarth
et al., 2000; Rasmussen et al., 2000; Serra et al.,
2001a; Wiest et al., 2003). In addition, LOH has
not been described in three neuroﬁbromas from
NF1 microdeletion patients reported in the litera-
ture (Sawada et al., 1996; Serra et al., 2001a; Upad-
hyaya et al., 2004). Combining the data on NF1
microdeletion patients presented here and in the
literature, none of the 43 neuroﬁbromas from
microdeletion patients showed LOH (0%; 95% CI,
0–6.7%) versus 48 of 233 neuroﬁbromas from NF1
individuals without a microdeletion (21%; 95% CI,
16–26%) (X2; P ¼ 0.001).
A similar discrepancy in the frequency of LOH
between patients with a germline gene deletion
and a germline intragenic mutation has been
observed in tumors of patients with the von Hip-
pel-Lindau (VHL) syndrome and in patients with
retinoblastoma. In VHL patients with a germline
deletion of VHL, no LOH was observed in eight
tumors analyzed (0/8 tumors, 95% CI, 0–31%)
(Vortmeyer et al., 2002; Wait et al., 2004), while
this is a frequent event in tumors without a germ-
line deletion (81/132 tumors ¼ 61%, 95% CI, 52–
70%) (Crossey et al., 1994; Zeiger et al., 1995;
Prowse et al., 1997; Bender et al., 2000; Glasker
et al., 2001; Vortmeyer et al., 2002). Also, no LOH
was observed for RB1 in 12 retinoblastoma patients
with a germline deletion of RB1 (0/12 tumors, 95%
CI, 0–22%), whereas 69% of the tumors from indi-
viduals without a germline deletion had LOH
(101/146 tumors, 95% CI, 61–77%) (Hagstrom and
Dryja, 1999). Germline/somatic mutation correla-
tions have also been observed in familial adenoma-
tous polyposis patients. In this disorder, the loca-
tion and the type of somatic mutation in APC
depends on the position of the germline mutation
in APC. If the germline APC mutation is near
codon 1300 (codon 1285–1398), then the inactiva-
tion of the wild type allele is associated with LOH
and is usually due to a mitotic recombination. If a
germline truncating point mutation is present
before codon 1285, then LOH is very rare and all
somatic mutations are located after codon 1285.
However, when the germline mutation is located
after codon 1399, then the majority of somatic
mutations are located before codon 1285 (Crabtree
et al., 2003).
Several hypotheses can be put forward to
explain the observed difference in LOH in the two
NF1 patient groups. The type I NF1microdeletion
region is known to contain at least 17 genes, and
thus LOH of this region, whether due to mitotic
recombination or a microdeletion, would lead to a
nullizygous state for all genes located within this
region.
Several hypotheses can be put forward to
explain the present ﬁndings:
1. Neuroﬁbromas contain a mixture of cells. Only
the Schwann cells show a complete inactiva-
tion of the NF1 gene (Serra et al., 2000). It
could be possible that for some unknown rea-
son the percentage of cells from microdeletion
neuroﬁbromas showing LOH in the NF1 re-
gion is lower than the 20% detection limit. If
less than 20% (criteria used for classiﬁcation of
LOH) of the cells in the neuroﬁbroma are
affected, LOH would not be detected result-
ing in a bias against LOH. It was estimated by
sequence analysis of the ﬁve frozen tumors
from microdeletion patients C174, C176, and
C186 that the second hit in the NF1 gene was
present in at least 30–60% of cells. Moreover,
in an additional ﬁve neuroﬁbromas of NF1
microdeletion patients, a second hit in the
NF1 gene was found in cultured Schwann cells
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and none of these tumors showed LOH (Table
2). Also, on the basis of marker analysis in the
neuroﬁbromas of non-microdeletion patients,
the minimum percentage of cells showing
LOH was 30%.
2. One or more of the genes in the microdeletion
region may be essential for the survival of the
cell. The complete loss of (some of) these
genes following LOH would therefore be le-
thal. Gene C17orf41 (OMIM No. 609534), also
known as FLJ12735 or FRAG1, is a good candi-
date to support this hypothesis. Real-time
quantitative PCR demonstrated that C17orf41
is expressed in Schwann cells. It is located in
the NF1 microdeletion region and in vitro ex-
periments have shown that mouse cells with a
reduced amount of C17orf41 protein enter the
apoptosis pathway. More speciﬁcally, a reduced
expression of C17orf41 leads to the induction of
apoptosis through the release of Rad9 (Ishii
et al., 2005). Hence, one can imagine that, in
humans, complete loss of C17orf41 resulting
from LOH in a cell with an NF1 microdeletion
might induce apoptosis. Not a lot is known on
the effect of a nullizygous state of the genes
present in the NF1 microdeletion region.
Besides the NF1 knock-out mouse models,
OMGP is the only gene in the NF1 microdele-
tion region of which a knock-out mouse model
exists (Huang et al., 2005). These nullizygous
OMGP mice are perfectly viable. Other genes
present in the NF1 microdeletion region might
also cause lethality; however, any direct evi-
dence is lacking at this moment.
3. A more mechanistic hypothesis is that the pres-
ence of a NF1 microdeletion on one chromo-
some 17 may suppress mitotic recombination
within the region. For a mitotic recombination
to occur, two chromatids of homologous chromo-
somes need to align. The presence of a microde-
letion close to the centromere (17q11.2) might
reduce the likelihood of a mitotic recombination
occurring between the centromere and NF1.
The end result would be a lower frequency of
LOH. Mitotic recombination has however been
demonstrated to be a common mechanism of
LOH at the NF1 locus in tumors of patients
with NF1 (Serra et al., 2001b), an observation
conﬁrmed in the present study. However, we
also demonstrate that the loss of copy number of
NF1 due to a somatic deletion is a frequent
mechanism underlying LOH in neuroﬁbromas
(3/6 neuroﬁbromas with LOH). This NF1 copy
number loss was thoroughly investigated using
both semiquantitative PCR and array CGH anal-
ysis. If LOH due to a mitotic recombination is
impossible in NF1 microdeletion patients, then
one would still expect LOH to occur because of
a somatic deletion of the NF1 region. However,
we failed to observe any evidence of LOH in 40
neuroﬁbromas from NF1 microdeletion patients.
This is in contrast to non-microdeletion patients,
where three cases of a somatic deletion of NF1
were found in 28 neuroﬁbromas. This difference
is only of borderline signiﬁcance (P ¼ 0.065,
Fisher’s exact test).
4. The observed data might also result from the
frequent use of alternative second hit mecha-
nisms in microdeletion patients, thus greatly re-
ducing the proportion of LOH observed in neu-
roﬁbromas of these patients. Assuming that the
absolute number of LOH events in Schwann
cells is similar in both NF1 microdeletion and
non-microdeletion patients, then the proportion
of LOH in neuroﬁbromas would be lower in
NF1microdeletion patients if alternative mech-
anisms leading to the inactivation of the normal
NF1 allele were more frequent. The observed
difference in LOH frequency could then point
to the presence of a mechanism that made the
wild type NF1 allele in NF1 microdeletion
patients more vulnerable to other somatic
mutations, excluding LOH, than in non-micro-
deletion patients. NF1 microdeletion patients
lack the homologous allele of NF1 and 16 other
genes. The repair of double-strand breaks
(DSBs) cannot be performed by the error-free
mechanism of homologous recombination at
the moment during the cell cycle when sister
chromatids are not present (G1 phase). This
would entail that in these phases of the cell
cycle, DSB in the NF1 region on the normal
chromosome 17 can only be repaired by the
error-prone mechanisms of non-homologous
end joining or single-strand annealing (Pfeiffer
et al., 2004). This would cause an excess of
small somatic mutations in the wild type alleles
of the 17 genes in the NF1 microdeletion
region. The question remains why this poten-
tial mechanism would not be at play in other
familial cancer syndromes where germline dele-
tions are not associated with a more severe tu-
mor phenotype (NF2 and VHL) (Lopez-Correa
et al., 2000b; Wait et al., 2004).
We believe that the observed ﬁndings are best
explained by the hypothesis that the presence of
one copy of certain genes in the NF1 microdeletion
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region is essential for the survival of Schwann cells
and/or by the hypothesis that the wild type genes
in the NF1 microdeletion region on the normal
chromosome 17 are more vulnerable to mutation.
Nonmosaic NF1 microdeletion patients have on
average a higher tumor burden than do non-micro-
deletion patients. One explanation might be that
the wild type NF1 gene is more vulnerable to
mutation. Another hypothesis is that haplo-insufﬁ-
ciency for one or more genes present in the NF1
microdeletion results in an aspeciﬁc growth advant-
age of different cell types, including Schwann cells.
NF1 microdeletion patients are known to have a
general tendency to overgrowth. Thus, children
with an NF1 microdeletion are often relatively tall,
and have large hands and feet, and sometimes they
even show a real overgrowth phenotype in infancy
(van Asperen et al., 1998). Recently Spiegel et al.
(2005) reported an advanced childhood height
growth in NF1 microdeletion patients. It can be
hypothesized that because of an aspeciﬁc growth
advantage of cells with an NF1 microdeletion, the
Schwann cells of subclinical neuroﬁbromas could
grow at a faster pace and hence give rise to more
visible tumors at a given age. Therefore, the num-
ber of visible tumors might be higher in NF1
microdeletion patients because of a faster growth
rate of the tumors. Aside from the overgrowth phe-
notype observed in NF1 microdeletion patients,
we do not have additional arguments for this hy-
pothesis.
In conclusion, we have demonstrated that a sig-
niﬁcant difference exists in the somatic inactiva-
tion mechanisms of NF1 in neuroﬁbromas of NF1
microdeletion versus non-microdeletion patients.
Hence, it is clear that both patient groups differ
not only at the phenotypic (different average tu-
mor burden) and the constitutional level (pres-
ence/absence of a microdeletion), but also at the
somatic level (LOH as rare/frequent mechanism of
NF1 inactivation). This new insight might open
new avenues for a better understanding of the
genetic basis underlying the high tumor burden of
NF1 microdeletion patients.
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Although Xuorescent in situ hybridization (FISH)1 and
loss of heterozygosity (LOH) analysis can pick up mosai-
cism for gross chromosomal rearrangements relatively eas-
ily, detection of small mosaic lesion mutations remains
technically challenging. Moreover, the presence of highly
homologous pseudogenes throughout the human genome
may complicate minor lesion mutation analysis at the geno-
mic DNA (gDNA) level. In an attempt to detect low-per-
centage mosaicism for point mutations against a
background of normal and pseudogene alleles, we have
developed a nested real-time quantitative PCR (qPCR)
assay taking advantage of 3 locked nucleic acid (LNA)
allele-speciWc PCR (AS-PCR) primers and the cost-eVective
SYBR Green I detection chemistry.
One conceptually simple strategy to detect single-base
substitutions is AS-PCR, which is based on positioning the
3 base of a PCR primer to match one variant allele [1].
Over the years, a number of strategies have been developed
to improve the speciWcity and reliability of primers in AS-
PCR. Among these are the incorporation of additional mis-
matches near the 3 end [2] and the use of high-aYnity
DNA analogues such as LNAs [3,4]. Although AS-PCR
assays provide an elegant method to discriminate between
alleles, accurate quantiWcation of the variants is not attain-
able because of the intrinsic endpoint detection by conven-
tional PCR methods. This limitation is fully addressed
using the real-time qPCR method, whereby PCR product
accumulation is monitored at each PCR cycle by means of
Xuorescent detection. In this article, we evaluate the dis-
criminating power of diVerent AS-PCR primers on a real-
time qPCR platform. As a model, we use various tissues
and cell types derived from a segmental neuroWbromatosis
type 1 (NF1, MIM 162200) patient.
To determine the NF1 mutation underlying the segmen-
tal phenotype, selectively cultured Schwann cells [5] derived
from peripheral nerve sheath tumors were screened by a
highly sensitive NF1 mutation detection cascade as
described previously [6]. A nonsense mutation (c.2041C > T
(p.R681X)) was revealed in NF1 exon 13. The region span-
ning the point mutation was ampliWed, and PCR products
were cloned in the pCR2.1-TOPO vector (Invitrogen).
The wild-type and mutant inserts were conWrmed by
gDNA sequencing on an ABI3730XL using BigDye chem-
istry (Applied Biosystems). Cloned fragments were reampli-
Wed and puriWed (MSB Spin PCRapace, Invitek), and
concentrations were determined using the PicoGreen double-
stranded DNA (dsDNA) QuantiWcation Reagent (Molecu-
lar Probes) on a TD-360 Xuorometer (Turner Designs).
The mutant allele-speciWc qPCR assay was optimized to
achieve a maximal discriminating power between mutant
and wild-type alleles, evaluated as the diVerence in the cycle
threshold (Ct) values of mutant ampliWcation products
between matched (mutant-speciWc) and mismatched (wild-
type-speciWc) primers while preserving high ampliWcation
eYciency. Real-time qPCR reactions were performed on an
iCycler iQ instrument (Bio-Rad) using a 1£ SYBR Green I
Master Mix (Eurogentec), 250 nM of primers, 10 nM Xuo-
rescein, and 5£ 103 molecules of mutant plasmid input.
Primers were designed with the freely available Primer 3
* Corresponding author. Fax: +32 9 240 6549.
E-mail address: joke.vandesompele@ugent.be (J. Vandesompele).
1 Abbreviations used: FISH, Xuorescent in situ hybridization; LOH, loss
of heterozygosity; gDNA, genomic DNA; qPCR, quantitative PCR; LNA,
locked nucleic acid; AS-PCR, allele-speciWc PCR; NF1, neuroWbromatosis
type 1; dsDNA, double-stranded DNA; Ct, cycle threshold.
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web tool (Whitehead Institute, http://frodo.wi.mit.edu/cgi-
bin/primer3) and consisted of a common forward primer
(5-tcttccacccttgactctca-3) together with an AS-PCR
reverse primer, resulting in an 82-bp amplicon. We evalu-
ated the following six AS-PCR reverse primers for their dis-
criminating power: a wild-type or mutant DNA primer
with an additional 3 subterminal mismatch (underlined)
(5-ctagtttggtctgggcttgttg/a-3) and two wild-type or
mutant 3 LNA (bold) primers (5-ctagtttggtctgggcttgtcg/a-
3 and 5-ctagtttggtctgggcttgttg/a-3). Although the muta-
tion itself dictates the choice of the 3 terminal nucleotide in
the primers, the nucleotide at the penultimate position was
chosen based on the previously observed reduced ampliWca-
tion eYciency when thymidine occupies this primer posi-
tion [7]. The thermal proWle consisted of 1 cycle at 95 °C for
10 min followed by 40 cycles at 95 °C for 15 s and at 61 °C
for 1 min. After PCR ampliWcation, a melting curve was
generated to check the speciWcity of the PCR reactions
(absence of primer–dimers or other nonspeciWc ampliWca-
tion products). Data acquisition and automated analysis
were done by the iCycler iQ software (version 3.1, Bio-
Rad). Real-time PCR results in Fig. 1 illustrate that the
diVerences in Ct value (Ct) between matched and mis-
matched primers are 0.3 for the DNA primer (with 3 sub-
terminal mismatch), 1.5 for the 3 LNA primer, and 6.8 for
the 3 LNA primer with 3 subterminal mismatch. Clearly,
the introduction of the 3 subterminal primer:template mis-
match shifts Ct values toward higher values but also signiW-
cantly increases the discriminating power of the 3 LNA
primer.
Equimolar dilutions of wild-type and mutant plasmid
PCR fragments were used to generate standard curves of 5
log-10 orders of magnitude. To enhance linearity and
reproducibility, dilutions were made in a 10-ng/l  DNA-
containing carrier solution. QuantiWcation of mutant alleles
in the presence of the wild-type form was tested by mixing
an excess (5£ 105 molecules) of wild-type allele with a 5-
point 10-fold dilution series of the mutant form (5£ 105–50
molecules). As a control, a standard curve containing only
the mutant allele was used. Ideally, both series should result
in overlapping ampliWcation plots. We observed that at low
levels of the mutant allele (<2500 molecules), the excess
of the wild-type allele (5£ 105 molecules) signiWcantly
impaired accurate quantiWcation of the low-abundant
alternative allele (Fig. 2). Therefore, the sensitivity of the
quantitative assay is estimated at 1/200 (mutant allele vs.
wild-type allele).
Comparative analysis revealed that the bona Wde NF1
mutation under study (c.2041C > T) is present as a variant
in at least three NF1 pseudogenes. To exclude interference
of NF1 pseudogenes with the quantiWcation of the bona Wde
NF1 mutation, all unknown samples were ampliWed with
NF1-speciWc exon 13 primers prior to nested real-time
qPCR. The Wrst-round ampliWcation was performed on a
PTC-200 Thermal Cycler (MJ Research) using 10 ng
gDNA input and a PCR touch-down program starting at
61 °C gradually reduced (1 °C /cycle) to 52 °C for an addi-
tional 30 cycles. Because both wild-type and mutant alleles
are ampliWed from the same NF1 exon 13 amplicon, the ini-
tial proportional representation of both alleles is preserved.
The Wrst-round ampliWcation products were puriWed with
Exonuclease I and Shrimp Alkaline Phosphatase (USB)
and were diluted (1/100,000) in a 10-ng/l  DNA-contain-
ing carrier solution.
Nested real-time quantitative PCRs were performed on
an iCycler iQ instrument. In each experiment, duplicates of
a standard dilution series of speciWc PCR fragments for
each allelic variant and triplicates of 2l of unknown sam-
ple template were ampliWed in a 15-l reaction containing
1£ SYBR Green I Master Mix and 250 nM of allele-spe-
ciWc primers. The thermal proWle was as described above.
Each experiment was performed twice, and data acquisition
and automated analysis were done by the iCycler iQ soft-
ware (version 3.1). The relative number of molecules of
Fig. 1. AmpliWcation plots of mutant plasmid using diVerent AS-PCR
primers: mutant (rectangle) and wild-type (triangle) DNA primer (green),
3 LNA primer (blue), and 3 LNA primer with 3 subterminal mismatch
(red) (replicates are shown). (For interpretation of the references to color
in this Wgure legend, the reader is referred to the web version of this
article.)
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Fig. 2. QuantiWcation of mutant alleles in the presence of the wild-type
form. An excess (5£ 105 molecules) of wild-type allele was mixed with a
dilution series of the mutant form (red dots). As a control, a standard
curve containing only the mutant allele was used (blue dots). At low levels
of the mutant allele (<2500 molecules or <1/200), the presence of the wild-
type allele signiWcantly impaired accurate quantiWcation of the low-abun-
dant alternative allele, as illustrated by lower Ct values for the red dots.
(For interpretation of the references to color in this Wgure legend, the
reader is referred to the web version of this article.)
10
15
20
25
30
35
40
1 10 100 1000 10,000 100,000 1,000,000
1/1
1/10
1/100
1/200
1/400
1/800
1/1000
1/10,000
C
t
number of molecules
  Chapter 2 
 71
146 Notes & Tips / Anal. Biochem. 359 (2006) 144–146
each allele was determined by interpolating the Ct values of
the unknown samples to each standard curve, followed by
determination of the fraction of mutant alleles. Quantita-
tive results of both experiments were highly concordant
(see Table 1 in Supplementary material), showing mutant
alleles in 1.41–47.40% of various tissues of the NF1 segmen-
tal patient.
In conclusion, we have described a real-time quantiWca-
tion strategy for the detection of low-percentage mosaic
point mutations. We evaluated the discriminating proper-
ties of diVerent AS-PCR primers and demonstrated that the
use of a 3 LNA primer with an artiWcial mismatch at the 3
subterminal position had the largest discriminating power.
To our knowledge, our method represents the Wrst quanti-
tative allele discrimination assay taking advantage of 3
LNA AS-PCR primers and SYBR Green I detection chem-
istry, allowing accurate, sensitive, and cost-eVective quanti-
Wcation of single-nucleotide changes. The presented
methodology oVers opportunities for research and molecu-
lar diagnostic applications where quantiWcation of two
DNA sequences that diVer by only one nucleotide is
desired. Examples include population SNP genotyping,
mutation detection, and risk assessment of disease trans-
mission to oVspring by mosaic patients.
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Abstract 
 
Mosaic neurofibromatosis type 1 (NF1) can present as mild generalized disease, segmental disease 
or gonadal mosaicism. Here we show that different clinical subtypes emerging within mosaic NF1 
result from a postzygotic NF1 mutation in neural crest derived cell types. The study of the affected 
cell types provides important insight into developmental concepts underlying particular NF1-related 
disease features. Four mosaic NF1 patients with different clinical manifestations (neurofibromas 
only, pigmentary changes only, and association of both symptoms) were investigated at the 
molecular level. For each patient various tissues and cell types were tested with quantitative assays 
capable of detecting low-percentage NF1 mutations. This approach confirmed the bi-allelic 
inactivation of Schwann cells in neurofibromas and demonstrated for the first time bi-allelic NF1 
inactivation in melanocytes in NF1-related café-au-lait macules. Interestingly, both disease features 
appear to arise even within a background containing predominantly NF1 wild-type cells. This report 
provides molecular evidence that the mosaic NF1 phenotype reflects the embryonic timing and 
accordingly the neural crest derived cell type involved in the somatic NF1 mutation. 
 
74  
  Chapter 2 
Introduction 
 
Neurofibromatosis type 1 (NF1, [MIM 162200]) is a common autosomal dominant disorder caused by 
alterations in the NF1 gene. The NF1 encoded protein, neurofibromin, functions as a negative 
regulator of Ras mediated signaling [1, 2, 3]. The primary clinical features of NF1 are café-au-lait 
macules (CALMs), freckling and benign peripheral nerve sheath tumors or neurofibromas [4]. NF1 
patients also have a predisposition to develop a wide spectrum of other symptoms, illustrating the 
critical function of neurofibromin in a variety of tissues and cell types. The biological context 
underlying the development of many NF1-related symptoms, however, remains largely unknown. 
Mosaic NF1 is caused by a postzygotic NF1 lesion [5, 6, 7] and can present as mild generalized 
disease, segmental disease or gonadal mosaicism [8]. The mosaic phenotype most probably reflects 
the timing of and tissues involved in the somatic mutation. Since segmental NF1 is characterized by 
the regionally limited distribution of NF1 diseases signs, it provides the opportunity to study cell 
populations differing only with regard to the mutation(s) giving rise to mosaicism. Determining when 
and in what cell types inactivation of the NF1 gene occurs is critical for understanding the basic 
pathology of NF1-related symptoms. 
In this report, we investigated one mildly affected and three segmental NF1 patients with different 
clinical manifestations, i.e. neurofibromas only, pigmentary changes only, and combination of both 
neurofibromas and pigmentary changes. In order to elucidate the involvement of particular cell 
types and mutational mechanisms in the respective phenotypes, we investigated various tissues and 
cell types derived from every mosaic patient with quantitative assays capable of detecting low-
percentage NF1 mutations. 
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Material and Methods 
 
Patient material 
Four mosaic NF1 patients with distinct clinical manifestations were included in the study. 
Neurofibromas only 
Patient SNF1-1 is a 46 years old female and has several small cutaneous neurofibromas within a 
limited body region on the trunk. Her two sons (20 and 23 years old) don’t show any NF1-related 
symptoms. Peripheral blood from the three individuals, together with buccal smears, hair roots, 
urine and Schwann cells and fibroblasts cultured from three neurofibromas of the female patient 
were available for analysis. 
Pigmentary defects only 
Patient SNF1-2 is a 23-year old male presenting with several CALMs within a background of 
hyperpigmented skin involving the entire right leg, hip and lower back (Figure 1A). Peripheral blood, 
buccal smears, hair roots and urine together with fibroblasts and melanocytes cultured from normal 
skin, CALM and the hyperpigmentation area were available for analysis. 
Patient SNF1-3 is a 37 year old female with freckling in the groin. Her both daughters (3 and 5 year 
old) present with full-blown NF1. Peripheral blood from the three individuals together with buccal 
smears, hair roots and urine of patient SNF1-3 were available for analysis. 
Pigmentary defects and neurofibromas 
Patient SNF1-4 is a 15-year old female with more than six CALMs scattered over the body and 
several small neurofibromas located on the right hand within a hyperpigmented background (Figure 
1B). Peripheral blood, buccal smears, hair roots and urine, together with Schwann cells and 
fibroblasts derived from one neurofibroma and fibroblasts and melanocytes derived from the 
hyperpigmentation area (right hand), two CALMs (left thigh and right lower back) and normal skin 
(right buttock) were available for analysis. Magnetic resonance imaging (MRI) of the patient’s right 
hand revealed a subcutaneous nodule with a few smaller surrounding subcutaneous satellite lesions. 
Histopathologically, the lesions arising within the hyperpigmentation area were determined as 
neurofibromas due to the absence of mitotic activity and the mixture of elongated spindle shaped 
Schwann cells and fibroblasts in a background of wavy collagenous fibers. This diagnosis was 
confirmed by immunohistochemistry (S100 positivity in the majority of spindle shaped cells). 
 
Cell culture 
Skin biopsy 
A biopsy of normally pigmented and/or hyperpigmented skin was taken using 5 mm punch biopsy 
excision. To separate the epidermal layer (with melanocytes anchored to the basal membrane) from 
the underlying dermis (with fibroblasts), skin biopsies were incubated overnight at 4 °C in dispase II 
(Boehringer Mannheim). Melanocytes were cultured in Ham’s F10 medium (Gibco, Invitrogen Ltd) 
supplemented with 2.5 % fetal calf serum (FCS), 1 % Ultroser, 5 ng/ml basic fibroblast growth 
factor, 10 ng/ml endohelin-1, 0.33 nM cholera toxin, 0.033 mM isobutyl-methyl-xanthine, 5.3 nM 12-
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O-tetradecanoyl phorbol-13-acetate and 20 ng/ml stem cell factor. Dermal fibroblasts were grown 
in DMEM medium (Gibco, Invitrogen Ltd) supplemented with 10% FCS. 
Neurofibroma 
Culture conditions for neurofibroma-derived Schwann cells and fibroblasts were as previously 
described [9, 10]. The presence of forskolin in the Schwann cell medium (SCM) promotes 
proliferation of cells bearing only the first hit (NF1+/-, SC F+). Replacement of proliferation medium 
by serum-free N2 medium and subsequently by proliferation medium without forskolin promotes 
proliferation of cells containing both hits (NF1-/-,SC F-). To estimate the purity of Schwann cell and 
fibroblast cultures derived from the neurofibroma of patient SNF1-4, immunofluorescence staining 
with rabbit S100 primary antibody (Dako) was performed as previously described [11]. For one SC F- 
culture (patient SNF1-1, neurofibroma 3), Schwann cells were separated from contaminating 
fibroblasts by using p75 (nerve growth factor receptor)-coupled MACS® Microbeads (Miltenyi Biotec) 
which magnetically label the Schwann cell target population. Subsequent growth of recovered cells 
in SCM resulted in a highly pure Schwann cell culture (>95%, estimated by S100 staining). 
 
NF1 mutation screening 
NF1 mutation analysis (GenBank reference sequence NM_000267.1) was performed essentially as 
described [12]. Briefly, genomic DNA (gDNA) was extracted from melanocyte cultures with the 
QiaAmp procedure (Qiagen) and from all other cell cultures with the Puregene procedure (Gentra). 
Cultures were treated with puromycin (200 µg/ml, 4-6 hours) before RNA extraction (RNeasy kit, 
Qiagen). The entire NF1 complementary DNA (cDNA) was sequenced using the ABI3730XL genetic 
analyser (Applied Biosystems). All mutations found at the cDNA level were confirmed on gDNA by 
cycle sequencing. Multiplex ligation-dependent probe amplification (MLPA) analysis was performed 
using the SALSA NF1 area kit (MRC Holland) following the manufacturer’s instructions to detect 
deletions. 
 
Fine mapping NF1 deletion breakpoints 
The genomic deletions detected by MLPA analysis were evaluated in further detail. The location of 
the NF1 multi-exon deletion breakpoints was determined by long-range PCR with primers residing in 
the segments adjacent to the deleted interval. Amplification products were subsequently sequenced 
by using the ABI3730XL genetic analyzer (Applied Biosystems). The location of the NF1 
microdeletion breakpoints was determined by aspecifically amplifying and sequencing paralogous 
sequence variants (PSVs) in the low copy repeats (LCRs) flanking the NF1 microdeletion region (De 
Raedt et al., in press). By scoring the relative intensity of both nucleotides of the PSV, the location 
of the breakpoint was determined: centromeric (higher relative intensity of the nucleotide specific 
for the telomeric LCR) or telomeric (higher relative intensity of the nucleotide specific for the 
centromeric LCR) of the PSV investigated. 
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Loss of heterozygosity NF1 region 
Loss of heterozygosity (LOH) in the NF1 gene region was evaluated by genotyping 2 microsatellite 
markers telomeric (3’NF1-3, 3’NF1-1) [13] and 4 within the NF1 gene (Alu, IVS27AC33.1, 
IVS38GT53.0, IVS27TG24.8) [14, 15, 16, 17]. Genomic DNA from paired melanocyte/Schwann cell 
and lymphocyte cultures of the same patient was investigated by touch-down PCR for the 
microsatellite markers and subsequently analyzed on the ABI3130XL genetic analyser (Applied 
Biosystems) with the GeneMapper software Version 3.7 (Applied Biosystems). To determine the 
extent of LOH in different samples from patient SNF1-4, additional SNPs proximal (rs6505129, 
rs6505165 and rs8071580) and distal (rs753750 and rs9904537) to the NF1 microdeletion region were 
evaluated as previously described [18]. LOH for a SNP was scored when the average ratio (SNP 
nucleotide/ control nucleotide) of the two alleles in the tested tissue fell outside the 95% 
confidence interval of the ratios observed in control blood DNA of the same patient and when the 
average ratios in tested tissue versus control blood were at least 20% different. The mechanism 
underlying LOH (deletion versus mitotic recombination) was evaluated by semi-quantitative PCR 
taking advantage of the amplification of NF1 exon 22 (103 bp) together with the corresponding 
fragment of its pseudogene located on chromosome 15 (107 bp) as previously described [18]. 
 
Cloning NF1 point mutations 
In order to determine whether both NF1 mutations detected in SCF- cultures derived from the 
neurofibromas of patient SNF1-1 resided on different alleles, cloning experiments were performed. 
For neurofibroma 1 (NF1 c.2041C>T and c.1655T>G), a fragment containing both alterations and an 
additional SNP in exon 13 (rs2285892) was amplified (516 bp), cloned in the pCR2.1-TOPO Vector 
(Invitrogen) and sequenced. For neurofibroma 2 (NF1 c.2041C>T and [c.603T>C; 604_621del]), a 
fragment containing the deletion and a SNP in exon 5 (rs1801052) was amplified (286 bp), cloned 
and sequenced. Since rs1801052 and rs2285892 are in complete linkage, information on the 
genotype of the SNP in exon 13 linked with the 1st hit (cloning experiment neurofibroma 1) and 
information on the genotype of the SNP in exon 5 linked with the 2nd hit (cloning experiment 
neurofibroma 2), provides information on the fact whether both mutations reside on the same (exon 
5/exon13: A/G or G/A) or different (exon5/exon13: A/A or G/G) haplotypes. 
 
Quantification of NF1 mutations 
Real-time quantitative PCR 
In order to detect low-percentage mosaicism for NF1 point mutations against a background of 
normal and pseudogene alleles, a nested real-time quantitative PCR (qPCR) assay was developed 
[19]. Briefly, the region spanning the NF1 point mutation was amplified (primer sequences available 
upon request) and equimolar dilutions of cloned PCR fragments (wild-type and mutant alleles) were 
used to generate standard curves of 5 orders of magnitude. For actual quantification, allele-specific 
3’ locked nucleic acid (LNA) primers (Eurogentec) were used. Since both somatic NF1 point 
mutations appeared to be present in several NF1 pseudogenes, samples were amplified with NF1 
specific primer pairs and diluted prior to nested real-time qPCR. In order to detect low-percentage 
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mosaicism for NF1 multi-exon deletions, a real-time qPCR assay using deletion-specific primers was 
developed. Briefly, a primer pair situated in the deletion specifically amplified the wild-type allele 
and a second breakpoint overlapping primer pair specifically amplified the mutant allele. Equimolar 
dilutions of both PCR fragments were used to generate standard curves of 5 orders of magnitude. 
Real-time qPCR reactions were performed on an iCycler iQ instrument (Bio-Rad). In each 
experiment, duplicates of a standard dilution series of specific PCR fragments for each allele variant 
(wild-type and mutant) and triplicates of 10 ng DNA of unknown samples (different tissues from 
segmental NF1 patient under study and non-NF1 control sample) were amplified in a 15µl reaction 
containing 1 x SYBR Green I Master Mix (Eurogentec) and 250 nM of allele-specific primers. The 
thermal profile consisted of 1 cycle at 95°C for 10 minutes followed by 40 cycles at 95°C for 15 
seconds and at 61°C (c.2042C>T), 63°C (c.2325+1G>A) or 60°C (c.1783_2000+205del422) for 1 
minute. Each experiment was performed twice and data acquisition and automated analysis was 
done by the iCycler iQ software version 3.1 (Bio-Rad). The relative number of molecules of each 
allele was determined by interpolating the Ct values of the unknown samples to each standard 
curve, followed by the determination of the fraction of mutant alleles (number of mutant molecules 
divided by sum of number of wild-type and mutant molecules). 
FISH analysis 
To determine submicroscopic NF1 deletions, dual color FISH was performed [20] using PAC clones 22 
(926B9; 5’NF1) and 13 (1002G3; 3’NF1) [13]. To investigate mosaicism, at least 100 interphase 
nuclei were evaluated. 
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Results 
 
Neurofibromas only (patient SNF1-1) 
NF1 mutation screening on selectively cultured Schwann cells (SC F-) derived from two 
neurofibromas revealed an identical mutation (c.2041C>T (p.R681X)) in each tumor in addition to 
two tumor specific alterations (c.1655T>G (p.L552R) and [c.603T>C; c.604_621del], respectively). 
Cloning experiments demonstrated that, for the two tumors, both NF1 mutations resided on 
different alleles. Quantification of mutant transcripts in the presence of the wild-type form was 
tested by mixing an excess (5x105 molecules) of wild-type allele with a 5 point 10-fold dilution 
series of the mutant form (5x105 – 50 molecules). As a control, a standard curve containing only the 
mutant transcript was used. Ideally, both series should result in overlapping amplification plots. We 
observed, however, that at low levels of mutant transcript (<2500 molecules), the presence of the 
wild-type transcript (5x105 molecules) significantly impaired accurate quantification of the low-
abundant alternative transcript. Therefore, the sensitivity of the quantitative assay is estimated at 
1/200. Real-time qPCR demonstrated the presence of the first hit (percentage mutant allele ± 
standard error of the mean (SEM)) in EBV transformed white blood cells (3.7±1.1%), hair follicles 
(1.8±0.5%), fibroblasts derived from both neurofibromas (8.4±1.6% and 19.4±7.9%, respectively) and 
selectively cultured Schwann cells from a third smaller neurofibroma (6.7±2.5%). Buccal smears, 
urine and fibroblasts derived from the third neurofibroma were negative as well as blood from both 
children of the patient and the control sample (Table 1). 
 
Pigmentary defects only 
Patient SNF1-2 
Combined NF1 cDNA sequencing and MLPA analysis revealed an NF1 microdeletion exclusively 
present in the melanocytes derived from CALMs and background hyperpigmentation area. A second 
alteration (c.1226_1227del) was only detected in the melanocytes of the CALM. Further 
characterization of the microdeletion revealed an atypical deletion with the proximal breakpoint 
residing within the centromeric LCR flanking the NF1 gene and the distal breakpoint located 
centromeric from the telomeric LCR flanking the NF1 gene before JJAZ1 exon 7 (minimum size of 
the deletion 1,30 Mb). FISH analysis of skin fibroblasts (CALM, hyperpigmented and unaffected skin) 
and blood lymphocytes with NF1 specific probes revealed low percentages of mosaicism (<5%) for 
the NF1 microdeletion (Table 2). 
Patient SNF1-3 
MLPA analysis on peripheral blood of one of the daughters of patient SNF1-3 pointed to an NF1 
multi-exon deletion (including exons 12a and 12b) at the genomic level. Long-range PCR confirmed 
the presence of a ~2kb deletion. Further characterization by sequencing localized the deletion 
breakpoints in exon 12a (c.1783) and intron 12b (c.2000+205) with additional bases at the deletion 
junction. Excess wild-type transcript did not influence quantification of low-abundant mutant 
transcript since identical amplification plots were obtained for mutant transcript and mutant 
transcript with excess wild-type fragment standard curves. Real-time quantitative PCR 
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demonstrated that the mutant allele was present in peripheral blood of both daughters with full-
blown NF1 (44.9±12.7% and 47.8±15.0%, respectively). The NF1 mutation was also detected in a low 
percentage of cells derived from different tissues from the mother: peripheral blood (1.5±0.6%), 
buccal smear (2.8±1.0%), urine (3.8±1.7%) and hair (7.2±2.9%), while the control sample was 
negative (Table 3). 
 
Pigmentary defects and neurofibromas (patient SNF1-4) 
Analysis of neurofibroma-derived Schwann cells (SC F+ and F-) and melanocytes derived from both 
the hyperpigmentation area and two CALMs remote from that zone revealed an identical NF1 
mutation (c.2325+1G>A) leading to out-of-frame skipping of exon 14 and deletion of the wild-type 
NF1 allele. For all samples, the proximal deletion breakpoint resided between rs6505129 
(chromosome 17 reference position 24777972, NCBI build 36.2) and rs6505165 (position 25598975), 
while the distal deletion breakpoint resided between the most distal PSV in the telomeric NF1 LCR 
(position 27439522) and rs9904537 (position 27579216) (minimum/maximum size of deletion 1.84 
Mb/2.80 Mb). To test the influence of excess wild-type transcript on detection of the mutant 
transcript (c.2325+1G>A), a 5 point 10-fold dilution series of the mutant form (5x105 – 50 molecules) 
was mixed with excess wild-type (5x105 molecules). Equal mounts of water (instead of wild-type 
transcript) were added to a second series of dilutions. Comparison of both amplification plots 
revealed that at low levels of mutant transcript (<1250 molecules), the presence of the wild-type 
transcript significantly impaired accurate quantification of the low-abundant alternative transcript. 
Therefore, the sensitivity of the quantitative assay is estimated at 1/400. Real-time qPCR 
demonstrated the presence of the intragenic NF1 mutation (percentage mutant allele ± SEM) in 
fibroblasts derived from both the neurofibroma (12.3±6.9%) and hyperpigmented area (2.0±0.6%). 
Peripheral blood, melanocytes and fibroblasts derived from normal skin, fibroblasts derived from 
both CALMs, buccal smear, urine and the control sample were negative. As expected, the mutation 
could not be detected in peripheral blood from the parents and siblings of the patient (Table 4). In 
order to pick up low-percentage mosaicism for the NF1 deletion, we are planning FISH experiments 
on skin fibroblasts (CALM, hyperpigmented and unaffected skin) and blood lymphocytes with NF1 
specific probes. Immunofluorescence staining revealed S100 positive cells in the SC F- (>95%), SC F+ 
(>95%) and fibroblast (~10%) cultures derived from the neurofibroma. 
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Discussion 
 
In this report, four mosaic NF1 patients with different clinical manifestations were investigated at 
the molecular level to provide insight into the cell types and mutational mechanisms involved in the 
development of particular NF1-related disease features. 
 
Neurofibromas only (patient SNF1-1) 
In selectively cultured Schwann cells (SC F-) derived from two neurofibromas, an identical NF1 
mutation in addition to two tumor specific alterations on the other allele were detected clearly 
confirming the tumor-initiating properties of Schwann cells in neurofibroma development [9, 21, 
22]. Quantitative mutation screening of fibroblasts derived from both neurofibromas revealed only 
low percentages of mutant -first hit- allele (8.4±1.6% and 19.4±7.9%, respectively), undetectable by 
conventional mutation detection techniques (i.e. PCR NF1 exon 13 and subsequent sequencing). 
Similarly, Shultz et al. (2000) [23] could not demonstrate any NF1 mutation in neurofibroma-derived 
fibroblasts from a segmental NF1 patient by use of the protein truncation test, enzymatic mutation 
detection and FISH. Remarkably, only a limited amount of mutant allele (6.7±2.5%) was detected in 
selectively cultured Schwann cells (purity estimated at >95%) from a third smaller tumor, further 
illustrating the high abundance of NF1+/+ cells in the tumor microenvironment. A growing body of 
experimental evidence supports the idea that NF1 haploinsufficiency in the tumor environment 
promotes (plexiform) neurofibroma formation in mice [24, 25, 26, 27, 28]. Haploinsufficient mast 
cells, for example, have been shown to be hypermigratory and to have increased survival and 
proliferation potential in response to stem cell factor (SCF), secreted by Nf1-/- Schwann cells [25, 
27]. Whether the abundance of NF1 wild-type cells in (dermal) neurofibromas from segmental NF1 
patients reflects a slightly different pathogenesis or, alternatively, is associated with the small size 
of these patients’ tumors (heterozygous neighboring cells may promote tumor growth more 
efficiently than wild-type neighboring cells) remains an important question. 
 
Pigmentary defects only (patient SNF1-2) 
Combined NF1 cDNA sequencing and MLPA analysis revealed an NF1 microdeletion exclusively 
present in melanocytes derived from affected skin of patient SNF1-2 (Table 2). Although a high 
frequency of mosaic NF1 microdeletions are caused by somatic recombination of the JJAZ1 gene 
[29], the current NF1 lesion does not represent a typical type II deletion. A second alteration 
(c.1226_1227del) was only present in melanocytes derived from the CALM, not in the 
hyperpigmented background area. Previously, Eisenbarth et al. (1997) [30] did not detect somatic 
NF1 inactivation in melanocytes cultured from 10 CALMs of patients with classical NF1. The 
discrepancy with the current data can probably be explained by different melanocyte culture 
conditions and by the fact that, before, the cells were only analyzed for LOH at the NF1 locus 
whereas we performed comprehensive NF1 mutation screening. Available evidence suggests that 
paracrine cytokines interacting between epidermal melanocytes and non-melanocytic cells in the 
skin play a central role in epidermal hyperpigmentation (reviewed in [31]). Although the 
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etiopathogenesis of NF1-related pigmentary lesions remains largely unknown, it has been postulated 
that the mechanism of epidermal hyperpigmentation and mast cell infiltration in NF1 CALMs might 
be associated with increased secretion of cytokines such as SCF and hepatocyte growth factor by 
dermal fibroblasts [32]. In the same line, De Schepper et al. (2006) [33] reported increased levels of 
soluble SCF in fibroblast supernatant from NF1 CALM but, importantly, also in NF1 normal skin 
compared with control individuals. In other words, paracrine networks are at play in the NF1 skin, 
but are not sufficient for CALM development. Here, we demonstrate that bi-allelic NF1 inactivation 
in the melanocyte may be required for CALM formation, while even in the haploinsufficient state 
the NF1 gene presumably has an effect on skin color. Recently, a significant increase in melanocyte 
density was demonstrated in NF1 CALM skin compared with NF1 normal skin, control normal skin and 
control CALM skin [33]. These NF1 CALM melanocytes also display a higher melanin content and 
melanogenesis [34]. In light of our current findings, it is tempting to speculate that bi-allelic NF1 
inactivation in melanocytes might be the underlying molecular mechanism for the distinct 
properties of these NF1-related pigmentary lesions. In a next step, it will be essential to determine 
the dysregulating consequences of neurofibromin loss and NF1 haploinsufficiency on signaling 
pathways in melanocytes. Previous studies on segmental pigmentary lesions revealed NF1 mutations 
in 9% and 18% of fibroblasts [6, 7] and in 20% of keratinocytes [7] cultured from CALMs. Also in this 
report, low percentages of the NF1 mutation were detected in the fibroblasts derived from the 
hyperpigmentary and CALM skin lesions of patient SNF1-2 (3% and 4%, respectively). Therefore, we 
speculate that pigmentary lesions can arise within an environment consisting of predominantly NF1 
wild-type cells. 
Although a definite association between malignant melanoma and NF1 has not yet been established, 
one clinical report describes the occurrence of malignant melanoma arising from a pre-existing 
CALM in an NF1 patient [35]. This may imply a model of multi-step tumor progression, a genetic 
scenario previously demonstrated for the plexiform neurofibroma – malignant peripheral nerve 
sheath tumor sequence. Stepwise transformation from melanocytes to melanoma has been 
described previously for non-NF1 related melanomas [36]. While BRAF and NRAS mutations occur at 
the stage of the benign nevus, additional molecular lesions in CDKN2A and PTEN are required for the 
progress towards malignancy. Interestingly, BRAF and NRAS mutations activate the MAP-Kinase 
pathway, an effect which can also be caused by NF1 inactivation. Therefore, the question emerges 
whether, instead of BRAF and NRAS mutations, NF1 inactivation in NF1-related CALMs might act as 
an alternative mechanism to activate the MAP-Kinase pathway. Interestingly, double inactivation of 
the NF1 gene was recently demonstrated in an early disease stage melanoma arising in a 15-year old 
NF1 patient [37]. 
 
Pigmentary defects and neurofibromas (patient SNF1-4) 
In patient SNF1-4 an identical NF1 mutation (c.2325+1G>A) was revealed in neurofibroma-derived 
Schwann cells and melanocytes derived from both the hyperpigmentation area and two CALMs 
remote from that zone. Moreover, all samples showed deletion (1.84 Mb-2.80 Mb) of the wild-type 
NF1 allele. Currently, we are further pinpointing the deletion breakpoints in these samples by using 
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high resolution techniques. Given the fact that melanocytes and Schwann cells can arise from a 
bipotent glial-melanocyte precursor [38], it is tempting to speculate that one or both NF1 mutations 
occurred in a common neural crest precursor (Figure 2). The clinical picture of neurofibromas 
arising within a hyperpigmented background might be compatible with this hypothesis. In other 
words, loss of heterozygosity for the underlying NF1 mutation in an early developmental stage (e.g. 
bipotent glial-melanocytic precursor [38]) might be responsible for the segmental involvement of 
epidermis (melanocyte) and several nerve branches (Schwann cell). Unexpectedly, the NF1 point 
mutation was also detected in neurofibroma-derived fibroblasts (culture passage 2), albeit at a 
significant lower frequency (12.3±6.9%). Immunofluorescence staining demonstrated that the latter 
observation most probably can be explained by the presence of S100 positive cells (Schwann cells 
and/or melanocytes) in the fibroblast cultures. It is well known that different neurofibromas from 
one NF1 patient bear different second hits (patient SNF1-1 and [11]) and arise during the second 
decade of life [4]. Strikingly, both inactivating NF1 mutations in the melanocytes derived from the 
hyperpigmentation zone (right hand) and two CALMs remote from that area (left thigh and right 
lower back) seem to be identical. This finding is particularly intriguing with respect to the typical 
congenital appearance of many NF1 CALM lesions. It remains to be explored whether the early 
presentation of pigmentary NF1 signs could be attributed to bi-allelic NF1 inactivation in 
melanocytic precursors (melanoblasts) during embryonic development (Figure 2). Melanoblasts 
migrate in mice from the neural crest dorsolaterally and enter the skin where they proliferate 
clonally and finally differentiate into mature skin melanocytes [39, 40]. One might assume that 
neurofibromin loss in melanoblasts will result in enhanced proliferation and, hence, increased 
melanocyte density [33] in NF1-related CALM lesions. It will be essential to molecularly dissect more 
CALM lesions derived from different areas of the body and to determine the (presumably different) 
second hit in NF1 clinical features arising only later in life. 
 
Mosaic transmission (patient SNF1-3) 
A somatic mutation may affect somatic cells only (somatic mosaicism), gonadal cells only (gonadal 
mosaicism) and a proportion of both cell types (gonosomal mosaicism). The clinical picture of 
patient SNF1-3 (freckling only) and her both daughters (full-blown NF1) together with the 
quantitative data (Table 3) illustrate that this patient is a gonosomal mosaic. Clearly, and as 
opposed to previous animal work [41], the risk of transmitting disease to offspring is not 
proportional to the percentage of body area involved. The molecular data obtained from patient 
SNF1-3, and all other mosaic patients described in this report, irrefutably indicate that the 
percentage of the NF1 mutation in non-neural crest derived cells is often so low that it would be 
missed by routine NF1 screening. This implies that an accurate diagnosis for mosaic NF1 can only be 
established by comprehensive screening of those cell populations giving rise to mosaicism, i.e. 
Schwann cells in neurofibromas and/or melanocytes in pigmentary lesions. This new insight will 
incontestably facilitate genetic counseling of individuals with mosaic NF1. Screening the relevant 
cell type in the mosaic NF1 patient can provide a molecular marker useful in the prenatal and 
presymptomatic diagnostic setting. 
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In conclusion, we provide for the first time molecular evidence that different NF1 mosaic 
phenotypes result from a postzygotic NF1 mutation in neural crest derived cell types. While NF1 
deficiency in Schwann cells is essential for neurofibroma development, bi-allelic NF1 inactivation in 
melanocytes seems to be required for NF1-related CALM development. Both disease features arise 
even within a background containing predominantly NF1+/+ cells. These findings provide important 
insight into developmental concepts underlying NF1-related disease features and open avenues for 
improved genetic counseling of individuals with mosaic NF1. 
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Table 1. Overview of NF1 mutations revealed by routine mutation detection techniques (Routine) 
and real-time quantitative PCR (qPCR) in different tissues derived from segmental patient SNF1-1 
presenting with neurofibromas only. 
 
(SC F-: Schwann cells grown without forskolin, Fibro: fibroblasts, +: mutation detectable, -: 
mutation not detectable, qPCR: percentage mutant allele ± standard error of the mean determined 
by real-time quantitative PCR) 
 
 
NF1 mutation 
c.2041C>T (p.R681X) 
Patient Sample 
Routine qPCR 
Second hit 
SC F- + 41.4±15.1% c.1655T>G (p.L552R) Neurofibroma 1 
Fibro - 8.4±1.6% - 
SC F- + 47.4±15.6% [c.603T>C; c.604_621del] Neurofibroma 2 
Fibro - 19.4±7.9% - 
SC F- - 6.7±2.5% - Neurofibroma 3 
Fibro - - - 
Blood - 3.7±1.1% - 
Buccal smear - - - 
Urine - - - 
SNF1-1 
Hair - 1.8±0.5% - 
Child 1 Blood - - - 
Child 2 Blood - - - 
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Table 2. Overview of NF1 mutations revealed by routine mutation detection techniques (Routine) 
and quantitative assays (FISH) in different tissues derived from segmental patient SNF1-2 presenting 
with pigmentary defects only. 
 
(MC: melanocytes, +: mutation detectable, -: mutation not detectable, FISH: percentage of 
interphase nuclei with NF1 microdeletion determined by FISH analysis, NA: no data available) 
 
 
NF1 mutation 
NF1 microdeletion 
Patient Sample 
Routine FISH 
Second hit 
MC + NA c.1226_1227del Café-au-lait spot  
Fibro - 4% - 
MC + NA - Hyperpigmentation 
Fibro - 3% - 
MC - NA - Unaffected skin 
Fibro - 0% - 
Blood - 2% - 
Buccal smear - NA - 
Urine - NA - 
SNF1-2 
Hair - NA - 
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Table 3. Overview of NF1 mutations revealed by routine mutation detection techniques (MLPA) and 
real-time quantitative PCR (qPCR) in different tissues derived from segmental patient SNF1-3 
presenting with freckling only. 
 
(+: mutation detectable, -: mutation not detectable, qPCR: percentage mutant allele ± standard 
error of the mean determined by real-time quantitative PCR) 
 
 
NF1 mutation 
c.1783_2000+205del422 
Patient Sample 
MLPA qPCR 
Child 1 Blood + 44.9±12.7% 
Child 2 Blood + 47.8±15.0% 
Blood - 1.5±0.6% 
Buccal smear - 2.8±1.0% 
Urine - 3.8±1.7% 
SNF1-3 
Hair - 7.2±2.9% 
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Table 4. Overview of NF1 mutations revealed by routine mutation detection techniques (Routine) 
and real-time quantitative PCR (qPCR) in different tissues derived from mosaic patient SNF1-4 
presenting with neurofibromas and pigmentary defects. 
 
(SC: Schwann cells grown with (F+)/ without (F-) forskolin, Fibro: fibroblasts, MC: melanocytes, +: 
mutation detectable, -: mutation not detectable, qPCR: percentage mutant allele ± standard error 
of the mean determined by real-time quantitative PCR, NA: no data available, S100: S100 
immunofluorescence data available) 
 
 
NF1 mutation 
c.2325+1G>A 
Patient Sample 
Routine qPCR 
deletion NF1 allele 
SC F- + 88.8±37.5% + S100 
SC F+ + 67.2±32.8% + S100 
Neurofibroma 
(hand, right) 
Fibro + 12.3±6.9% - S100 
MC + 96.9±75.1% + Hyperpigmentation 
(hand, right) Fibro - 2.0±0.6% - 
MC + 71.8±20.8% + Café-au-lait spot 
(thigh, left) Fibro - - - 
MC + 54.9±33.6% + Café-au-lait spot 
(lower back, right) Fibro - - - 
MC - - - Normal skin 
(buttock, right) Fibro - - - 
Blood - - - 
Buccal smear - - - 
Urine - - - 
SNF1-4 
Hair - NA - 
Mother  Blood - - - 
Father Blood - - - 
Brother Blood - - - 
Sister Blood - - - 
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Figure 1. Illustration clinical subtypes of mosaic NF1 patients 
 
A. Patient SNF1-2 presents with several CALMs (illustrated by asterisks) within a pigmented 
background involving the entire right leg, hip and lower back. 
B. Patient SNF1-4 presents with more than six café-au-lait macules (one depicted on the left) 
scattered over the body and several small neurofibromas (illustrated by asterisks) located on the 
hand within a hyperpigmented background (depicted on the right). 
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Figure 2. Proposed genetic model for neurofibroma and café-au-lait macule development in mosaic 
NF1 patients. 
 
The clinical mosaic phenotype reflects the timing and accordingly the cell type involved in the 
somatic mutation. While mutations occurring in terminally differentiated cells (i.e. Schwann cells or 
melanoblasts/melanocytes) will give rise to solitary symptoms (i.e. neurofibromas only (patient 
SNF1-1) or pigmentary lesions only (patient SNF1-2)), somatic alterations earlier in embryonic 
development (i.e. common precursor of both cell types) will result in associated symptoms (i.e. 
neurofibomas and pigmentary defects (patient SNF1-4)). Interestingly, both disease features appear 
to arise even within a background containing predominantly NF1+/+ cells. 
 
(Z: zygote, NC: neural crest stem cell, GM: glial-melanocytic precursor, G: glial cell, SC: Schwann 
cell, Mb: melanoblast, Mc: melanocyte, NFB: neurofibroma; CALM: café-au-lait macule) 
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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal
tract. KIT and PDGFRA activating mutations are the oncogenic mechanisms in most sporadic GISTs. In
addition to sporadic occurrences, GISTs are increasingly being recognized in association with neurofibroma-
tosis type 1 (NF1), yet the underlying pathogenic mechanism remains elusive. To gain an insight into the
mechanisms underlying GIST formation in NF1 patients, we studied seven GISTs from three NF1 patients
with a combination of different techniques: mutation analysis (KIT, PDGFRA and NF1), western blotting,
array CGH and ex vivo imatinib response experiments. We demonstrate that (i) the NF1-related GISTs do
not have KIT or PDGFRA mutations, (ii) the molecular event underlying GIST development in this patient
group is a somatic inactivation of the wild-type NF1 allele in the tumor and (iii) inactivation of neurofibromin
is an alternate mechanism to (hyper) activate the MAP-kinase pathway, while the JAK-STAT3 and PI3K-AKT
pathways are less activated in NF1-related GIST compared with sporadic GISTs. In conclusion, we report for
the first time the molecular pathogenesis of GISTs in NF1 individuals and demonstrate that this type of tumor
clearly belongs to the spectrum of clinical symptoms in NF1.
INTRODUCTION
Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the gastrointestinal tract (1). They
occur predominantly in the stomach (70%) and small intestine
(10–20%) and originate from primitive cells with character-
istics of the interstitial cells of Cajal (ICCs), the autonomic
pacemaker cells which regulate peristalsis in the digestive
tract (1–3). Most sporadic GISTs contain gain-of-function
mutations in KIT (80–85%) (4,5) and strongly express the
constitutively activated protein (6). Some GISTs contain
gain-of-function PDGFRA mutations as an alternate onco-
genic mechanism (7,8). Both receptor tyrosine kinases trans-
duce their signals through the downstream PI3K-AKT (9),
MAP-kinase (10,11) and JAK-STAT3 signaling cascades
(12–16). Therapeutic targeting with the tyrosine kinase inhibi-
tor imatinib (Gleevec, Novartis, Basel, Switzerland) shows a
clinical benefit in up to 80% of patients with sporadic GIST
(17,18).
GISTs are increasingly recognized in adults with neuro-
fibromatosis type 1 (NF1), an autosomal dominant genetic
disorder caused by alterations of the NF1 gene and affecting
1/3500 individuals worldwide. Neurofibromin, the protein
encoded by NF1, functions as a GTPase-activating protein
for Ras by catalyzing the hydrolysis of active Ras-GTP to
an inactive Ras-GDP (19–23). The primary clinical features
of the disease are cafe´-au-lait spots, freckling and benign
peripheral nerve sheath tumors or neurofibromas (24).
{
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Neurofibromin deficiency in neurofibromas results in hyper-
activation of the MAP-kinase pathway. On the basis of a
single Swedish study of 70 NF1 patients, it is estimated that
adults with NF1 might have a risk for GISTs as high as 7%
(25). GISTs in NF1 patients tend to be multiple and are
located predominantly within the small intestine (26–28).
Morphologically and immunohistochemically, GISTs occur-
ring in the NF1 patients are similar to sporadic GISTs
(26–29). Little is known about the molecular basis underlying
GIST formation in NF1, and whether there is a difference in
the molecular pathogenesis of sporadic and NF1-related
GISTs. It remains an intriguing question why NF1 patients
are at an increased risk for this type of tumor.
RESULTS
Histopathological analysis
The NF1-related intestinal tumors corresponded to bona fide
spindle cell type GISTs (Fig. 1A). The tumor cells were
strongly positive for CD117 (Fig. 1B and 1C). The mast
cells served as positive control for CD117, whereas the
other tissue elements of the mucosa and submucosa were
negative (Fig. 1B and 1C). There was a variable positivity
for alpha smooth muscle actin, CD34 and S-100 protein,
whereas desmin was negative.
Mutation analysis
KIT/PDGFRA. Analysis of the entire KIT and PDGFRA coding
region did not reveal any activating mutation in the NF1-related
GIST specimens (Table 1). One single nucleotide polymorphism
(SNP) in the 30-UTR region ofKIT (rs2213181, http://www.ncbi.
nlm.nih.gov/SNP) was revealed in all GISTs derived from
patient NF1-1. In the GIST of patient NF1-3, one silent poly-
morphism was found in KIT (p.K546K) and five alterations
were found in PDGFRA: three silent mutations (p.N204N,
p.G313G and p.A603A), one 30-UTR SNP (rs7680422, http://
www.ncbi.nlm.nih.gov/SNP) and one missense mutation
[c.1825T.C (p.S478P)]. The missense mutation was not pre-
dicted to have an impact on protein activity (Polyphen algorithm,
http://tux.embl-heidelberg.de/ramensky) and was found in
19/98 (19%) control individuals. All detected variants were
also present in DNA extracted from peripheral white blood
cells of the respective patients. The detection of heterozygous
polymorphisms indicates the presence of both KIT alleles in
one out of seven tumors and both PDGFRA alleles in four out
of seven tumors.
NF1. Mutation screening of peripheral blood revealed NF1
germline mutations in all three patients (Table 1). The
somatic alterations in the NF1 gene region detected in six
of the seven GISTs (Table 1) were three nonsense
mutations, one donor splice site mutation, a multi-exon del-
etion encompassing NF1 exons 10c–21 and one loss of het-
erozygosity (LOH) event including the NF1 gene. All NF1
mutations are assumed to have an inactivating effect
(Table 1). Analysis of the nonsense mutation p.R2616X in
different cell types derived from tumor II of patient NF1-2
demonstrated that the somatic NF1 mutation was exclu-
sively present in the cells cultured with the medium selec-
tive for ICC culture and not in fibroblasts grown from the
same tumor.
Western blotting
All seven NF1-related tumors showed only rudimentary
neurofibromin expression in comparison with the control
GIST882 cell line harboring the KIT p.K642E mutation and
the sporadic GIST with the KIT p.557–558delWK mutation
(Fig. 2). NF1-related GISTs demonstrated normal total KIT
expression but low levels of constitutive KIT autophosphory-
lation in comparison to the control GIST882 and sporadic
GIST cells (Table 2). Total MAPK and MAPK phosphory-
lation was ubiquitously more pronounced in NF1-related
GIST tissue. On the basis of the densitometric quantification
of autoradiographic signals, the relative p-MAPK expression
in NF1-related GIST was 3–18-fold higher than in sporadic
GIST (Table 2). Expression of total AKT was variable in
NF1-related GISTs and not associated with protein phos-
phorylation. Moreover, NF1 tumors did not express STAT3
protein.
Figure 1. Histopathological analysis of NF1-related GISTs. (A) Low power view, showing the spindle cell character of the NF1-related GIST (H&E stain,
200). (B) KIT staining shows strong expression in the tumor (immunoperoxidase stain for CD117, 50). (C) Detail of the mucosa. Only the mast cells
are KIT positive (immunoperoxidase stain for CD117, 350).
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Array CGH experiments
Array CGH experiments on NF1-related GISTs showed
similar losses of chromosome regions as seen in sporadic
GISTs (i.e. losses of chromosomes 11, 14, 22 and 1p) in
addition to several extra alterations (Table 3). These additional
chromosomal abnormalities seem not to be recurrent in the
different tested NF1-related GISTs. Array CGH confirmed
LOH of the NF1 gene in the large tumor of patient NF1-3
[loss of the clones containing the NF1 gene (RPCI5-926B9
and RP11-229K15)] while no other aberrations were observed
(Table 3 and Fig. 3).
Phenotype of cultured cells
After 3 days in culture, the primary cells of tumor III from
patient NF1-2 exhibited spindle shape type of growth and
95% were KIT immunopositive. The Ki-67 labeling index
was 0.5 and 8.7% in ligand unstimulated and ligand stimulated
cultures, respectively (Fig. 4).
Imatinib assay
As shown in Figure 5, KIT phosphorylation of primary
NF1-related GIST cells seeded in culture is ligand-
dependent as shown by very limited KIT phosphorylation
in the absence of stem cell factor (SCF). SCF-dependent
KIT phosphorylation of NF1-related GIST cells is totally
inhibited by exposure to imatinib at concentration of
0.5 mM. The same inhibition is observed in the control
autophosphorylated GIST882 cell line harboring the KIT
p.K642E mutation. The level of MAPK phosphorylation of
primary NF1-related GIST cells was moderately decreased
after exposure to imatinib but the inhibition was neither
complete nor dose-dependent. Imatinib decreased in a dose-
dependent way the level of MAPK autophosphorylation at
concentrations lower than 1.0 mM in the GIST882 cell line
but not at any tested doses in control fibroblasts. The rela-
tive p-KIT and p-MAPK expressions, based on the densito-
metric quantification of autoradiographic signals, are shown
in Table 4.
DISCUSSION
Although activating mutations of KIT and PDGFRA are
known to be the most frequent genetic events in the develop-
ment of sporadic GISTs, the underlying pathogenic mechan-
ism leading to GIST formation in the NF1 setting remains
elusive. In this study, total screening of KIT and PDGFRA
in seven GISTs from three NF1 patients did not reveal any
activating mutation. Several sequence variants were detected:
three silent mutations in PDGFRA (p.N204N, p.G313G and
p.A603A), 1 silent mutation in KIT (p.K546K), one SNP in
the 30-UTR region of both KIT and PDGFRA and one mis-
sense mutation in exon 10 of PDGFRA (p.S478P) that was
not predicted to have an impact on protein activity (Polyphen
algorithm) and that is a frequent polymorphism (19/98 con-
trols, 19%) in the examined population. All variants were
also present in normal control tissue (white blood cells) of
the respective patients. In conclusion, the alterations do not
correspond to known mutation hot spots in sporadic GISTs,
are not tumor specific and have not been demonstrated to
result in activation of the tyrosine kinases. This finding is in
line with published reports (27–31). Of the 113 NF1-related
GISTs previously published, only eight showed KIT/
PDGFRA alterations. Takazawa et al. (2005) (30) reported
three KIT (p.L558L, p.P627L and p.I653T) and two
PDGFRA (p.P589S and p.R822S) mutations in 34 NF1-related
GISTs. None have been demonstrated to result in activation of
the protein nor have they been previously reported in sporadic
or familial GIST. Yantiss et al. (2005) (29) detected an iden-
tical point mutation in KIT exon 11 in three tumors from one
patient. As control tissue was not analyzed, this patient may
have had a germline KIT mutation. Taken together, these
results indicate that KIT or PDGFRA mutations are not
playing a role in the development of GISTs in NF1 patients.
In accordance with Knudson’s two-hit hypothesis (32),
somatic inactivation of the NF1 tumor suppressor gene leads
to tumor formation in NF1 (33–36). In line with this
concept, we detected somatic NF1 alterations in six of seven
NF1-related GISTs (Table 1). Analysis of different cell
types derived from tumor II of patient NF1-2 demonstrated
that the somatic NF1 mutation was only present in tumoral
cells cultured using specific conditions for ICCs (37). This is
the first time that somatic NF1 inactivation is demonstrated
Table 1. Molecular analysis of seven GISTs derived from three NF1 patients
Patient Tumor Material KIT PDGFRA NF1
Germline Somatic Mutation effect
NF1-1 I F 2 2 c.4269þ1G.T c.5546þ2T.A Frameshift leading to PTC
II F 2 2 c.5242C.T (p.R1748X) PTC
III F 2 2 ND
NF1-2 I F 2 2 c.6791dupA c.279T.A (p.C93X) PTC
II ICCþ F 2 2 c.7846C.T (p.R2616X) PTC
III ICCþ F 2 2 del [ex10c–21] Truncating
NF1-3 I F 2 2 c.7807delG LOH Loss wild-type NF1 allele
F, frozen; 2, negative; ND, no mutation detected; PTC, premature termination codon; ICC, interstitial cells of Cajal.
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in neoplastic GIST cells and it illustrates that the lack of func-
tional neurofibromin, in the absence of KIT or PDGFRA
mutations, can lead to GIST formation.
Neurofibromin functions as a negative regulator of the
MAP-kinase pathway by catalyzing the hydrolysis of active
Ras-GTP to an inactive Ras-GDP. In this light, inactivation
of neurofibromin in NF1-related GISTs is the mechanism
leading to tumor formation. To further elucidate this hypo-
thesis, we evaluated the expression of KIT, neurofibromin
and several downstream signaling molecules. Clear differ-
ences were observed between sporadic and NF1-related
GISTs (Fig. 2). First, NF1-related GISTs demonstrated com-
parable total KIT expression but low levels of constitutive
KIT autophosphorylation. Secondly, in contrast to sporadic
tumors, NF1-related GISTs showed a dramatically reduced
level of neurofibromin, confirming the inactivating effect of
the NF1 somatic mutations. Thirdly, strong expression and
activation of MAPK in NF1-related GISTs illustrated
increased signaling through the MAP-kinase pathway when
compared with sporadic GIST cells. Fourthly, the
JAK-STAT3 and PI3K-AKT pathways were shown to be
less active in NF1-related GISTs. These data suggest that
activation of the MAP-kinase cascade is a common cause of
GIST development in both NF1 and non-NF1 patients,
although there are important differences in the mechanism
of activation (inactivation of NF1 versus activation of
KIT/PDGFRA).
Recurrent cytogenetic aberrations in sporadic GISTs
include deletion of 14q, 22q, 1p, 11p and 9p and gain of 8p
and 17q (reviewed in 5). These chromosomal changes can
be viewed as secondary events acquired after the oncogenic
mutations in the receptor tyrosine kinases and are associated
with clinical progression. While deletion of chromosome
arms 14q (38–43) and 22q (39,42–45) are frequent findings
in sporadic GISTs and likely represent sites for tumor suppres-
sor genes that play a role early in GIST formation, losses on
chromosomes 1p, 9p and 11p are more significantly associated
with malignancy (40,46–48). Gains on chromosomes 8q and
17q are associated with metastatic behavior (41,42,49). The
array CGH experiments on NF1-related GISTs showed
similar gains and losses of chromosome regions as seen in
sporadic GISTs, i.e. losses of chromosomes 11, 14, 22 and
1p, in addition to several extra alterations (Table 3). These
additional chromosomal abnormalities seem not to be recur-
rent in the different tested NF1-related GISTs. Remarkable
is the array CGH profile of the very large tumor from
patient NF1-3 where only the clones containing the NF1
gene are deleted while no other aberrations are observed
(Fig. 3). Taken together, the genomic changes observed in
the analyzed NF1-related GISTs were similar to those
described in sporadic GISTs and did not indicate any change
that could be associated particularly with NF1-related
GISTs, except for the deletion of the NF1 gene region. It
remains elusive why clinically symptomatic GISTs arise in
only a minority of NF1 patients and why, in contrast to spora-
dic tumors, they tend to be multiple and predominantly located
in the small intestine. The presence of multiple GISTs in NF1
might reflect a distinct rate-limiting step in oncogenesis com-
pared with sporadic GIST. While a broad spectrum of in-
activating genetic mechanisms might lead to suppression of
the wild-type NF1 allele and hence GIST formation in NF1
patients, only a limited set of specific activating mutations
in KIT/PDGFRA will result in sporadic GIST. Moreover,
genotypes at modifying loci, not detectable by array CGH,
might trigger the development, location and number of mul-
tiple GISTs in NF1 patients.
On the basis of the array CGH profiles of the three tumors
from patient NF1-2 and tumors I and II from patient NF1-1
(Table 3), one might argue that clustered GISTs are clonal.
In this light, the identical chromosomal alterations in the
tumors of each patient (loss 1pter!1p12 and 14 for NF1-2;
loss 1pter!1p12, 14 and 22 for NF1-1) would reflect a
common precursor lesion, whereas the tumor-specific altera-
tions (cytogenetic aberrations and NF1 somatic mutation)
could be seen as secondary events. However, as illustrated
by the same alterations in the tumors from two different
patients, deletion of chromosomes 1p, 14 and 22 are recurrent
cytogenetic aberrations in GISTs. Moreover, the apparently
identical breakpoints at chromosome band 1p12 can be
explained by the poor clone coverage at the centromere
[21 Mb gap between RP11-418J17 (1p12) and RP11-417J8
(1q12)]. Overall, different tumors derived from the same
Figure 2. Analysis of KIT/PDGFRA downstream signaling pathways in two
sporadic [GIST882 cell line (KIT p.K642E) and sporadic GIST (KIT p.557–
558delWK)] and seven NF1-related GISTs by western blotting. Equal
protein loading was demonstrated with anti-actin staining. On the basis of
the densitometric quantification of autoradiographic signals, the relative
p-MAPK expression in the NF1-related GISTs was 3–18-fold higher than in
the sporadic GIST. Because of short exposure time, phosphorylation of
MAPK of GIST882 is less visible.
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patient bear different NF1 somatic mutations and, with the
exception of the typical GIST-related chromosomal altera-
tions, array CGH profiles are quite diverse. Therefore, it is
most likely that multiple GISTs in NF1 patients are indepen-
dent tumors.
The tyrosine kinase inhibitor imatinib (Gleevec, Novartis)
has tremendously improved the treatment of advanced sporadic
GISTs, showing a clinical benefit in up to 80% of patients
(17,18). To determine whether this drug could also be effec-
tive in NF1-related GISTs, we performed an ex vivo imatinib
response experiment. As illustrated in Figure 5, ligand-
dependent KIT autophosphorylation of primary NF1-related
GIST cells and the control GIST882 cell line is totally inhib-
ited by the exposure to imatinib at a concentration of 0.5 mM.
In contrast to control fibroblasts, the level of MAPK autophos-
phorylation of primary NF1-related GIST cells was lowered
after exposure to imatinib, although the inhibition was
neither complete nor dose-dependent as clearly illustrated in
the GIST882 cell line. These experiments thus suggest that
imatinib might only have a mild effect on NF1-related
GISTs. It will be important to determine whether this
ex vivo observation can be translated into clinical benefit for
NF1 patients with GISTs. As it was proven by in vitro
studies (18), wild-type KIT is equally sensitive to imatinib
as mutated KIT protein. Nevertheless, this observation does
not translate to clinical response of patients with tumors that
do not harbor KIT mutations (who poorly respond to the treat-
ment). Therefore, in vitro assays may have only restricted
predictive value.
In conclusion, we report for the first time the molecular
pathogenesis of GISTs in NF1 individuals. Somatic NF1
inactivation in the ICCs seems to be the molecular event
underlying GIST development in the NF1 setting. Inactivation
of neurofibromin in the absence of KIT or PDGFRA mutations
is an alternate mechanism leading to GIST formation. More-
over, NF1-related GISTs show an increased signaling
through the MAP-kinase pathway when compared with spora-
dic GIST cell lines. These findings clearly position GISTs in
the range of clinical symptoms seen in NF1. It will be import-
ant to determine whether the tyrosine kinase inhibitor Gleevec
used in the treatment of sporadic GIST also has an effect on
NF1-related GIST.
MATERIAL AND METHODS
Patient material
Studies were performed on seven GISTs derived from three
consenting NF1 patients. Peripheral blood was available for
all patients as well as frozen tissue from the seven tumors
and two tumor cell cultures from patient NF1-2. Control
GIST cells included a GIST882 cell line harboring a KIT
p.K642E mutation (50) and a sporadic GIST with a KIT
p.557–558delWK mutation.
Phenotype NF1 patients
Patient NF1-1 is a 72-year-old female patient with widespread
cutaneous neurofibromas. At the age of 59 years, a carcinoid
tumor originating from the duodenum was resected. A GIST
in the small intestine was diagnosed at the age of 68 and
another in the retroperitoneal area adjacent to the bladder 4
years later. During surgery, both tumors were resected as
well as a third not previously noted. The patient died post-
operatively due to pulmonary complications. Her mother had
had NF1 and had died due to complications related to a
GIST at the age of 40.
Patient NF1-2 is a 59-year-old male with family history of
neurofibromatosis type 1 and multiple cutaneous neuro-
fibromas. Multiple GISTs of the duodenum were diagnosed
by endoscopy following massive upper gastrointestinal tract
bleeding. The episode of bleeding was preceded by the inges-
tion of a non-steroidal anti-inflammatory drug (nimesulide).
During surgery, tumors were palpated at the serosal side of
the duodenum and the proximal jejunum. No tumors could
be palpated in the rest of the intestinal tract. Twelve small
tumors (diameters of 3–22 mm) were removed from the duo-
denum and the proximal jejunum. A large lesion was localized
in D2 and protruded at the anti-mesenterial side (diameter
20 mm). Two other large lesions (diameters 20 and 22 mm)
Table 3. Summary of array CGH experiments on seven GISTs derived from
three NF1 patients
Patient Tumor Array CGH
Gain Loss
NF1-1 I No gain 1pter!1p12, 2pter!2p11.2,
6q12!qter, 11pter!11p11.2,
13, 14, 18, 22
II 10q25.1!10qter 1pter!1p12, 3q11.2!3qter,
11, 14, 19q13.11!19qter, 22, X
III 6, 10, 20, 20 no loss
NF1-2 I 9q21.13!9qter 1pter!1p12, 14
II 9q21.11!9qter 1pter!1p12, 14, 15, 22
III Xq22.1!Xqter 1pter!1p12, 14, 15
NF1-3 I No gain 17q11.2 only RPCI5-926B9
and RP11-229K15 (¼NF1)
Table 2. Relative p-KIT and p-MAPK expression based on densitometric quantification of autoradiographic signals obtained by western blotting (data correspond-
ing to Fig. 2)
Sporadic GIST NF1-related GIST
GIST882 Sporadic GIST GIST NF1-1 GIST NF1-2 GIST NF1-3
III II I III II I
p-KIT/KIT 0.44 3.05 0.64 0.67 0.30 0.22 0.18 0 0.81
p-MAPK/MAPK 0.10 0.11 1.78 0.82 1.50 1.73 1.46 0.98 0.32
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showed mucosal ulcerations and were located in D2–D3.
Pathological examination showed very few mitoses (less
than 5 per 50 high-power fields). There were no post-operative
complications, and post-operative follow-up at 2 years was
uneventful. He did not receive adjuvant therapy.
Patient NF1-3 is a male with a severe thoraco-lumbar
kyphoscoliosis and multiple cutaneous neurofibromas. At the
age of 55, surgery was performed for a growing pelvic mass
with nycturia and frequent micturition. The large tumor fills
the pelvic cavity completely and is connected to the ileum
over a distance of 4 cm. The large tumor was removed from
the peritoneum, the bladder and the mesenterial side of the
rectum and subsequently resected together with 7 cm of
jejunum. The tumor measured 110  110  50 mm3 and
showed central necrosis. Pathological examination showed
only one mitosis per 50 high-power fields. In the resected frag-
ment of the jejunum, a tumor with a diameter of 20 mm was
present (no mitoses detected) and three additional smaller
GISTs (diameter 3–5 mm, no mitoses). The post-operative
evolution was uneventful and the patient did not receive adju-
vant therapy. At follow-up 2.5 years later, he is free of symp-
toms and a CT-scan of the abdomen did not reveal any mass.
Histopathology
Histopathological sections (5 mm) were cut from tumor para-
ffin blocks for routine H&E staining. Immunohistochemical
Figure 3. Array CGH profiles of seven NF1-related GISTs. Profiles are com-
posed of numerically ordered autosomes (1–22) followed by X and Y. Arrows
below and above profiles mark losses and gains, respectively.
Figure 4. Phenotype of cultured cells. (A) After 3 days in culture, the primary
cells of tumor III from patient NF1-2 exhibited spindle shape type of growth
and 95% were KIT immunopositive. (B) The Ki-67 labeling index was 0.5 and
8.7% in ligand unstimulated and ligand stimulated cultures, respectively.
Figure 5. Ex vivo effect of imatinib on the phosphorylation of KIT Y703 and
MAPK T202/Y204 residues in control GIST882 cell line (KIT p.K642E),
primary NF1-related GIST cells cultured in medium supplemented with stem
cell factor (SCF) and control human fibroblasts determined by western blot
assay. Equal protein loading was demonstrated with anti-actin staining. The
relative p-MAPK expression was evaluated on the basis of the densitometric
quantification of autoradiographic signals. In contrast to control GIST882
cells with activating KIT mutation, the phosphorylation of wild-type KIT in
primary NF1-related GIST cells under in vitro condition is ligand-dependent.
Imatinib treatment resulted in only partial and dose-independent inhibition of
MAPK posphorylation of NF1-GIST cells cultured under ligand stimulation.
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staining was conducted using the avidin–biotin–peroxidase
complex method. Commercially available monoclonal (mc)
or polyclonal (pc) antibodies specific for CD117 (pc, 1:250;
DAKO, Glostrup, Denmark), CD34 (mc, 1:10; Becton
Dickinson, San Jose, CA, USA), a-Smooth Muscle Actin
(mc, 1:100; DAKO), desmin (mc, 1:20; ICN, Aurora,
OH, USA) and S-100 (pc, 1:300; DAKO) were used.
The CD117 immunostaining was performed without antigen
retrieval and the presence of mast cells served as an internal
control.
KIT/PDGFRA mutation analysis
Genomic DNA was extracted from snap-frozen tumor tissue of
NF1-related GISTs using the High Pure PCR Template Prep-
aration Kit (Roche). The entire KIT and PDGFRA coding
region and the splice junctions were amplified by PCR.
All amplicons were bidirectionally cycle sequenced using
the ABI3730XL machine (Applied Biosystems).
NF1 mutation analysis
Germline NF1 mutation analysis was performed (51). An
improved strategy for NF1 somatic mutation detection was
developed (Maertens et al., manuscript in preparation) and
applied specifically to the primary GIST cell cultures.
Briefly, the second passage of ICC cell cultures from tumors
II and III from patient NF1-2 was treated with puromycin
before RNA extraction (RNeasy kit, Qiagen). Genomic DNA
was extracted with the PureGene DNA purification kit
(Gentra). The entire NF1 cDNA was sequenced. Mutations
found at the cDNA level were confirmed on gDNA. Detection
of LOH was performed by genotyping microsatellite markers
telomeric (30NF1-3, 30NF1-1) (52) and within (Alu,
IVS27AC33.1, IVS38GT53.0, IVS27TG24.8) (53–56) NF1.
Genomic DNA from paired frozen tissue or primary GIST
cell cultures and lymphocyte cultures was investigated by
multiplex PCR and analyzed on the ABI3100 genetic analyzer
(Applied Biosystems) with the Genescan software (Applied
Biosystems). Loss of the wild-type NF1 allele was confirmed
by at least one of the following techniques: FISH, array CGH,
MLPA or SNP analysis. Frozen tumor specimens negative for
LOH were subsequently submitted to PCR amplification and
cycle sequencing of all NF1 exons.
Western blotting
Proteins were isolated from snap-frozen tumor specimens and
western blotting was performed as described in
Debiec-Rychter et al. (57). In short, equivalent amounts of
protein (30 mg) from clarified lysates were resolved with
SDS–PAGE, transferred to PDVF membranes and immuno-
blotted sequentially with antisera specific for anti-NF1
(sc-67; 1:200; Biotechnology, Santa Cruz, CA, USA),
anti-phospho-KIT (Y703) (1:250; Zymed, San Francisco,
CA, USA), anti-KIT (1:500; DAKO), anti-phospho MAPK
(T202/Y204) (1:1000; Cell Signaling Technology Inc.,
Beverly, MA, USA), anti-MAPK (1:1000; Zymed), anti-
phospho AKT (S473) (1:500; Cell Signaling Technology
Inc.), anti-AKT (1:500; Cell Signaling Technology Inc.), anti-
STAT3 (1:500; Zymed) and anti-actin (1:500; Sigma, Saint
Louis, MI, USA). After washes, membranes were probed
with anti-rabbit or anti-goat immunoglobulin-HRP conjugate
and incubated with ECL substrate (Pierce, Rockford, IL,
USA). On the basis of the densitometric quantification of auto-
radiographic signals, the relative p-MAPK expression was
determined in NF1-related GISTs.
Array CGH
Array CGH was performed as published previously (58).
Tumor DNA was compared with DNA extracted from blood
lymphocytes of a sex-matched control individual. Every case
was analyzed twice and tumor DNA was once labeled with
Cy3 and once with Cy5. Clones that gave the same result
twice were taken into account.
Primary GIST cell culture and imatinib assay
The GIST specimen used for this experiment was tumor III of
patient NF1-2. Primary cells were obtained from a disaggregated
tumor specimen seeded at 60–70% confluence in 100 mm cell
culture dishes and grown for 3 days in DMEM supplemented
with 10% FBS, 20 ng/ml SCF, 0.1 mM non-essential amino
acids, 1.0 mM sodium pyruvate, 100 U/ml penicillin, 0.1 mg/ml
streptomycin and 0.5 mM 3-isobutyl-1-methylxanthine (Sigma).
As a control, the same NF1-2 primary GIST cells, GIST882
cell line and normal human fibroblasts were grown in similar
conditions but without the SCF ligand. For evaluation of the
phenotype, NF1-2 primary GIST cells from tumor III were
seeded at 60–70% confluence in slide chambers and grown for
3 days in the same conditions as above. After fixation in 4%
Table 4. Relative p-KIT and p-MAPK expression based on densitometric quantification of autoradiographic signals obtained by western blotting (data correspond-
ing to Fig. 5)
GIST-NF1 GIST-882 GIST-NF1 (þSCF) Fibroblasts
SCF(þ) SCF(2) Imatinib (mM) Imatinib (mM) Imatinib (mM)
0 0.1 0.5 1.0 0 0.1 0.5 1.0 0 0.1 0.5 1.0
p-KIT/KIT 1.01 ,0.01 0.90 0.21 0 0 1.02 0.33 , 0.1 , 0.1 / / / /
p-MAPK/MAPK 1.79 0.45 1.13 0.37 0.12 0 1.05 0.76 0.84 0.78 1.10 1.15 1.14 1.10
/: not applicable.
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paraformaldehyde, immunohistochemical staining using the
polyclonal rabbit antihuman antibody against CD117 (1:250;
DAKO) and Ki-67 antibody (1:250; DAKO) was performed by
the avidin–biotin–peroxidase complex method. The prolifer-
ation index was determined as the percentage of Ki-67 positive
cells of the total number of cells. Imatinib mesylate was provided
by Novartis Pharmaceuticals Corporation. The compound was
dissolved at 10 mM in 100% DMSO (Sigma). Controls were per-
formed with solvent (DMSO) dilutions. The effect of imatinib on
the autophosphorylation of the KIT Y703 and the MAPK T204/
Y202 residues in cultured primary NF1-related GIST cells (either
ligand stimulated or unstimulated), the control GIST882 cell line
and human fibroblasts was determined by western blot assay. In
short, cells were exposed to either vehicle alone or to imatinib
mesylate within a range of doses (0.1, 0.5 and 1.0 mM) for
90 min, washed with ice-cold PBS and lysed. Lysates were incu-
bated for 30 min atþ48C and then centrifuged for 20 min. Super-
natants were removed and used for SDS gel electrophoresis and
immunoblotting as described previously (57). Equivalency of
loading intracellular proteins was demonstrated by stripping the
membrane and re-blotting using anti-actin antibody (1:500;
Sigma).
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  Chapter 3 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
 
 
Neurofibromatosis type 1 (NF1), one of the most common autosomal dominant genetic disorders 
worldwide, is caused by defects in the NF1 gene. The NF1 encoded protein, neurofibromin, 
functions as a negative regulator of Ras mediated signaling1-3. The wide spectrum of clinical 
manifestations observed in NF1 patients clearly illustrates the critical function of neurofibromin in a 
wide variety of tissues and cell types. Given the central role of Ras signaling pathways in so many 
biological processes, perhaps this is not surprising. Nevertheless, the basic pathology of many of the 
NF1-related symptoms, and thus the exact role of neurofibromin in different cellular contexts, 
remains largely unknown. 
 
Elucidating the biological framework underlying the development of NF1-related symptoms has 
proven to be difficult. Aggravating factors include the large size of the gene, the presence of 
several NF1 pseudogenes, the complex interactions between cell types, the NF1 haploinsufficient 
state of all cells in the body, and the involvement of modifier genes. Despite this complexity, 
important progress has been made in deciphering the molecular and biochemical events that 
underlie NF1-associated tumor development in NF1 mouse models4-7. However, the concern that the 
mechanisms and signaling pathways by which Ras effects its biological consequences might exhibit 
significant species-specific differences8, emphasize the value of dissecting tumorigenic as well as 
non-tumorigenic lesions in human cells. Determining when and in what cell type the crucial 
molecular defect occurs, is critical for understanding the basic pathology of any phenotype. 
Moreover, this information is essential for elucidating the normal function of the NF1 gene and 
developing tailored treatment protocols in the long term. In this thesis, we exploited improved 
somatic mutation detection strategies on a diverse spectrum of cellular entities in order to gain 
insight into the developmental concepts underlying various NF1-related symptoms. 
 
The requirement for second hit mutations to develop benign neurofibromas has been controversial. 
Early work in this area concluded that such mutations were not present in this tumor type9. More 
recently, investigators have reported second hit mutations or loss of heterozygosity (LOH) in human 
neurofibromas, albeit at low frequency (15-40%)10-15. Based on dual-label immunofluorescence data, 
one group speculated lately that neurofibromas develop in haploinsufficient tissues without the 
need for a second hit at the NF1 tumor suppressor locus16, 17. In our opinion, it is risky to draw 
conclusions on the mutation status of a particular gene based on immunohistochemical data only. 
We hypothesized that the relatively low detection rates reported may be due to (1) the cellular 
heterogeneity of neurofibromas, i.e. the fraction of Schwann cells carrying the second hit may be 
too low to reveal the somatic mutation, and (2) the low sensitivity of the applied mutation 
detection strategies. In Paper 1, we present an improved NF1 somatic mutation detection strategy. 
Extensive screening of the NF1 gene in selectively grown Schwann cells (SC F-) derived from a large 
panel of neurofibromas resulted in the highest NF1 somatic mutation detection rate described up to 
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now (76%). Moreover, our data strongly suggested that the acquired second hit underlies reduced 
NF1 expression in Schwann cell cultures. Therefore, our work shows for the first time irrefutable 
evidence that the occurrence of two inactivating NF1 mutations in a subpopulation of the Schwann 
cells is required for neurofibroma formation, which is in line with Knudson’s two-hit hypothesis18. 
Moreover, the high somatic mutation detection rate emphasizes that genetic alterations, and not 
epigenetic events, constitute the prevailing mechanism for NF1 inactivation in neurofibroma 
development. 
 
In a next step, we compared the germline versus the somatic mutation spectrum. For several 
familial cancer syndromes, similar studies have provided important insights into the underlying 
mechanisms of tumorigenesis and mutagenesis. In familial adenomatous polyposis (FAP), for 
example, the non-random distribution of mutations in the APC gene reflects an optimal level of β-
catenin signalling in colorectal tumors19, 20. A significant difference in the somatic inactivation 
mechanism in neurofibromas derived from NF1 microdeletion patients and the general NF1 
population was initially observed in Paper 1 and firmly established in Paper 2. While LOH is 
responsible for the somatic inactivation of NF1 in a quarter of the neurofibromas from non-
microdeletion patients, this mechanism was never observed in neurofibromas derived from NF1 
microdeletion patients. Compared to the general NF1 population, individuals with an NF1 
microdeletion frequently show a phenotype with more dermal neurofibromas at an earlier age. Now 
it becomes clear that both patient groups not only differ at the phenotypic and constitutional level, 
but also at the somatic level. This important new insight may open new avenues for a better 
understanding of the genetic basis underlying the high tumor burden of NF1 microdeletion patients. 
Whether the wild-type NF1 allele in microdeletion patients is, for an as yet undetermined reason, 
more vulnerable to other types of somatic inactivation remains an important question. 
 
Compared to the age-matched NF1 population, most individuals included in Paper 1 suffered from a 
severe to excessive neurofibroma burden. Strikingly, the somatic mutation spectrum consisted 
predominantly of NF1 minor lesion mutations, especially frameshift mutations. To our opinion, this 
mutation signature might reflect slightly reduced DNA repair efficiency as a trigger for NF1 somatic 
inactivation preceding tumorigenesis. Several lines of evidence strengthen this hypothesis. First, 
there is increasing evidence that mild reductions in DNA repair capacity, assumed to be the 
consequence of common genetic variation, affect cancer predisposition21. Second, the NF1 gene has 
been shown to be a mutational target in cells deficient for the mismatch repair process22. Third, 
epidemiologic studies suggest that the molecular basis underlying the phenotypic variability in NF1 
is determined to a large extent by the genotype at modifying loci23-26. Future large and well-
designed candidate gene association studies are needed to help further illuminate the putative role 
of common variants in DNA repair genes as contributing factors in NF1 tumor predisposition. 
 
In Paper 4, four mosaic NF1 patients with different clinical manifestations (neurofibromas only, 
pigmentary changes only, and association of both symptoms) were investigated at the molecular 
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level. For this purpose, a real-time quantitative PCR approach capable of detecting low-percentage 
mosaic point mutations against backgrounds of normal and pseudogene alleles was optimized (Paper 
3). For every mosaic patient, various tissues and cell types were tested to gain insight into the 
developmental concepts underlying particular NF1-related disease features. This approach elegantly 
confirmed the tumorigenic properties of Schwann cells in neurofibroma development. Moreover, we 
demonstrated for the first time that bi-allelic NF1 inactivation in melanocytes seems to be the 
underlying trigger for NF1-related café-au-lait macule (CALM) development. Clearly, this finding 
provides an important stimulus for further research. First of all, additional NF1-related CALMs will 
need to be tested to confirm our initial observations. Screening different CALMs derived from the 
same NF1 patient will provide insight into the developmental timing of the second hit. In the 
context of the early onset and frequent congenital manifestation of CALMs, identical NF1 second 
hits in different CALMs might point to inactivation of the NF1 wild-type allele in melanocyte 
precursors (melanoblasts) during embryonic development. Besides NF1-related CALMs, it will also be 
of particular interest to screen the NF1 mutation status in CALMs from healthy control individuals. 
The next step will be to determine the dysregulating consequences of neurofibromin loss on 
signaling pathways in melanocytes. In this respect, it will be of fundamental importance to study 
whether NF1 inactivation in melanocytes triggers particular autocrine and paracrine networks 
resulting in increased melanocyte density27, and a higher melanin content and melanogenesis28, 
features which have been shown to be specific for NF1 CALMs. 
 
Interestingly, both neurofibromas and CALMs in mosaic NF1 patients appear to arise even within a 
background containing predominantly NF1 wild-type cells. Deciphering the complex interactions 
between the different cell types within the neurofibroma microenvironment is currently a major 
topic and challenge in NF1 research. Previous findings in mouse models have led to the emerging 
view that NF1 haploinsufficiency in the tumor environment actively contributes to, or is even 
necessary for, neurofibroma formation4-6. However, considering the recurrent discrepancies in the 
tumor phenotypes between human and mice, especially in the context of Ras-related neoplasms29, 
caution must be exercised in extrapolating these observations to humans. Moreover, the tumors that 
have been observed in the murine model to date have been plexiform neurofibromas derived from 
dorsal root ganglia and cranial nerves. Whether this is a consequence of the expression pattern of 
the Cre transgene used to generate the conditional mouse model or alternatively reflects a slightly 
different pathogenesis from the dermal neurofibromas remains an important question. At this 
moment, it is unclear whether the abundance of NF1 wild-type cells in neurofibromas from 
segmental NF1 patients reflects a slightly different pathogenesis in humans or, alternatively, is 
associated with the small size of these patients’ tumors (heterozygous neighboring cells may 
promote tumor growth more efficiently than wild-type neighboring cells). In this respect, it will be 
of particular importance to evaluate the involvement of NF1 haploinsufficient mast cells in human 
neurofibroma development. Currently, we are undertaking efforts to isolate mast cells from 
neurofibromas of segmental patients in order to determine their NF1 mutational status. 
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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract and are increasingly being recognized in association with NF1. In contrast to 
the sporadic tumors where KIT and PDGFRA activating mutations are the oncogenic mechanisms, the 
molecular basis underlying GIST formation in NF1 remained elusive at the start of this thesis. Using 
a combination of mutation analysis, Western blotting and array CGH we demonstrated in Paper 5 
that (1) the NF1-related GISTs do not have KIT or PDGFRA mutations, (2) the molecular event 
underlying GIST development in this patient group is a somatic inactivation of the wild-type NF1 
allele specifically in the interstitial cells of Cajal and (3) inactivation of neurofibromin is an 
alternate mechanism to (hyper) activate the MAP-Kinase pathway, while the JAK-STAT3 and PI3K-
AKT pathways are less activated in NF1-related compared to sporadic GISTs. These findings clearly 
position GISTs in the spectrum of clinical symptoms seen in NF1. It will be important to determine if 
the tyrosine kinase inhibitor Gleevec used in the treatment of sporadic GIST also has an effect on 
NF1-related GIST. 
 
The results of this thesis offer several future perspectives for guiding impending research efforts. 
First of all, the presented data demonstrate that a growing body of NF1-related symptoms, as well 
tumoral as non-tumoral lesions, require somatic inactivation of the wild-type NF1 allele. This 
observation emphasizes the value of dissecting additional, as yet unexplored, NF1 clinical 
manifestations at the somatic level. Such studies are essential for identifying the cell types, the 
cellular processes and the molecular pathways altered by NF1 defects. The analyses reported in this 
thesis mainly focused on pinpointing the cells and molecular defects underlying the development of 
various NF1-related symptoms. Accurately identifying the biochemical and cellular consequences of 
these cell-autonomous molecular defects, however, requires more functionally oriented analyses. As 
we enter into an era of targeted cancer therapeutics, an improved understanding of the signaling 
pathways dysregulated as a consequence of neurofibromin loss will ultimately provide additional 
molecular targets for drug design. 
Identifying modifying genes is an important challenge in NF1 research. Such genes may be 
indispensable determinants of risk prediction, the current lack of which substantially contributes to 
the psychological burden where NF1 patients and their families are suffering from. Also motivating 
this search is the hypothesis that genetic modifiers might control rate-limiting steps during disease 
development, and as such may represent good therapeutic targets. To identify these modifiers, 
National Institute of Health (NIH) funded NF1 Consortia are in the process of collecting material and 
detailed phenotypic information from thousands of NF1 patients. Indeed, only genetic association 
studies on large well-defined patient groups offer a powerful approach for mapping causal genes 
with modest effects. In this thesis, we suggested a putative role for DNA repair genes as 
contributing factors in NF1 tumor predisposition. To help further test this hypothesis, well-designed 
candidate gene association studies on patient cohorts that can only be gathered by well-coordinated 
collaborative efforts will be of fundamental importance. 
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SUMMARY 
 
 
Neurofibromatosis type 1 (NF1; OMIM 162200) is one of the most common autosomal dominant 
genetic disorders, affecting approximately 1 in 3500 individuals worldwide. The most common 
clinical manifestations are pigmentary abnormalities together with the development of benign 
peripheral nerve sheath tumors or neurofibromas. In addition, NF1 patients are prone to a 
pleiotropy of other phenotypic features. Determining when and in what cell type the crucial 
molecular defect actually occurs has proven to be surprisingly difficult for many NF1-related 
symptoms. Impeding factors include the large size of the NF1 gene, the presence of several NF1 
pseudogenes, the complex interactions between cell types within affected tissues, and the NF1 
heterozygous state of all cells in the body. The major goal of this thesis was to gain insight into the 
developmental concepts underlying various NF1-related symptoms by exploiting improved somatic 
mutation detection strategies on a diverse spectrum of cellular entities. 
 
First, we investigated thoroughly the status of the somatically affected NF1 allele in cultured 
Schwann cells derived from neurofibromas (Paper 1). The high somatic mutation detection rate 
together with the observation that the acquired second hit underlies reduced NF1 expression, 
irrefutably demonstrated that two inactivating mutations in this particular cell type are required for 
neurofibroma formation. Given the high occurrence of somatic frameshift mutations, a putative role 
of reduced DNA repair efficiency as a trigger for NF1 somatic inactivation preceding tumorigenesis 
was suggested. In a next step, we compared the germline versus the somatic mutation spectrum. A 
significant difference in the somatic inactivation mechanism in neurofibromas derived from NF1 
microdeletion patients and the general NF1 population was observed in Paper 1 and firmly 
established in Paper 2. This important new insight may open new avenues for a better 
understanding of the genetic basis underlying the high tumor burden of NF1 microdeletion patients. 
 
As opposed to classic NF1 where all cells of the body bear at least one mutated NF1 allele, NF1 
segmental phenotypes provide the opportunity to study cell populations differing only with regard 
to the mutation(s) giving rise to mosaicism. For this purpose, we developed a real-time quantitative 
PCR assay capable of detecting low-percentage mosaic point mutations against backgrounds of 
normal and pseudogene alleles (Paper 3) and molecularly dissected different clinical subtypes 
emerging within mosaic NF1 (Paper 4). This approach elegantly confirmed the tumorigenic 
properties of Schwann cells in neurofibroma development. Moreover, we demonstrated for the first 
time that bi-allelic NF1 inactivation in melanocytes seems to be the underlying trigger for NF1-
related café-au-lait macule development. Clearly, this finding provides an important stimulus for 
further research aiming to understand the etiopathogenesis of pigmentary lesions in NF1. 
 
Finally, we unraveled the molecular pathogenesis of gastrointestinal stromal tumors (GISTs) arising 
in the NF1 setting (Paper 5). We demonstrated that, in comparison with sporadic GISTs, NF1-related 
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tumors do not bear KIT or PDGFRA mutations, but show somatic inactivation of the wild-type NF1 
allele in the interstitial cells of Cajal. In this respect, inactivation of neurofibromin constitutes an 
alternate mechanism to activate the MAP-Kinase pathway, while the Jak-Stat3 and PI3K-Akt 
pathways are less activated in NF1-related GIST compared to sporadic tumors. It will be important 
to determine if the tyrosine kinase inhibitor Gleevec used in the treatment of sporadic GIST also has 
an effect on NF1-related GIST. 
 
In conclusion, we have provided significant new insights in the cell types and molecular defects 
underlying the development of various NF1-related symptoms. Accurately identifying the 
biochemical and cellular consequences of these cell-autonomous molecular defects will be of 
fundamental importance to elucidate the exact role of neurofibromin in different cellular contexts 
and may ultimately provide additional targets for tailored drug design. 
 
 
 116
  Chapter 3 
SAMENVATTING 
 
 
Neurofibromatose type 1 (NF1; OMIM 162200) is één van de meest voorkomende autosomaal 
dominante genetische aandoeningen, die wereldwijd ongeveer 1 op 3500 individuen treft. De meest 
voorkomende klinische kenmerken zijn pigmentaire afwijkingen en de ontwikkeling van perifere 
zenuwschede tumoren of neurofibromen. Daarnaast kunnen NF1 patiënten ook een wijde waaier aan 
andere symptomen vertonen. Voor veel NF1 gerelateerde klinische kenmerken is het verrassend 
moeilijk gebleken om te bepalen wanneer en in welk cel type het cruciale moleculaire defect 
plaatsvindt. Bemoeilijkende factoren omvatten de grootte van het NF1 gen, de aanwezigheid van 
meerdere NF1 pseudogenen, de complexe interacties tussen verschillende cel types in aangetaste 
weefsels, en de heterozygotie voor NF1 in alle cellen van het lichaam. De belangrijkste doelstelling 
van deze thesis was om inzicht te verwerven in de ontwikkeling van verschillende NF1 gerelateerde 
symptomen, en dit door de toepassing van verbeterde somatische mutatie detectie strategieën op 
een divers spectrum van cellulaire entiteiten. 
 
Eerst en vooral onderzochten we, in gekweekte Schwann cellen afkomstig van neurofibromen, de 
status van het somatisch aangetaste NF1 allel (Artikel 1). Het hoge somatische mutatie detectie 
cijfer en de bevinding dat de verworven tweede hit aanleiding geeft tot een verlaagde NF1 
expressie, toonde ontegensprekelijk aan dat twee inactiverende mutaties in dit specifieke cel type 
noodzakelijk zijn voor de vorming van neurofibromen. Wegens het hoge percentage aan somatische 
mutaties met een effect op het leesraam, werd vooropgesteld dat een verlaagde efficiëntie van het 
DNA herstel mechanisme mogelijk een katalysator zou kunnen zijn voor somatische inactivatie van 
het NF1 gen, en bijgevolg tumorvorming. In een volgende stap vergeleken we het germinale met het 
somatische mutatie spectrum. Een significant verschil in het mechanisme van somatische inactivatie 
in neurofibromen afkomstig van NF1 microdeletie patiënten en de algemene NF1 populatie werd 
opgemerkt in Artikel 1, en vervolgens uitgebreid bevestigd in Artikel 2. Dit belangrijk inzicht kan 
nieuwe wegen openen naar een beter begrip van de genetische basis voor het verhoogd voorkomen 
van tumoren bij NF1 microdeletie patiënten. 
 
In tegenstelling tot klassieke NF1, waar in alle cellen van het lichaam tenminste één gemuteerd NF1 
allel aanwezig is, bieden NF1 segmentaire fenotypes de mogelijkheid om cel populaties te 
bestuderen die enkel verschillen in de mutatie die aanleiding geeft tot mosaïcisme. Voor deze reden 
ontwikkelden we een real-time kwantitatieve PCR techniek die in staat is om lage percentages aan 
mosaïsche puntmutaties op te pikken tegen een achtergrond van normale en pseudogen allelen 
(Artikel 3) en ontleedden we op moleculair niveau verschillende klinische subtypes die voorkomen 
binnen mosaïsche NF1 (Artikel 4). Deze aanpak bevestigde op elegante wijze de tumorigene 
eigenschappen van Schwann cellen in de ontwikkeling van neurofibromen. Bovendien toonden we 
voor de eerste keer aan dat bi-allelische NF1 inactivatie in melanocyten de onderliggende oorzaak 
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zou kunnen zijn voor de ontwikkeling van NF1 gerelateerde café-au-lait vlekken. Onmiskenbaar 
verschaft deze bevinding een belangrijke stimulans voor verder onderzoek. 
 
Tenslotte analyseerden we de moleculaire pathogenese van gastrointestinale stromale tumoren 
(GISTen) die voorkomen binnen de NF1 setting (Artikel 5). We toonden aan dat, in tegenstelling tot 
sporadische GISTen, NF1 gerelateerde tumoren geen KIT of PDGFRA mutaties dragen, maar een 
somatische inactivatie van het wild-type NF1 allel vertonen in de interstitiële cellen van Cajal. 
Inactivatie van neurofibromine vormt een alternatief mechanisme om de MAP-Kinase signaal 
transductie cascade te activeren, terwijl de Jak-Stat3 en PI3K-Akt signaal transductie cascades 
minder geactiveerd zijn in NF1 gerelateerde dan in sporadische GISTen. Het zal belangrijk zijn om 
na te gaan of de tyrosine kinase inhibitor Gleevec, die gebruikt wordt bij de behandeling van 
sporadische GISTen, ook een effect zou kunnen hebben op NF1 gerelateerde GISTen. 
 
Samenvattend kunnen we stellen dat we een significante bijdrage hebben geleverd in de 
identificatie van de cel types en de moleculaire defecten die verantwoordelijk zijn voor de 
ontwikkeling van verschillende NF1 gerelateerde symptomen. Het nauwkeurige bepalen van de 
biochemische en cellulaire gevolgen van deze cel autonome moleculaire defecten zal van cruciaal 
belang zijn om de exacte functie van neurofibromine in verschillende cellulaire omgevingen te 
ontrafelen. Uiteindelijk kan dit inzicht leiden tot bijkomende doelwitten voor op maat gemaakte 
geneesmiddelen. 
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RESUME 
 
 
La neurofibromatose de type 1 (NF1; OMIM 162200) est une des maladies génétiques les plus 
communes qui affecte environs 1 individu sur 3500 mondialement. Les manifestations cliniques les 
plus caractéristiques sont les anomalies pigmentaires et les tumeurs des etuis de nerfs 
périphériques ou neurofibromes. En plus, les individus affectés peuvent présenter un éventail 
d’autres symptômes. Pour beaucoup de manifestations cliniques, il est apparu difficile de 
déterminer quand, et dans quel type de cellule le défaut moléculaire se situe. Des éléments qui 
compliquent cette analyse comprennent la grande taille du gène NF1, la présence de plusieurs 
pseudogènes NF1, les interactions complexes entre les différents types de cellules dans les tissus 
affectés, et l’état hétérozygote de NF1 dans toutes les cellules du corps. Le but principal de cette 
thèse était d’obtenir une compréhension plus profonde du développement de différents symptômes 
relatés à la NF1, par appliquer des stratégies de détection des mutations somatiques améliorées à 
un éventail diverse des entités cellulaires. 
 
D’abord, nous avons examiné profondément l’état de l’allèle NF1 somatiquement affecté, 
spécifiquement dans les cellules de Schwann cultivées de neurofibromes (Article 1). Le taux élevé 
de détection de mutations somatiques et l’observation que la mutation seconde aboutit à une 
expression abaissée du gène NF1, a indiqué incontestablement que deux mutations inactivantes 
dans ce type de cellule spécifique est nécessaire pour le développement de neurofibromes. A cause 
du taux élevé de mutations somatiques avec un effet sur le cadre de lecture, il a été proposé qu’un 
efficience abaissé du mécanisme de réparation de l’ADN pourrait catalyser l’inactivation du gène 
NF1, et ainsi le développement de tumeurs. Ensuite, nous avons comparé le spectre des mutations 
germinales et somatiques. Une différence significative entre le mécanisme d’inactivation somatique 
des neurofibromes dérivés des patients avec une microdélétion de NF1 et la population NF1 
generale a été remarquée dans l’Article 1 et profondément examinée dans l’Article 2. Cette notion 
pourrait ajouter à une compréhension améliorée de la cause génétique de la présentation surélevée 
de tumeurs chez les patients avec une microdélétion de NF1. 
 
Contrairement à la NF1 classique, où toutes les cellules du corps portent au moins un allèle NF1 
muté, les phénotypes segmentaires de la NF1 offrent la possibilité d’étudier des populations de 
cellules qui diffèrent seulement au niveau de la mutation causant le mosaïcisme. Pour cette raison, 
nous avons développé un essai de PCR quantitatif capable de détecter des pourcentages très bas de 
mutations ponctuelles mosaïques dans un contexte d’allèles normaux et de pseudogènes (Article 3) 
et nous avons analysé au niveau moléculaire de différentes manifestations cliniques qui se 
présentent dans la NF1 mosaique (Article 4). Cette approche a conformé avec élégance les 
caractéristiques tumeurigènes des cellules de Schwann dans le développement des neurofibromes. 
En plus, nous avons démontré pour la première fois que l’inactivation bi-allèlique du gène NF1 
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pourrait être la cause principale du développement des taches de café-au-lait relatées à la NF1. 
Indéniablement, cette constatation comporte un stimulant important pour la recherche d’avenir. 
 
Finalement, nous avons analysé la pathogenèse moléculaire des tumeurs stromales gastro-
intestinales (GISTs) qui se présentent dans le contexte de la NF1 (Article 5). Nous avons démontré 
que, contrairement aux GISTs sporadiques, les tumeurs relatées à la NF1 ne présentent pas de 
mutations dans les gènes KIT ou PDGFRA, mais montrent une activation somatique de l’allèle normal 
de NF1 dans les cellules interstitielles de Cajal. L’inactivation de la neurofibromine compose un 
mécanisme alternatif pour activer les voies de signalisation de Map-Kinase, tandis que les voies de 
signalisation de Jak-Stat3 et PI3K-Akt sont moins activées dans les GISTs relatées à la NF1 que 
sporadiques. Il sera important de vérifier si l’inhibiteur de tyrosine kinase Gleevec, utilisé pour le 
traitement des GISTs sporadiques, aurait aussi un effet sur les GISTs relatées à la NF1. 
 
En conclusion, nous avons apporté à la perspicacité des types cellulaires et défauts moléculaires 
responsables pour le développement des manifestations cliniques différentes de la NF1. Déterminer 
consciencieusement les répercussions biochimiques et cellulaires de ces défauts moléculaires et 
cellulaires autonomiques sera fondamental pour établir la fonction de la neurofibromine dans des 
contextes cellulaires différents. Finalement, cette perspicacité pourrait aboutir à l’identification 
des cibles additionnelles pour le développement des médicaments sur mesure. 
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LIST OF ABBREVIATIONS 
 
 
AA  amino acid 
aCGH  array comparative genomic hybridisation 
APP  amyloid precursor protein 
AC  adenylate cyclase 
bp  base pair 
CALM  café-au-lait macule 
cAMP  cyclic adenosine monophosphate 
cDNA  complementary DNA 
CSRD  cysteine / serine rich domain 
DNA  deoxyribonucleic acid 
F  forskolin 
FAP  familial adenomatous polyposis 
FSNF  familial spinal neurofibromatosis 
FTI  farnesyl transferase inhibitor 
EGFR  epidermal growth factor receptor 
ERK  extracellular signal-regulated protein kinase 
EVI2A  ecotropic viral insertion site 2 protein A 
EVI2B  ecotropic viral insertion site 2 protein B 
GAP  GTPase activating protein 
GEF  guanine nucleotide exchange factor 
GIST  gastrointestinal stromal tumor 
GM-CSF  granulocyte / macrophage colony-stimulating factor 
GPCR  G-protein coupled receptor 
GRD  GAP related domain 
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A 
HNPCC  hereditary non-polyposis colorectal cancer 
IBMX  3-isobutyl-1-methylxanthine 
JMML  juvenile myelomonocytic leukaemia 
kb  kilobase 
KitL  kit ligand 
kDa  kilodalton 
LOH  loss of heterozygosity 
MAPK  mitogen activated protein kinase 
MPNST  malignant peripheral nerve sheath tumor 
MRI  magnetic resonance imaging 
mRNA  messenger RNA 
Min  murine intestinal neoplasia 
miRNA  micro RNA 
Mom  modifier of Min 
mTOR  mammalian target of rapamycin 
NF1  neurofibromatosis type 1 
NIH  National Institute of Health 
OMGP  oligodendrocyte-myelin glycoprotein 
OMIM  online mendelian inheritance in man 
PCR  polymerase chain reaction 
PDGFRA platelet derived growth factor alpha 
PI3K  phosphatidylinositol-3-kinase 
PKA  cAMP-dependent protein kinase A 
qPCR  quantitative PCR 
RNA  ribonucleic acid 
RT-PCR  reverse transcriptase PCR 
SC  Schwann cell 
SCF  stem cell factor 
TSG  tumor suppressor gene 
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